Davidson's Rheuma + Neuro
Davidson's Rheuma + Neuro
Davidson's Rheuma + Neuro
Ralston
I.B. McInnes
25
Rheumatology and
bone disease
Clinical examination of the musculoskeletal Fibromyalgia 1092 Diseases of bone 1120
system 1058 Osteoporosis 1120
Bone and joint infection 1094
Functional anatomy and physiology 1060 Septic arthritis 1094 Osteomalacia and rickets 1125
Viral arthritis 1095 Paget’s disease of bone 1128
Investigation of musculoskeletal
disease 1064 Osteomyelitis 1095 Other bone diseases 1130
Joint aspiration 1064 Tuberculosis 1096 Reflex sympathetic dystrophy
syndrome 1130
Imaging 1064 Rheumatoid arthritis 1096 Osteonecrosis 1130
Blood tests 1066
Pathophysiology 1096 Scheuermann’s osteochondritis 1130
Tissue biopsy 1068
Clinical features 1097 Polyostotic fibrous dysplasia 1131
Electromyography 1068
Investigations 1100 Osteogenesis imperfecta 1131
Presenting problems in musculoskeletal Management 1100 Osteopetrosis 1131
disease 1069
Juvenile idiopathic arthritis 1103 Sclerosing bone dysplasias 1131
Acute monoarthritis 1069
Polyarthritis 1069 Seronegative spondyloarthropathies 1104 Bone and joint tumours 1131
Fracture 1071 Ankylosing spondylitis 1105 Osteosarcoma 1132
Generalised musculoskeletal pain 1071 Reactive arthritis 1107 Metastatic bone disease 1132
Back pain 1072 Psoriatic arthritis 1108 Rheumatological involvement in other
Regional musculoskeletal pain 1074 Enteropathic arthritis 1109 diseases 1132
Neck pain 1074 Connective tissue diseases 1109 Malignant disease 1132
Shoulder pain 1074 Endocrine disease 1132
Systemic lupus erythematosus 1109
Elbow pain 1075 Haematological disease 1133
Systemic sclerosis 1112
Hand and wrist pain 1075 Neurological disease 1133
Mixed connective tissue disease 1113
Hip pain 1075 Sjögren’s syndrome 1114 Miscellaneous conditions 1133
Knee pain 1075 Polymyositis and dermatomyositis 1114 Spondylolisis and spondylolisthesis 1133
Ankle and foot pain 1076 Inclusion body myositis 1115 Diffuse idiopathic skeletal hyperostosis 1133
Muscle pain and weakness 1076 Pigmented villonodular synovitis 1134
Vasculitis 1115
Principles of management of Takayasu’s disease 1116 Joint hypermobility 1134
musculoskeletal disorders 1077 Dupuytren’s contracture 1134
Kawasaki disease 1116
Education and lifestyle interventions 1077 Carpal tunnel syndrome 1134
Polyarteritis nodosa 1117
Pharmacological treatment 1078 Trigger finger 1134
Giant cell arteritis and polymyalgia
Non-pharmacological interventions 1080 rheumatica 1117 Periodic fever syndromes 1135
Osteoarthritis 1081 Antineutrophil cytoplasmic antibody-associated Anterior tibial compartment syndrome 1135
vasculitis 1118 Synovitis–acne–pustulosis–hyperostosis–
Crystal-induced arthritis 1086 osteitis syndrome 1135
Churg–Strauss syndrome 1118
Gout 1087
Henoch–Schönlein purpura 1119
Calcium pyrophosphate dihydrate crystal
Cryoglobulinaemic vasculitis 1119
deposition disease 1090
Behçet’s syndrome 1119
Basic calcium phosphate deposition
disease 1091 Relapsing polychondritis 1119
1057
RHEUMATOLOGY AND BONE DISEASE
Extensor surfaces 2
Rheumatoid nodules 3 Face
Swollen bursa Rash
Psoriasis rash Alopecia
Mouth ulcers
Eyes
Hands 1
Swelling
Deformity
Nail changes
Tophi Scleritis in rheumatoid
Raynaud’s arthritis
4 Trunk
Kyphosis
Scoliosis
Tender spots
5 Legs
Deformity
Swelling
Restricted movement
Nail dystrophy in
psoriatic arthritis
Bone deformity in
Synovitis and deformity Paget’s disease
in rheumatoid arthritis
6 Feet
Deformity
Swelling
Redness
Observation
• General appearance
• Gait
Heberden and Bouchard • Deformity
nodes in osteoarthritis • Swelling
• Redness Acute gout
• Rash
1058
Clinical examination of the musculoskeletal system
1 Gait 2 Arms
Inspect
hands for
swelling or
deformity
Press over supraspinatus
(tests for hyperalgesia)
Ask patient to put hands behind
Ask patient to head (tests shoulder movements)
make a fist and
open and close
fingers (tests
hand function)
Squeeze
metacarpals Patient turns palms up and
Ask patient to walk for a down with elbows at side (tests
few steps, then come back. (tests for
inflammation) supination and pronation Patient flexes elbows to touch
Look for pain or limp of wrists and elbow) shoulder (tests elbow flexion)
3 Legs
4 Spine
1059
RHEUMATOLOGY AND BONE DISEASE
Fascicle
Tendon Subchondral
bone
Epiphyseal plate Enthesis
Bone Synovium
Calcified zone
Growth
plate Hypertrophic zone
Proliferative zone
Cortical bone
Synovial
lining cells Joint
Bone capsule
Trabecular bone
Bone-lining cells
RANK RANKL
Mineralisation Quiescence OPG
Osteoclasts
Osteocyte
Osteoblasts
Osteoid Microdamage Stromal cell
Osteocyte
Formation Apoptotic Resorption
osteoclast
T cell
Osteoclast
precursor
Reversal
Osteoblast Stromal
precursor cell LRP5 Wnt
SOST
25
Osteoclast
H+ Cl-
Osteoblast
Osteocyte
Proton pump Chloride pump
Fig. 25.2 Regulation of bone remodelling. Bone is renewed and repaired during the bone remodelling cycle, in which old and damaged bone is
removed by osteoclasts and replaced by osteoblasts. Osteocytes play a central role in bone remodelling by secreting RANKL, which promotes osteoclast
differentiation and activity by binding to RANK. Osteocytes regulate bone formation by producing SOST, which binds to the LRP5 receptor and prevents
its activation by members of the Wnt family. Osteocytes also regulate phosphate homeostasis by producing fibroblast growth factor 23 (FGF23), which
is a circulating hormone that acts on the kidney to promote phosphate excretion. (CatK = cathepsin K; LRP5 = lipoprotein receptor protein 5; OPG =
osteoprotegerin; RANK = receptor activator of nuclear factor kappa B; RANKL = RANK ligand; SOST = sclerostin)
condensations of mesenchymal tissue during early fetal centre of the bone and consists of an interconnecting
life. Long bones, such as the femur and radius, develop meshwork of trabeculae, separated by spaces filled with
by endochondral ossification from a cartilage template. bone marrow.
During development, the cartilage is invaded by vascu- There are three main cell types in bone:
lar tissue containing osteoprogenitor cells and is gradu- • Osteoclasts: multinucleated cells of haematopoietic
ally replaced by bone from centres of ossification origin, responsible for bone resorption.
situated in the middle and at the ends of the bone.
A thin remnant of cartilage called the growth plate or • Osteoblasts: mononuclear cells of mesenchymal
epiphysis remains at each end of long bones, and origin, responsible for bone formation.
chondrocyte proliferation here is responsible for skeletal • Osteocytes: these differentiate from osteoblasts
growth during childhood and adolescence. During during bone formation and become embedded in
puberty, the rise in levels of sex hormones halts cell divi- bone matrix. Osteocytes are responsible for sensing
sion in the growth plate. The cartilage remnant then dis- and responding to mechanical loading of the
appears as the epiphysis fuses and longitudinal bone skeleton and play a critical role in regulating bone
growth ceases. formation and bone resorption, by producing
The normal skeleton has two forms of bone tissue (see receptor activator of nuclear factor kappa B ligand
Fig. 25.1). Cortical bone is formed from Haversian (RANKL) and sclerostin (SOST). They also play a
systems, comprising concentric lamellae of bone tissue central role in regulating phosphate metabolism by
surrounding a central canal that contains blood vessels. producing the hormone fibroblast growth factor 23
Cortical bone is dense and forms a hard envelope around (FGF23), which acts on the kidney to promote
the long bones. Trabecular or cancellous bone fills the phosphate excretion (Fig. 25.2). 1061
RHEUMATOLOGY AND BONE DISEASE
INVESTIGATION OF MUSCULOSKELETAL
DISEASE Imaging
Clinical history and examination usually provide suffi- Plain radiography
cient information for the diagnosis and management Radiographs show anatomical changes that are of value
of most musculoskeletal diseases. Investigations are in the differential diagnosis of many bone and joint dis-
helpful in confirming the diagnosis, assessing disease eases (Box 25.4). The bones and joints to be X-rayed are
activity and indicating prognosis. usually selected on the basis of symptoms or patterns of
involvement identified at clinical assessment.
Radiographs are of diagnostic value in osteoarthritis
Joint aspiration (OA), where they demonstrate joint space narrowing
that tends to be focal rather than widespread, as in
Joint aspiration with examination of synovial fluid (SF) inflammatory arthritis. Other features of OA detected on
is pivotal in patients suspected of having septic arthritis, X-ray include osteophytes, subchondral sclerosis, bone
crystal arthritis or intra-articular bleeding. It should be cysts and calcified loose bodies within the synovium (see
done in all patients with acute monoarthritis, and Fig. 25.20, p. 1084). Radiographs may show erosions and
samples sent for microbiology and clinical chemistry. sclerosis of the sacroiliac joints and syndesmophytes in
It is possible to obtain SF by aspiration from most the spine in patients with seronegative spondyloarthritis
peripheral joints, and only a small volume is required (see Fig. 25.36, p. 1106). In peripheral joints, so-called
for diagnostic purposes. Normal SF is present in small proliferative erosions, associated with new bone forma-
volume, and is clear and either colourless or pale yellow tion and a periosteal reaction, may be observed. In
with a high viscosity. It contains few cells. With joint tophaceous gout, well-defined punched-out erosions
inflammation, the volume increases, the cell count and may occur (see Fig. 25.26, p. 1089). Calcification of carti-
the proportion of neutrophils rise (causing turbidity), lage, tendons and soft tissues or muscle may occur in
and the viscosity reduces (due to enzymatic degradation chondrocalcinosis (see Fig. 25.27, p. 1090), calcific peri-
of hyaluronan and aggrecan). Turbid fluid with a high arthritis and connective tissue diseases.
neutrophil count occurs in sepsis, crystal arthritis and Radiographs are of limited value in the diagnosis of
reactive arthritis. High concentrations of urate crystals rheumatoid arthritis (RA) since features such as ero-
or cholesterol can make SF appear white. Non-uniform sions, joint space narrowing and periarticular osteoporo-
blood-staining usually reflects needle trauma to the syn- sis may only be detectable after several months or even
ovium. Uniform blood-staining is most commonly due years. The main indication for radiographs in RA is in
to a bleeding diathesis, trauma or pigmented villonodu- the assessment of advanced disease, when structural
lar synovitis (p. 1134), but can occur in severe inflamma- damage of the joints is suspected and arthroplasty is
tory synovitis. A lipid layer floating above blood-stained being considered. Early evidence of articular damage in
fluid is diagnostic of intra-articular fracture and is RA is more usually obtained using magnetic resonance
caused by release of bone marrow fat into the joint. imaging or ultrasonography.
Crystals can be identified by compensated polarised
light microscopy of fresh SF (to avoid crystal dissolution
and post-aspiration crystallisation). Urate crystals are
long and needle-shaped, and show a strong light inten- 25.4 X-ray abnormalities in selected
sity and negative birefringence (Fig. 25.5A). Calcium rheumatic diseases
Rheumatoid arthritis
• Periarticular osteoporosis • Joint space narrowing
A B
• Bone erosions
Osteoporosis
• Osteopenia • Non-vertebral fractures
• Vertebral fractures
Paget’s disease
• Bone expansion • Osteosclerosis
• Abnormal trabecular pattern • Pseudofractures
• Osteolysis
Spondyloarthritis
• Sacroiliitis • Ligament calcification
• Syndesmophytes • Squaring of vertebral bodies
Fig. 25.5 Compensated polarised light microscopy of synovial
fluids (× 400). A Monosodium urate crystals showing bright negative Osteoarthritis
birefringence under polarised light and needle-shaped morphology. • Joint space narrowing • Peaking of tibial spines
B Calcium pyrophosphate crystals showing weak positive birefringence • Osteophytes • Subchondral cysts
under polarised light and are few in number. They are more difficult to • Subchondral sclerosis
1064 detect than urate crystals.
Investigation of musculoskeletal disease
Computed tomography
Computed tomography (CT) can be used in the as-
sessment of patients with bone and joint disease but
has largely been superseded by MRI, which gives
better visualisation of soft tissue structures. CT may be
used when MRI is contraindicated, or for evaluation
of articular regions in which an adjacent joint replace-
ment creates image artefacts on MRI.
Blood tests
Haematology
Abnormalities in the full blood count (FBC) often occur
in inflammatory rheumatic diseases but changes are
usually non-specific. Examples include neutrophilia in
vasculitis, acute gout and sepsis; neutropenia in lupus;
and a raised erythrocyte sedimentation rate (ESR) in
many inflammatory diseases. Reduced levels of haemo-
B globin are a common and important finding in a range
1.3 +2.0
of rheumatological disorders. Many disease-modifying
+1.0 antirheumatic drugs (DMARDs) cause marrow toxicity
and require regular monitoring of the FBC.
BMD (g/cm2)
1.0 0.0
T-score
−1.0
Biochemistry
T
Routine biochemistry is useful for assessing metabolic
0.7 −2.0 bone disease, muscle diseases and gout. Several bone
Osteoporosis Z diseases, including Paget’s disease, renal bone disease
T-score −3.0 −3.0
Z-score −1.0
and osteomalacia, give a characteristic pattern that can
0.4 −4.0 be helpful diagnostically (Box 25.7). Serum levels of uric
20 40 60 80 acid are usually raised in gout but a normal level does
Age (years) not exclude it, especially during an acute attack, when
urate levels temporarily fall. Equally, an elevated serum
Fig. 25.8 Typical output from a dual energy X-ray absorptiometry
uric acid does not confirm the diagnosis, since most
(DEXA) scanner. A DEXA scan of the hip. B Bone mineral density
(BMD) values plotted in g/cm2 (left axis) and as the T-score values (right hyperuricaemic people never develop gout. Levels of
axis). The solid line represents the population average plotted against age, C-reactive protein (CRP) are a useful marker of infection
and the interrupted lines are ± 2 standard deviations from the average. and inflammation, and are more specific than the ESR.
The patient shown, aged 72, has an osteoporotic T-score of −3.0 but a An exception is in connective tissue diseases such as
Z-score of −1.0, which is within the ‘normal range’ for that age, reflecting systemic lupus erythematosus (SLE) and systemic scle-
the fact that bone is lost with age. rosis, where CRP may be normal but ESR raised in active
(ALP = alkaline phosphatase; N = normal; PTH = parathyroid hormone; single arrow = increased or decreased; double arrow = greatly increased or decreased)
1066
Investigation of musculoskeletal disease
Normal healthy people can be positive for rheumatoid factor. N.B. 5% of healthy individuals have an ANA titre > 1:80.
1067
RHEUMATOLOGY AND BONE DISEASE
*In children, both leukaemia and osteomyelitis may present with (CMC = carpometacarpal; DIP = distal interphalangeal; PIP = proximal
monoarthritis. interphalangeal)
1069
RHEUMATOLOGY AND BONE DISEASE
25 Clinical assessment
The hallmarks of inflammatory arthritis are early morn-
25.14 Extra-articular features of
inflammatory arthritis
ing stiffness and worsening of symptoms with inactiv- Clinical feature Disease association
ity, along with synovial swelling and tenderness on
Skin, nails and mucous membranes
examination. Clinical features in other systems can Psoriasis, nail pitting and Psoriatic arthritis
be helpful in determining the underlying cause (Box dystrophy
25.14). The most important diagnosis to consider is Raynaud’s phenomenon SLE, systemic
rheumatoid arthritis, which is characterised by sym- sclerosis
metrical involvement of the small joints of the hands Photosensitivity SLE
and feet, often in association with other joints. Viral Livedo reticularis SLE
arthritis should also be considered. This presents with Splinter haemorrhages, Vasculitis
an acute symmetrical inflammatory polyarthritis affect- nail-fold infarcts
ing small and large joints of upper and lower limbs, Oral ulcers SLE, reactive arthritis,
often with a rash. Behçet’s syndrome
The pattern of involvement can be helpful in reaching Large nodules (mainly extensor RA, gout
a diagnosis (Fig. 25.9). Asymmetry, lower limb pre- surfaces)
dominance and greater involvement of large joints are Clubbing Enteropathic arthritis,
characteristic of seronegative spondyloarthritis. Other metastatic lung cancer,
extra-articular features may also be present, giving a endocarditis
clue to the diagnosis. In psoriatic arthritis, the small Eyes
joints of the hand and feet are often affected, but Uveitis Seronegative
with involvement of the proximal and distal inter- spondyloarthritis
phalangeal (PIP and DIP) joints, as opposed to the meta- Conjunctivitis Reactive arthritis
carpophalangeal (MCP) and PIP joints in RA. The Episcleritis, scleritis RA, vasculitis
pattern of involvement also tends to be asymmetrical in Heart, lungs
psoriatic arthritis, and other clues such as nail pitting Pleuro-pericarditis SLE, RA
and a rash may be present. SLE can be associated with Fibrosing alveolitis RA, SLE, other connective
polyarthritis but more usually causes polyarthralgia and tissue disease
tenosynovitis (p. 1110). Abdominal organs
Hepatosplenomegaly RA, SLE
Investigations
Haematuria, proteinuria SLE, vasculitis, systemic
Blood samples should be taken for routine haematol- sclerosis
ogy, biochemistry, ESR, CRP, viral serology and an Urethritis Reactive arthritis
immunological screen, including ANA, RF and ACPA. Fever, lymphadenopathy Infection, systemic
Ultrasound examination or MRI may be required to juvenile idiopathic
confirm the presence of synovitis if this is not obvious arthritis
clinically.
A B C D
Fig. 25.9 Patterns of joint involvement in different forms of polyarthritis. A Rheumatoid arthritis typically targets the metacarpophalangeal and
proximal interphalangeal joints of the hands and metatarsophalangeal joints of the feet, as well as other joints, in a symmetrical pattern. B Psoriatic
arthritis targets proximal and distal interphalangeal joints of the hands and larger joints in an asymmetrical pattern. Sacroiliitis (often asymmetrical) may
occur. C Ankylosing spondylitis targets the spine, sacroiliac joints and large peripheral joints in an asymmetrical pattern. D Osteoarthritis targets the
1070 proximal and distal interphalangeal joints of the hands, first carpometacarpal joint at the base of the thumb, knees, hips, lumbar and cervical spine.
Presenting problems in musculoskeletal disease
25 Investigations
Radionuclide bone scanning is of value in patients sus-
25.18 Causes of low back pain
pected of having bone metastases and Paget’s disease, • Mechanical back pain • Spondylolysis (p. 1133)
along with further imaging as appropriate. Myeloma • Prolapsed intervertebral • Bone metastases
(p. 1046) should be excluded by plasma and urinary disc • Spondylolisthesis (p. 1133)
protein electrophoresis. If these results are positive, a • Osteoarthritis • Arachnoiditis
radiological skeletal survey should be performed, since • Vertebral fracture (p. 1071) • Scheuermann’s disease
the isotope bone scan may be normal in myeloma. • Spinal stenosis (p. 1130)
Routine biochemistry, vitamin D levels and PTH meas- • Paget’s disease
urement should be performed if osteomalacia is sus-
pected. In Paget’s disease, ALP may be elevated but can
be normal in localised disease. Laboratory investigations
consult their GP each year with back pain. The most
are normal in patients with fibromyalgia and benign
important causes are summarised in Box 25.18.
hypermobility.
Clinical assessment
Management
The main purpose of clinical assessment is to differenti-
Management should be directed towards the underlying ate the self-limiting disorder of acute mechanical back
cause. Chronic pain of unknown cause and that associ- pain from serious spinal pathology, as summarised in
ated with fibromyalgia responds poorly to analgesics Figure 25.10. Mechanical back pain is the most common
and NSAID, but may respond partially to antineuro- cause of acute back pain in people aged 20–55. This
pathic agents such as amitriptyline, duloxetine, gaba- accounts for more than 90% of episodes, and is usually
pentin and pregabalin. acute and associated with lifting or bending. It is exac-
erbated by activity and is generally relieved by rest (Box
25.19). It is usually confined to the lumbar–sacral region,
Back pain buttock or thigh, is asymmetrical, and does not radiate
beyond the knee (which would imply nerve root irrita-
Back pain is a common symptom that affects 60–80% of tion). On examination, there may be asymmetric local
people at some time in their lives. Although the preva- paraspinal muscle spasm and tenderness, and painful
lence has not increased, reported disability from back restriction of some but not all movements. Low back
pain has risen significantly in the last 30 years. In pain is more common in manual workers, particularly
Western countries, back pain is the most common cause those in occupations that involve heavy lifting and
of sickness-related work absence. In the UK, 7% of adults twisting. The prognosis is generally good. After 2 days,
Back pain
Clinical assessment
(Box 25.21)
Persistent pain
Fever/weight loss Nerve root pain Cauda equina
Inflammatory features persisting > 4 wks syndrome
Elbow pain
The most common causes are repetitive strain injury
affecting the lateral epicondyle (tennis elbow) and
medial epicondyle (golfer’s elbow) (Box 25.25). Manage-
ment is by rest, analgesics and topical or systemic
NSAID. Symptoms may also respond to local applica-
tion of glyceryl trinitrate patches. Local corticosteroid
injections may be required in resistant cases. Olecranon
bursitis can also follow local repetitive trauma but other
causes include infections, gout and RA.
25.28 Causes of proximal muscle pain 25.29 Core interventions for patients with
or weakness rheumatic diseases
Inflammatory Core
• Polymyositis • Inclusion body myositis • Education • Reduction of adverse
• Dermatomyositis • Polymyalgia rheumatica • Exercise mechanical factors
Endocrine (Ch. 20) Aerobic conditioning Pacing of activities
Strengthening Appropriate footwear
• Hypothyroidism • Cushing’s syndrome • Simple analgesia • Weight reduction if obese
• Hyperthyroidism • Addison’s disease
Other options
Metabolic (Ch. 16)
• Other analgesic drugs • Local corticosteroid injections
• Myophosphorylase • Carnitine deficiency Oral NSAIDs • Physical treatments
deficiency • Myoadenylate deaminase Topical agents Heat, cold, aids, appliances
• Phosphofructokinase deficiency Opioid analgesics • Surgery
deficiency • Osteomalacia (p. 1125) Amitriptyline • Coping strategies
• Hypokalaemia Gabapentin/pregabalin
Drugs/toxins • Disease-modifying
therapy
• Alcohol • Statins
• Cocaine • Penicillamine
• Fibrates • Zidovudine
Infections (Ch. 13) Simple and safe interventions should be tried first.
• Viral (HIV, cytomegalovirus, • Bacterial (Clostridium Symptoms and signs will change with time, so the plan
rubella, Epstein–Barr, echo) perfringens, staphylococci, requires regular review and re-adjustment. Effective
• Parasitic (schistosomiasis, tuberculosis, Mycoplasma) management may require the expertise of a variety of
cysticercosis, toxoplasmosis) health professionals, with a coordinated multidiscipli-
nary team approach.
Core interventions that should be considered for 25
everyone with a painful musculoskeletal condition
are listed in Box 25.29. There are also other non-
pharmacological and drug options, the choice depend-
PRINCIPLES OF MANAGEMENT OF ing largely on the nature and severity of the diagnosis.
MUSCULOSKELETAL DISORDERS
Although management of musculoskeletal disease Education and lifestyle interventions
depends on the underlying diagnosis, certain aspects of
management are common to many disorders. The Education
general aims of management are to: Patients must always be informed about the nature of
• educate the patient their condition and its investigation, treatment and
• control pain prognosis, as education can improve outcome. Informa-
• optimise function tion and therapist contact can reduce pain and disability,
• modify the disease process where this is improve self-efficacy and reduce the health-care costs
possible of many musculoskeletal conditions, including OA and
• identify and treat related comorbidity. RA. The mechanisms are unclear but in part may
These aims are interrelated and success in one area often result from improved adherence. Benefits are modest
benefits others. Successful management requires careful but potentially long-lasting, safe and cost-effective (Box
assessment of the person as a whole, as well as his 25.30). Education can be provided through one-to-one
or her musculoskeletal system. The management plan discussion, written literature, patient-led group educa-
should be individualised and patient-centred, should tion classes and interactive computer programs. Inclu-
involve all necessary members of the multidisciplinary sion of the patient’s partner or carer is often appropriate;
team, and should be agreed and understood by both the this is essential for childhood conditions but also helps
patient and involved practitioners. It must also take into in many chronic adult conditions, such as RA or
account: fibromyalgia.
• the person’s daily activity requirements, and work
and recreational aspirations Exercise
• risk factors and associations of the musculoskeletal Two types of exercise should be prescribed (Box 25.30):
condition (obesity, muscle weakness, non- • Aerobic fitness training can produce long-term
restorative sleep) reduction in pain and disability. It improves
• the person’s perceptions and knowledge of the well-being, encourages restorative sleep and
condition benefits common comorbidity such as obesity,
• medications and coping strategies already tried by diabetes, chronic heart failure and hypertension.
the patient • Local strengthening exercise for muscles that act
• comorbid disease and its therapy over compromised joints also reduces pain and
• the availability, costs and logistics of appropriate disability, with improvements in the reduced
evidence-based interventions. muscle strength, proprioception, coordination and 1077
RHEUMATOLOGY AND BONE DISEASE
n
Heredity
ili
Co
• Avoiding negative situations or activities that produce stress,
ty
and increasing pleasant activities that give satisfaction Gender/hormonal status
• Information and discussion to alter beliefs about and Obesity
perspectives on disease High bone mineral density
• Reducing or avoiding catastrophising and maladaptive pain
behaviour
• Imagery and distraction techniques for pain
• Expanding social contact and better use of social services Ageing
25 A B
25.37 Symptoms and signs of osteoarthritis
Pain
• Insidious onset over months or years
• Variable or intermittent over time (‘good days, bad days’)
• Mainly related to movement and weight-bearing, relieved
by rest
• Only brief (< 15 mins) morning stiffness and brief (< 5 mins)
‘gelling’ after rest
• Usually only one or a few joints painful
C
Clinical signs
• Restricted movement due to capsular thickening, or blocking
by osteophyte
• Palpable, sometimes audible, coarse crepitus due to rough
articular surfaces
• Bony swelling around joint margins
• Deformity, usually without instability
• Joint-line or periarticular tenderness
• Muscle weakness and wasting
• Synovitis mild or absent
Fig. 25.15 Pathological changes in osteoarthritis. A Abnormal
nests of proliferating chondrocytes (arrows) interspersed with matrix devoid
of normal chondrocytes. B Fibrillation of cartilage in OA. C Radiograph
The correlation between the presence of structural
of knee joint affected by OA, showing osteophytes at joint margin (white
arrows), subchondral sclerosis (black arrows) and subchondral cyst (open change, pain and disability varies markedly according
arrow). to site. It is stronger at the hip than the knee, and poor
at most small joints. Risk factors for pain and disability
may differ from those for structural change. At the knee,
Fibrocartilage is produced at the joint margin, which
for example, reduced quadriceps muscle strength and
undergoes endochondral ossification to form osteo-
adverse psychosocial factors (anxiety, depression) cor-
phytes. Bone remodelling and cartilage thinning slowly
relate more strongly with pain and disability than the
alter the shape of the OA joint, increasing its surface
degree of radiographic change.
area. Patients with OA also have higher BMD values at
Radiological evidence of OA is very common in
sites distant from the joint, and this is particularly related
middle-aged and older people, and the disease may
to osteophyte formation. The reason for this is not com-
coexist with other conditions, so it is important to remem-
pletely understood but it may reflect the fact that
ber that pain in a patient with OA may be due to another
common signalling pathways are involved in the regula-
cause. Generalised OA, knee OA, hip OA and spine OA
tion of bone and cartilage metabolism.
(spondylosis) will be considered individually.
The synovium undergoes variable degrees of hyper-
plasia, and inflammatory changes may sometimes be Generalised nodal OA
observed, although to a much lesser extent than in RA
and other inflammatory arthropathies. Osteochondral Characteristics of this common form of OA are shown
bodies commonly occur within the synovium, reflecting in Box 25.38. Some patients are asymptomatic whereas
chondroid metaplasia or secondary uptake and growth others develop pain, stiffness and swelling of one or
of damaged cartilage fragments. The outer capsule also more PIP joints of the hands from the age of about
thickens and contracts, usually retaining the stability of 40 years onward. Gradually, these develop postero-
the remodelling joint. The muscles surrounding affected lateral swellings on each side of the extensor tendon
joints commonly show evidence of wasting and non- that slowly enlarge and harden to become Heberden’s
specific type II fibre atrophy. (DIP) and Bouchard’s (PIP) nodes (Fig. 25.16). Typically,
each joint goes through a phase of episodic symptoms
(1–5 years) while the node evolves and OA develops.
Clinical features Once OA is fully established, symptoms may subside
and hand function often remains good. Affected joints
The main presenting symptoms are pain and functional are enlarged as the result of osteophyte formation and
restriction in a patient over the age of 45, but more
often over 60 years. The causes of pain in OA are not
completely understood but may relate to increased
25.38 Characteristics of generalised nodal
pressure in subchondral bone (mainly causing night
osteoarthritis
pain), trabecular microfractures, capsular distension and
low-grade synovitis, or may result from bursitis and • Polyarticular finger interphalangeal joint OA
enthesopathy secondary to altered joint mechanics. • Heberden’s (± Bouchard’s) nodes
Typical OA pain has the characteristics listed in Box • Marked female preponderance
• Peak onset in middle age
25.37. For many people, functional restriction of the
• Good functional outcome for hands
hands, knees or hips is an equal, if not greater, problem
• Predisposition to OA at other joints, especially knees
than pain. The clinical findings vary according to sever-
• Strong genetic predisposition
1082 ity but are principally those of joint damage.
Osteoarthritis
25
Hip OA
Hip OA most commonly targets the superior aspect of
the joint (Fig. 25.20). This is often unilateral at presenta-
tion, frequently progresses with superolateral migration
of the femoral head, and has a poor prognosis. The less
common central (medial) OA shows more central carti-
lage loss and is largely confined to women. It is often
bilateral at presentation and may associate with gener-
alised nodal OA. It has a better prognosis than superior
hip OA and progression to axial migration of the femoral
head is uncommon.
The hip shows the best correlation between symp-
toms and radiographic change. Hip pain is usually
maximal deep in the anterior groin, with variable radia-
tion to the buttock, anterolateral thigh, knee or shin. Fig. 25.21 X-ray of spine showing typical changes of
osteoarthritis. Cervical spondylosis showing disc space narrowing
Lateral hip pain, worse on lying on that side with ten-
between C6 and C7, osteophytes at the anterior vertebral body margins
derness over the greater trochanter, suggests secondary (arrows) and osteosclerosis at the apophyseal joints.
trochanteric bursitis. Common functional difficulties are
the same as for knee OA; in addition, restricted hip
abduction in women may cause pain on intercourse. Spine OA
Examination may reveal: The cervical and lumbar spine are predominantly tar-
• an antalgic gait geted by OA, then referred to as cervical spondylosis
• weakness and wasting of quadriceps and gluteal and lumbar spondylosis, respectively (Fig. 25.21). Spine
muscles OA may occur in isolation or as part of generalised OA.
• pain and restriction of internal rotation with the hip The typical presentation is with pain localised to the low
flexed – the earliest and most sensitive sign of hip back region or the neck, although radiation of pain to
OA; other movements may subsequently be the arms, buttocks and legs may also occur due to nerve
restricted and painful root compression. The pain is typically relieved by rest
• anterior groin tenderness just lateral to the femoral and worse on movement. On physical examination, the
pulse range of movement may be limited and loss of lumbar
• fixed flexion, external rotation deformity of the hip lordosis is typical. The straight leg-raising test or femoral
• ipsilateral leg shortening with severe joint attrition stretch test may be positive and neurological signs may
and superior femoral migration. be seen in the legs where there is complicating spinal
Although obesity is not a major risk factor for devel- stenosis or nerve root compression.
opment of hip OA, it is associated with more rapid
progression.
Early-onset OA
Unusually, typical symptoms and signs of OA may
present before the age of 45. In most cases, a single joint
is affected and there is a clear history of previous trauma.
C However, specific causes of OA need to be considered
N S in people with early-onset disease affecting several
O joints, especially those not normally targeted by OA,
rare causes need to be considered (Box 25.39). Kashin–
Beck disease is a rare form of OA that occurs in children,
O typically between the ages of 7 and 13, in some regions
25 Corticosteroid injections
Intra-articular corticosteroid injections are effective in
most provide life-long, pain-free function. However,
some 20% of patients are not satisfied with the outcome,
and a few experience little or no improvement in pain.
the treatment of knee OA and are also used for sympto-
matic relief in the treatment of OA at the first CMC joint.
The duration of effect is usually short but trials of serial CRYSTAL-INDUCED ARTHRITIS
corticosteroid injections every 3 months in knee OA
have shown efficacy for up to 1 year. A variety of crystals can deposit in and around joints
and cause an acute inflammatory arthritis, as well as a
Chondroitin and glucosamine
Chondroitin sulphate and glucosamine sulphate have
been used alone and in combination for the treatment of 25.42 Crystal-associated arthritis and deposition
knee OA. There is evidence from randomised controlled in connective tissue
trials that these agents can improve knee pain to a small Crystal Associations
extent (3–5%), as compared with placebo. Although Common
NICE did not consider these differences to be clinically Monosodium urate Acute gout
significant, the beneficial effects of paracetamol in knee monohydrate Chronic tophaceous gout
OA are equally small. Calcium pyrophosphate Acute ‘pseudogout’
dihydrate Chronic (pyrophosphate) arthropathy
Hyaluronan injections Chondrocalcinosis
In knee OA, intra-articular injection of one of several Basic calcium Calcific periarthritis
forms of hyaluronan (polymers of hyaluronate), usually phosphates Calcinosis
given as a course of weekly injections for 3–5 weeks, Uncommon
may give modest pain relief for several months. Cholesterol Chronic effusions in RA
However, evidence for efficacy is heterogeneous and the Calcium oxalate Acute arthritis in dialysis patients
expense of this treatment and the common requirement Extrinsic crystals/semi-
for serial injection mean that hyaluronan injections are crystalline particles
not recommended for OA by NICE. Synthetic crystals Acute synovitis
Plant thorns/sea Chronic monoarthritis, tenosynovitis
Disease-modifying therapies urchin spines
There are no licensed drugs that can halt the progression
of OA. Glucosamine sulphate was shown in one study
Solute excess
to slow the rate of radiological progression in knee OA
and to reduce the number of subjects who progressed to
[X] x [Y]
joint replacement but the study has been criticised on
methodological grounds. A recent randomised control-
led trial suggested that strontium ranelate might also be (pH) (Temperature)
(Pressure)
effective in reducing the rate of progression of knee OA
but it is not licensed for this indication. Nucleating
Tissue inhibitory
factors
Surgery factors
Gout
25
Gout is an inflammatory disease caused by deposition Renal excretion Intestinal excretion
(≅ 600 mg/day) (≅ 300 mg/day)
of monosodium urate monohydrate crystals in and
around synovial joints. Fig. 25.23 The uric acid pool. Origins and disposal of uric acid.
Epidemiology
The prevalence of gout varies between populations but 25.43 Causes of hyperuricaemia and gout
is approximately 1–2%, with a greater than 5 : 1 male
preponderance. It is the most common inflammatory Diminished renal excretion
arthritis in men and in older women. The risk of devel- • Increased renal tubular • Drugs
oping gout increases with age and with serum uric acid reabsorption* Thiazide and loop diuretics
(SUA) levels, which are normally distributed in the • Renal failure Low-dose aspirin
general population. Levels are higher in men, increase • Lead toxicity Ciclosporin
with age and are associated with body weight. Levels • Lactic acidosis Pyrazinamide
are higher in some ethnic groups (such as Maoris and • Alcohol
Pacific islanders). Hyperuricaemia is defined as an SUA Increased intake
level greater than 2 standard deviations above the mean
• Red meat • Offal
for the population. Gout has become more common over
• Seafood
recent years in parallel with increased longevity and the
higher prevalence of metabolic syndrome, of which Over-production of uric acid
hyperuricaemia is an integral component. Although • Myeloproliferative and • Inherited disorders
hyperuricaemia is an independent risk factor for hyper- lymphoproliferative disease Lesch–Nyhan syndrome
tension, vascular disease, renal disease and cardiovascu- • Psoriasis (HPRT mutations)
lar events, only a minority of hyperuricaemic people • High fructose intake Phosphoribosyl
develop gout. There is currently no evidence to support • Glycogen storage disease pyrophosphate synthetase
the use of urate-lowering therapy in patients with (p. 450) 1 mutations
asymptomatic hyperuricaemia.
*Usually genetically determined (see text).
(HPRT = hypoxanthine guanine phosphoribosyl transferase)
Pathophysiology
About one-third of the body uric acid pool is derived
from dietary sources and two-thirds from endogenous conversion of hypoxanthine to xanthine and then xan-
purine metabolism (Fig. 25.23). The concentration of uric thine to uric acid.
acid in body fluids depends on the balance between The causes of hyperuricaemia are shown in Box 25.43.
endogenous synthesis, and elimination by the kidneys In over 90% of patients, the main abnormality is reduced
(two-thirds) and gut (one-third). Purine nucleotide syn- uric acid excretion by the renal tubules, which impairs
thesis and degradation are regulated by a network of the body’s ability to respond to a purine load. In many
enzyme pathways. Xanthine oxidase catalyses the end cases, this is genetically determined and recent studies 1087
RHEUMATOLOGY AND BONE DISEASE
12 months in patients with chronic renal failure. Occa- prescribed with caution in old age. Local ice packs can
sionally, tophi may develop in the absence of previous also be used for symptomatic relief. Patients with recur-
acute attacks, especially in patients on thiazide therapy rent episodes can keep a supply of an NSAID and take
who have coexisting OA. it as soon as the first symptoms occur, continuing until
In addition to causing musculoskeletal disease, the attack resolves. Oral colchicine, which works by
chronic hyperuricaemia may be complicated by renal inhibiting microtubule assembly in neutrophils, is also
stone formation (p. 507) and, if severe, renal impairment very effective. It is usually given in doses of 0.5 mg twice
due to the development of interstitial nephritis as the or 3 times daily. The most common adverse effects are
result of urate deposition in the kidney. This is particu- nausea, vomiting and diarrhoea. Joint aspiration can
larly common in patients with chronic tophaceous gout give pain relief, and may be combined with an intra-
who are on diuretic therapy. articular steroid injection if the diagnosis is clear and
infection can be excluded. A short course of oral or intra-
Investigations muscular corticosteroids can also be highly effective in
The diagnosis of gout can be confirmed by the identifica- treating acute attacks.
tion of urate crystals in the aspirate from a joint, bursa Patients who have more than one acute attack within
or tophus (see Fig. 25.5A, p. 1064). In acute gout, syno- 12 months and those with complications should be
vial fluid shows increased turbidity due to the greatly offered urate-lowering therapy (Box 25.44). The long-
elevated cell count (> 90% neutrophils). In chronic gout, term therapeutic aim is to prevent attacks occurring by
the appearance is more variable but occasionally the bringing uric acid levels below the level at which mono-
fluid appears white due to the high crystal load. Between sodium urate monohydrate crystals form. A therapeutic
attacks, aspiration of an asymptomatic first MTP joint or target of 360 μmol/L (6 mg/dL) is recommended in the
knee may still reveal crystals. British Society of Rheumatology guidelines, whereas the
A biochemical screen, including renal function, uric European League Against Rheumatism guidelines rec-
acid, glucose and lipid profile, should be performed ommend a threshold of 300 μmol/L (5 mg/dL).
because of the association with metabolic syndrome. Allopurinol is the drug of first choice. It is a xanthine
Although hyperuricaemia is usually present, this does oxidase inhibitor, which reduces the conversion of
not confirm the diagnosis. Conversely, normal uric acid
levels during an attack do not exclude gout, as serum
hypoxanthine and xanthine to uric acid. The recom-
mended starting dose is 100 mg daily, or 50 mg in older
25
urate falls during the acute phase response. Elevated patients and in renal impairment. The dose of allopuri-
ESR and CRP and a neutrophilia are typical of acute nol should be increased by 100 mg every 4 weeks (50 mg
gout, and they return to normal as the attack subsides. in the elderly and those with renal impairment) until the
Tophaceous gout may be accompanied by a modest but target uric acid level is achieved, side-effects occur or the
chronic elevation in ESR and CRP. maximum recommended dose is reached (900 mg/day).
Radiographs are usually normal in acute gout but Acute flares of gout often occur following initiation of
well-demarcated erosions may be seen in patients with urate-lowering therapy. The patient should be warned
chronic or tophaceous gout (Fig. 25.26). Tophi may also about this and told to continue therapy, even if an attack
be visible on X-rays as soft tissue swellings. In late occurs. The risk of flares can be reduced by administra-
disease, destructive changes may occur similar to those tion of oral colchicine (0.5 mg twice daily) or NSAID
in other forms of advanced inflammatory arthritis. therapy for the first few months. In the longer term,
annual monitoring of uric acid levels is recommended.
Management In most patients, urate-lowering therapy needs to be
Oral NSAIDs are effective for pain relief in the acute continued indefinitely.
attack and are the standard treatment, but have to be Febuxostat is a xanthine oxidase inhibitor that is
useful in patients who fail to respond adequately to
allopurinol, and those in whom it is contraindicated or
has been poorly tolerated. It undergoes hepatic metabo-
lism and so no dose adjustment is required for renal
impairment. It is more effective than allopurinol at
reducing uric acid levels and, as a result, commonly
provokes attacks at the recommended starting dose
(80 mg daily). In view of this, treatment with colchicine
or NSAID should be considered for the initial 6 months.
Uricosuric drugs, such as probenecid or sulfinpyra-
zone, can be effective but require several doses each
day and maintenance of a high urine flow to avoid uric
erythematous joint with signs of a large effusion. Fever 25.47 Rheumatic diseases associated with
is common and the patient may appear confused and ill. basic calcium phosphate deposition
The knee is most commonly affected, followed by the
Disease Site of calcification
wrist, shoulder, ankle and elbow. Trigger factors include
trauma, intercurrent illness and surgery. Sepsis and gout Calcific periarthritis Tendons and ligaments
are the main differential diagnoses. Dermatomyositis and Subcutaneous tissue
Chronic arthropathy may also occur in association polymyositis
with CPPD crystal deposition disease, affecting the same Systemic sclerosis and Subcutaneous tissue
joints that are involved in acute pseudogout. The pres- CREST syndrome
entation is with chronic pain, early morning stiffness,
inactivity gelling and functional impairment. Acute Mixed connective tissue Subcutaneous tissue
attacks of pseudogout may be superimposed. Affected disease
joints usually show features of OA, with varying degrees Paget’s disease of bone Blood vessels
of synovitis. Effusion and synovial thickening are Ankylosing spondylitis Ligaments
usually most apparent at knees and wrists; wrist involve-
Fibrodysplasia ossificans Subcutaneous tissues and muscle
ment may result in carpal tunnel syndrome. Inflamma-
progressiva
tory features may be sufficiently pronounced to suggest
RA, but tenosynovitis and extra-articular involvement Milwaukee shoulder Tendons and ligaments
are absent, and large and medium rather than small syndrome
joints are targeted. Severe damage and instability of Albright’s hereditary Muscle
knees or shoulders may occasionally lead to considera- osteodystrophy
tion of a neuropathic joint, but no neurological abnor-
malities will be found. (CREST = calcinosis, Raynaud’s, oesophageal dysmotility, sclerodactyly,
telangiectasia)
Investigations
Examination of synovial fluid using compensated polar-
ised microscopy will demonstrate CPPD crystals (see
Fig. 25.5B, p. 1064) and permit distinction from gout. The
Pathophysiology 25
Under normal circumstances, inhibitors of mineralisa-
aspirated fluid is often turbid and may be uniformly tion, such as pyrophosphate and proteoglycans, inhibit
blood-stained, reflecting the severity of inflammation. calcification of soft tissues. When these protective mech-
Since sepsis and pseudogout can coexist, Gram stain anisms break down, abnormal calcification occurs. There
and culture of the fluid should be performed to are many causes (Box 25.47). In most situations, calcifica-
exclude sepsis, even if CPPD crystals are identified in tion is of no consequence, but when the crystals are
synovial fluid. released, an inflammatory reaction may be initiated,
X-rays of the affected joint may show evidence of causing local pain and inflammation.
calcification in hyaline cartilage and/or fibrocartilage,
although absence of calcification does not exclude the Calcific periarthritis
diagnosis. Signs of OA are frequently present. Screening
Deposition of BCP in tendons may result in an acute
for secondary causes (see Box 25.46) should be under-
inflammatory response. The most commonly affected
taken, especially in patients who present under the age
site is the supraspinatus tendon (Fig. 25.28) but other
of 25 and those with polyarticular disease.
sites may also be affected, including the tendons around
Management the hip, feet and hands. The presentation is with acute
pain, swelling and local tenderness that develops rapidly
Joint aspiration can often provide symptomatic relief in
pseudogout and sometimes no further treatment is
required. Patients with persistent symptoms can be
treated with intra-articular corticosteroids, colchicine
or NSAID. Since most patients with pseudogout are
elderly, NSAID must be used with caution. Early active
mobilisation is also important. Chronic pyrophosphate-
induced arthropathy should be managed as for OA
(p. 1085).
25 over 4–6 hours. The overlying skin may be hot and red,
raising the possibility of infection. Attacks sometimes 25.48 Predisposing factors for fibromyalgia
occur spontaneously but can also be triggered by trauma.
Modest systemic upset and fever are common. X-rays ‘Epidemiological studies show that widespread body pain,
fatigue, psychological distress and multiple hyperalgesic tender
show tendon calcification. If the affected joint or bursa
sites cluster together and associate with stressful life events.’
is aspirated, inflammatory fluid containing many
calcium-staining (alizarin red S) aggregates may be • Wolfe F, et al. Arthritis Rheum 1995; 38:19–28.
• Croft P, et al. BMJ 1994; 309:696–699.
obtained. During an acute attack, there may be a neu-
trophilia with an elevation in ESR and CRP. Routine
biochemistry is normal. Treatment is with analgesics
and NSAID. Attacks may also respond to a local injec- Regional pain Disease Anxiety
syndrome Illness Life crisis
tion of corticosteroid. The condition usually resolves
spontaneously over 1–3 weeks and this is often accom-
panied by dispersal and disappearance of small to
medium-sized BCP deposits on X-ray. Large deposits
sometimes accumulate, causing limitation of joint move- Sleep disturbance
ment, and may require surgical removal.
caudate and thalamus with an augmented processing they may be unable to perform tasks such as shopping
response on functional MRI; low basal free cortisol and or housework. They may have experienced major
reduction in evening trough; and altered descending difficulties at work or even retire because of pain
inhibition via the hypothalamic–pituitary–adrenal and and fatigue.
growth hormone somatomedin axes. Examination is unremarkable, apart from the pres-
ence of hyperalgesia on moderate digital pressure in
Clinical features multiple sites (Fig. 25.30). The tenderness can be quan-
The main presenting feature is widespread pain, which titated using metered dolorimeters but moderate digital
is often worst in the neck and back (Box 25.49). The pain pressure, enough just to whiten the nail, is sufficient for
is characteristically diffuse and unresponsive to analge- clinical diagnosis. Patients with other musculoskeletal
sics and NSAID. Physiotherapy often makes it worse. diseases can develop fibromyalgia and it is important to
Fatiguability, most prominent in the morning, is another determine to what extent symptoms are related to fibro-
major problem and disability is often marked. Although myalgia or a coexisting disease.
people can usually dress, feed and groom themselves,
Investigations and management
There are no abnormalities on routine blood tests or
25.49 Clinical features in fibromyalgia imaging, but it is important to screen for other condi-
tions that could contribute to some of the patient’s
Usual symptoms symptoms (Box 25.50).
• Multiple regional pain • Low affect, irritability, The aims of management are to educate the patient
• Marked fatigability weepiness about the condition, achieve pain control and improve
• Marked disability • Poor concentration, sleep. Wherever possible, education should include the
• Broken, non-restorative forgetfulness
sleep
Variable locomotor symptoms 25.50 Minimum investigation screen in
fibromyalgia
• Early morning stiffness
• Swelling of hands, fingers
• Numbness, tingling of all
fingers Test Condition screened 25
Additional, variable, non-locomotor symptoms Full blood count Anaemia, lymphopenia of SLE
• Non-throbbing bifrontal headache (tension headache) Erythrocyte sedimentation Inflammatory disease
• Colicky abdominal pain, bloating, variable bowel habit rate, C-reactive protein
(irritable bowel syndrome) Thyroid function Hypothyroidism
• Bladder fullness, nocturnal frequency (irritable bladder)
• Hyperacusis, dyspareunia, discomfort when touched Calcium, alkaline Hyperparathyroidism,
(allodynia) phosphatase osteomalacia
• Frequent side-effects with drugs (chemical sensitivity) Antinuclear antibodies SLE
Interspinous
ligaments L4/5
1 cm distal to
lateral epicondyle Mid-gluteal
Abatacept
T cell Blood
Co-stimulation vessel Vasculitis
Antigen Vasodilatation
presentation Immune
complexes
Dendritic cell Rituximab
IL-6 PGE
B cell
Macrophage IL-17 Co-stimulation Autoantibodies
T cell
IL-1
TH17 Synovial IL-6
TNF fibroblast
Acute phase
response Tocilizumab IL-6 Plasma
cell
Cartilage
erosion
Cartilage
Chondrocyte
Bone
Osteoclast
erosion Bone 25
Fig. 25.31 Pathophysiology of rheumatoid arthritis. Some of the cytokines and cellular interactions believed to be important in RA are shown, along
with the targets for currently available biological drugs. (ADAMTS5 = aggrecanase; IL = interleukin; MMP = matrix metalloproteinases; PGE = prostaglandin
E; TNF = tumour necrosis factor; RANKL = RANK ligand)
A B
neutropenia with RA (Box 25.56). Generalised and local 25.58 How to calculate the DAS28 score
lymphadenopathy affecting nodes draining actively
inflamed joints may both occur. Patients with persistent
lymphadenopathy should be biopsied since there is an
increased risk of lymphoma in patients with long-
standing RA.
Investigations
The diagnosis of RA is based on clinical grounds but
investigations are useful in confirming the diagnosis and
assessing disease activity (Box 25.57). The ESR and CRP
are usually raised but normal results do not exclude the
diagnosis. ACPA are positive in about 70% of cases and
are highly specific for RA, occurring in many patients
before clinical onset of the disease. Similarly RF is posi-
tive in about 70% of cases, many of whom also test posi-
tive for ACPA. Low titres of RF are found in about 10%
of the normal population and in other diseases (p. 1067).
Ultrasound examination and MRI are not routinely
required in patients with obvious clinical signs. Their
main value is in patients with symptoms suggestive of • Count the number of tender joints
an inflammatory arthritis, where there is uncertainty • Count the number of swollen joints
about the presence of synovitis. They are also a sensitive • Measure the ESR
means of detecting early erosions. Plain X-rays of the • Ask the patient to rate global activity of arthritis during the
hands, wrist and feet are of limited value in early RA past week from 0 (no symptoms) to 100 (very severe)
• Enter data into an online calculator1 or work out using a
but certain changes are characteristic, including peri-
formula2
articular osteoporosis and marginal joint erosions. The
main indication for X-ray is in the assessment of patients 1
www.4s-dawn.com/DAS28.
with problem joints to determine if significant structural 2
DAS28 = 0.56 × square root (tender joints) + 0.28 × square
damage has occurred. Patients who are suspected of root (swollen joints) + 0.70 × loge(ESR) + 0.014 (global activity
having atlanto-axial disease should have lateral X-rays score)
taken in flexion and extension, and the degree of
cord compression should be established with MRI. In
patients with Baker’s cyst, ultrasound may be required visual analogue scale, to generate a numerical score. The
to establish the diagnosis, since DVT and Baker’s cyst higher the value, the more active the disease (Box 25.58).
may coexist.
The DAS28 score is widely used to assess disease
activity, the response to treatment and the need for Management
biological therapy. It involves counting the number
of swollen and tender joints in the upper limbs The mainstay of treatment in RA comprises the early
and knees, and combining this with the ESR and the use of small-molecule disease-modifying antirheumatic
1100 patient’s assessment of his/her general health on a drugs (DMARDs), and corticosteroids for induction of
Rheumatoid arthritis
remission. There is evidence that early use of DMARD especially during the first trimester (Box 25.59). Patients
therapy improves clinical outcome in RA. Partial or non- who wish to become pregnant should be counselled to
response to DMARD therapy should prompt escalation stop DMARD treatment while they try to conceive. Since
of the dose or use of an additional DMARD, with pro- RA almost always undergoes remission during preg-
gression to biological drugs if necessary (Fig. 25.35). nancy, it is usually possible to manage the condition
Regular monitoring of DMARD therapy is essential without DMARD therapy over this period. Details of the
because of the risk of liver and haematological toxicity. dose regimens, toxicity and monitoring requirements
Some DMARDs are contraindicated in pregnancy, are shown in Box 25.60.
NS
ula
AID
Tocilizumab
discontinued for at least 3 months before trying to conceive.
-ar
Anti-TNF #2
an
• Paracetamol: the oral analgesic of choice during pregnancy.
a
ntr
da
• Oral NSAIDs and selective COX-2 inhibitors: can be used
di
na
an
Diagnosis of RA
cyclophosphamide, gold and penicillamine.
• Biological therapies: safety during pregnancy is currently
25
unclear.
Fig. 25.35 Management of early rheumatoid arthritis. See text for • Breastfeeding: methotrexate, leflunomide,
details of each drug. (DMARD = disease-modifying antirheumatic drug; cyclophosphamide, ciclosporin, azathioprine, sulfasalazine
NSAID = non-steroidal anti-inflammatory drug; TNF = tumour necrosis and hydroxychloroquine are contraindicated.
factor)
(BP = blood pressure; FBC = full blood count; LFT = liver function tests; U&E = urea and electrolytes)
1101
RHEUMATOLOGY AND BONE DISEASE
25 Disease-modifying antirheumatic
drugs
monthly. Penicillamine is given in a starting dose of
125–250 mg daily on an empty stomach, and increased
in 125-mg increments every 6 weeks until benefit occurs
Methotrexate or adverse effects develop. Ciclosporin A inhibits lym-
Methotrexate is the anchor DMARD in RA. It is usually phocyte division and activation. It is given in a dose of
given as a starting weekly oral dose of 7.5–10 mg and 150–300 mg/day with monitoring of blood pressure and
this is increased in 2.5 mg increments every 2–4 weeks renal function.
until benefit occurs or toxicity is limiting. The maximum
recommended dose is 25 mg. The benefits of methotrex- Corticosteroids
ate usually start to appear within 1–2 months but a Systemic corticosteroids have disease-modifying activ-
6-month course should be given before concluding that ity, but their primary role is in the induction of remis-
it has been ineffective. The most common adverse effects sion in patients with early RA who are starting synthetic
are nausea, vomiting and malaise within 24–48 hours of DMARD treatment. Various regimens have been used
administration. Patients who experience these can some- but there is little evidence to suggest that one is supe-
times be successfully treated with subcutaneous metho- rior to another. One strategy is to give a high dose of
trexate. Folic acid (5 mg/week) reduces the incidence oral prednisolone initially (60 mg daily) and to reduce
of adverse effects without reducing efficacy. Patients and stop this gradually over a period of 3 months as the
should be warned of drug interaction with sulphona- DMARD starts to take effect. Another is to employ low-
mides and to avoid excess alcohol, which enhances dose prednisolone (5–10 mg daily for 6–24 months) or
methotrexate hepatotoxicity. Acute pulmonary toxicity to give intramuscular injections of methylprednisolone
(pneumonitis) is rare but can occur at any time during or triamcinolone every 6–8 weeks. Intramuscular ster-
treatment. Patients should therefore be warned to seek oids are often used to treat flares of disease activity in
early advice if they develop any new respiratory symp- patients who are established on DMARD therapy. Intra-
toms. Methotrexate should be stopped immediately if articular corticosteroids are primarily indicated when
pneumonitis is suspected and high-dose steroids should there are one or two ‘problem joints’ with persistent
be given. synovitis despite good general control of the disease.
Although corticosteroids are very useful, they also
Sulfasalazine have significant adverse effects (p. 776). In the context
Sulfasalazine (SSZ) is widely used, both alone and in of RA, osteoporosis is probably the most important
combination with methotrexate and other drugs. The since this is a known complication of RA, even in the
mechanism of action is incompletely understood. absence of corticosteroid therapy. Accordingly DEXA
Nausea and gastrointestinal intolerance are the main scanning followed by bone protection should be consid-
adverse effects. The usual starting dose is 500 mg ered in any patient with RA who is expected to be on
daily, building up gradually to a maintenance dose of more than 7.5 mg prednisolone daily for more than
2–4 g/day. The patient should be warned of possible 3 months.
orange staining of urine and contact lenses. Monitoring
should be performed for liver and haematological Biological therapies
toxicity. The use of biological agents (often abbreviated to ‘bio-
logics’) is reserved for the treatment of patients who
Hydroxychloroquine have high disease activity despite having had an ade-
Hydroxycholoroquine is given in a dose of 400 mg daily, quate trial of traditional DMARDs. These agents are
usually in combination with other DMARDs. Ocular targeted towards specific cytokines and other cell-
toxicity can occur with long-term use due to retinal surface molecules regulating the immune response.
damage. It is usual to check visual acuity before starting Although generally well tolerated, biological therapies
treatment and to repeat this periodically whilst treat- increase the risk of serious infections due to suppression
ment is continued. of the immune response. Although biological treatment
is more effective than standard DMARD therapy, treat-
Leflunomide ment costs are significantly greater. Because of this,
Leflunomide can be used alone or in combination with many countries have set guidelines restricting their use.
other drugs. It works by inhibiting lymphocyte prolif- Current UK recommendations are that biological therapy
eration and activation. It is usually well tolerated and should be initiated only in active RA (DAS28 > 5.1;
has low marrow toxicity, but may cause liver dysfunc- p. 1100) when an adequate trial of at least two other
tion. The usual maintenance dose is 10–20 mg/day. It is DMARDs (including methotrexate) has failed. Details of
possible to give a loading dose of 100 mg on 3 consecu- the individual agents, their mechanisms of action and
tive days at the start of treatment, but this is seldom used their toxicity are shown in Box 25.61.
in routine clinical practice. Monitoring should be per-
formed for liver and haematological toxicity. Anti-TNF therapy
Anti-TNF therapy is the first-line biological drug in RA.
Gold, penicillamine and ciclosporin A Several agents are available, as summarised in Box 25.61.
These are only occasionally used due to the availability With the exception of infliximab, which must be pre-
of drugs with a better risk–benefit profile. Gold (sodium scribed with methotrexate to reduce the risk of neutralis-
aurothiomalate) is given by deep intramuscular injection ing antibodies developing, these agents can be used as
of 50 mg after an initial 10 mg test dose. Treatment is monotherapy. In clinical practice, however, most are
continued weekly for up to 6 months until benefit occurs, co-prescribed with methotrexate, as this is more effica-
1102 when the frequency is reduced to fortnightly and then cious. The main adverse effects are serious infections
Juvenile idiopathic arthritis
25
and reactivation of latent tuberculosis. There is evidence infections. It is generally used as second-line treatment
that TNF blockade can increase the risk of some malig- in patients who have failed to respond to anti-TNF
nancies, particularly basal cell carcinoma of the skin, and therapy, except in those who are intolerant of methotrex-
that it can accelerate progression of cancer in patients ate, in which case it is used as a first-line treatment.
with prior malignant disease. In contrast, the risk of
vascular disease in RA patients seems to be reduced by Anakinra
anti-TNF therapy. Anakinra is a decoy receptor for IL-1. It has some activ-
ity in RA but is seldom used since it appears to be less
Rituximab effective than other biological drugs.
Rituximab is an antibody directed against the CD20
receptor, which is expressed on B lymphocytes and Other treatments
immature plasma cells. It is given by two intravenous Surgery
infusions, 2 weeks apart, usually in combination with Synovectomy of the wrist or finger tendon sheaths of the
intravenous corticosteroid. It causes depletion of periph- hands may be required for pain relief or to prevent
eral and synovial B cells, which is sustained for several tendon rupture when medical interventions have failed.
months after administration. The treatment is repeated In later stages when joint damage has occurred, osteo-
usually when signs of improvement are wearing off tomy, arthrodesis or arthroplasty may be required (see
(anything from 6 months to 1 year). It is mostly used in Box 25.35, p. 1080).
the treatment of patients with resistant RA who have
failed to respond to TNF blockade. General measures
Abatacept The general principles outlined on page 1077 should be
followed. Physical rest, analgesics and NSAID may be
Abatacept is an agent in which the Fc domain of IgG is required to control symptoms. Passive exercises and
fused to the extracellular domain of CTLA4. It blocks the joint protection measures should be encouraged with
interaction between CD28 and CD80/86 that is required the aim of conserving function in affected joints. During
for full activation of T cells following antigen presenta- treatment, periodic assessment of disease activity, pro-
tion by dendritic cells or macrophages. Abatacept has a gression and disability is essential. In the vast majority,
good safety profile and is as efficacious as anti-TNF management is outpatient- or day patient-based, but
therapy in biological-naïve patients who fail to respond hospital admission can be helpful in patients with very
to conventional DMARD therapy. active disease for a period of bed rest, multiple joint
Tocilizumab injections, splinting, regular hydrotherapy, physio-
therapy and education.
This agent is an antibody directed against the IL-6 recep-
tor, and is licensed for the treatment of rheumatoid
arthritis. It prevents IL-6 activating its receptor within
the synovial membrane and in other tissues such as liver JUVENILE IDIOPATHIC ARTHRITIS
and muscle. It has similar efficacy to anti-TNF therapy
and is licensed for use as monotherapy or in combina- Inflammatory arthritis occurs rarely in children. Several
tion with methotrexate. Adverse effects include leuco- distinct subtypes are recognised (Box 25.62). Systemic
penia, hypercholesterolaemia and an increased risk of juvenile idiopathic arthritis (JIA; formerly known as 1103
RHEUMATOLOGY AND BONE DISEASE
A B
Fig. 25.36 X-ray changes in spondyloarthropathies. A Fine symmetrical marginal syndesmophytes typical of ankylosing spondylitis (arrow).
1106 B Coarse, asymmetrical non-marginal syndesmophytes typical of psoriatic/Reiter’s spondylitis (arrow).
Seronegative spondyloarthropathies
Reactive arthritis
Fig. 25.37 ‘Bamboo’ spine of severe late ankylosing spondylitis.
Reactive arthritis (previously known as Reiter’s disease)
25
Note the symmetrical marginal syndesmophytes (arrows), sacroiliac joint
fusion and generalised osteopenia. is predominantly a disease of young men, with a male
preponderance of 15 : 1. It is the most common cause
of inflammatory arthritis in men aged 16–35 but may
occur at any age. Between 1 and 2% of patients with
non-specific urethritis seen at genitourinary medicine
clinics have reactive arthritis (p. 415). Following an epi-
demic of Shigella dysentery, 20% of HLA-B27-positive
men developed reactive arthritis. Reactive arthritis may
present with the triad described in Box 25.68 but many
patients present with arthritis only.
Clinical features
The onset is typically acute, with an inflammatory
oligoarthritis that is asymmetrical and targets lower
limb joints, such as the knees, ankles, midtarsal and
MTP joints. It occasionally presents with single joint
Fig. 25.38 MRI appearances in sacroiliitis. Coronal MRI short T1
inversion recovery (STIR) sequence showing bilateral sacroiliitis in early
ankylosing spondylitis. Bone marrow oedema (circles) is present around
both sacroiliac joints, which show irregularities due to erosions (arrows). 25.68 Reiter’s disease
Classic triad*
The ESR and CRP are usually raised in active disease • Non-specific urethritis • Reactive arthritis
but may be normal. Testing for HLA-B27 can be helpful, • Conjunctivitis (~50%)
especially in patients with back pain suggestive of an
Additional extra-articular features
inflammatory cause, when other investigations have
yielded equivocal results. Autoantibodies such as RF, • Circinate balanitis • Nail dystrophy
ACPA and ANA are negative. (20–50%) • Buccal erosions (10%)
• Keratoderma
Management blennorrhagica (15%)
The aims of management are to relieve pain and stiff- Precipitated by
ness, maintain a maximal range of skeletal mobility and • Bacterial dysentery, mainly Salmonella, Shigella,
avoid the development of deformities. Education and Campylobacter or Yersinia
appropriate physical activity are the cornerstones of • Sexually acquired infection with Chlamydia
management. Early in the disease, patients should be
*Incomplete forms with just one or two of the classic triad are more
taught to perform daily back extension exercises, includ- frequent than the full syndrome.
ing a morning ‘warm-up’ routine, and to punctuate 1107
RHEUMATOLOGY AND BONE DISEASE
Life-threatening disease
High-dose corticosteroids and immunosuppressants are
required for the treatment of renal, CNS and cardiac ischaemia (Fig. 25.43). The peak age of onset is in the
involvement. A commonly used regimen is pulse fourth and fifth decades, and overall prevalence is 10–20
methylprednisolone (10 mg/kg IV), coupled with cyclo- per 100 000, with a 4 : 1 female preponderance. It is sub-
phosphamide (15 mg/kg IV), repeated at 2–3-weekly divided into diffuse cutaneous systemic sclerosis (DCSS:
intervals for six cycles. Cyclophosphamide may cause 30% of cases) and limited cutaneous systemic sclerosis
haemorrhagic cystitis, but the risk can be minimised (LCSS: 70% of cases). Many patients with LCSS have
by good hydration and co-prescription of mesna, features that are phenotypically grouped into the
which binds its urotoxic metabolites. Because of the ‘CREST’ syndrome (Calcinosis, Raynaud’s, oEsophageal
risk of azoospermia and anovulation (which may be per- involvement, Sclerodactyly and Telangiectasia). The
manent), pre-treatment sperm or ova collection and prognosis in DCSS is poor, with a 5-year survival of
storage need to be considered prior to treatment with approximately 70%. Features that associate with a poor
cyclophosphamide. prognosis include older age, diffuse skin disease, pro-
Mycophenolate mofetil has been used successfully in teinuria, high ESR, a low TLCO (gas transfer factor for
combination with high-dose steroids for renal involve- carbon monoxide) and pulmonary hypertension.
ment in SLE, with results equivalent to those of pulse Pathophysiology
cyclophosphamide but fewer adverse effects. The role of
The cause of systemic sclerosis is poorly understood.
belimumab in life-threatening SLE remains to be estab-
There is evidence for a genetic component, and associa-
lished since clinical trials of this agent excluded patients
tions with alleles at the HLA locus have been found. The
with renal and cerebral lupus.
disease occurs in all ethnic groups, and race may influ-
Maintenance therapy ence severity, since DCSS is significantly more common
Following control of the acute episode, the patient in black women than white. Isolated cases have been
should be switched to oral immunosuppressive medica- reported in which a systemic sclerosis-like disease has
tion. A typical regimen is to start oral prednisolone in a been triggered by exposure to silica dust, vinyl chloride,
dose of 40–60 mg daily on cessation of pulse therapy, hypoxyresins and trichloroethylene. There is clear evi-
gradually reducing to reach a target of 10–15 mg/day or dence of immunological dysfunction: T lymphocytes,
less by 3 months. Azathioprine (2–2.5 mg/kg/day), especially those of the Th17 subtype, infiltrate the skin
methotrexate (10–25 mg/week) or MMF (2–3 g/day) and there is abnormal fibroblast activation, leading to
should also be prescribed. The long-term aim is to con- increased production of extracellular matrix in the
tinue the lowest dose of corticosteroids and immuno- dermis, primarily type I collagen. This results in sym-
suppressant that will maintain remission. Cardiovascular metrical thickening, tightening and induration of the
risk factors, such as hypertension and hyperlipidaemia, skin (sclerodactyly). Arterial and arteriolar narrowing
should be controlled and patients advised to stop occurs due to intimal proliferation and vessel wall
smoking. inflammation. Endothelial injury causes release of vaso-
Lupus patients with the antiphospholipid antibody constrictors and platelet activation, resulting in further
syndrome (p. 1055) who have had previous thrombosis ischaemia, which is thought to exacerbate the fibrotic
require life-long warfarin therapy. process.
Clinical features
Systemic sclerosis Skin
Initially, there is non-pitting oedema of fingers and
Systemic sclerosis, or scleroderma, is a generalised dis- flexor tendon sheaths. Subsequently, the skin becomes
order of connective tissue affecting the skin, internal shiny and taut, and distal skin creases disappear. This is
organs and vasculature. It is characterised by sclero- accompanied by erythema and tortuous dilatation of
1112 dactyly in combination with Raynaud’s and digital capillary loops in the nail-fold bed, readily visible with
Connective tissue diseases
Investigations
Scleroderma is primarily a clinical diagnosis but various
laboratory abnormalities are characteristic. The ESR is
usually elevated and raised levels of IgG are common,
but CRP values tend to be normal unless there is severe
Fig. 25.44 Typical facial appearance in the CREST syndrome. organ involvement or coexisting infection. ANA is posi-
tive in about 70%, and approximately 30% of patients
with DCSS have antibodies to topoisomerase 1 (Scl-70).
an ophthalmoscope or dissecting microscope (and oil About 60% of patients with CREST syndrome have anti-
placed on the skin). The face and neck are usually centromere antibodies (p. 1068).
involved next, with thinning of the lips and radial fur-
rowing. In some patients, skin thickening stops at this Management
stage. Skin involvement restricted to sites distal to No treatments are available that halt or reverse the
the elbow or knee (apart from the face) is classified as fibrotic changes that underlie the disease. The focus of
‘limited disease’ or CREST syndrome (Fig. 25.44). management, therefore, is to ameliorate the effects of the
Involvement proximal to the knee and elbow and on the disease on target organs.
trunk is classified as ‘diffuse disease’. • Raynaud’s syndrome and digital ulcers. Raynaud’s
should be treated by avoidance of cold exposure
25
Raynaud’s phenomenon and use of mittens (heated mittens are available),
This is a universal feature and can precede other features supplemented if necessary with calcium
by many years. Involvement of small blood vessels in antagonists. Intermittent infusions of prostacyclin
the extremities may cause critical tissue ischaemia, may benefit severe digital ischaemia. The endothelin
leading to skin ulceration over pressure areas, localised 1 antagonist bosentan can be of value in promoting
areas of infarction and pulp atrophy at the fingertips. healing of digital ulcers. If these become infected,
antibiotics may be required, but as these penetrate
Musculoskeletal features tissues poorly in scleroderma, they need to be given
Arthralgia, morning stiffness and flexor tenosynovitis at higher doses for a longer duration than usual.
are common. Restricted hand function is due to skin • Oesophageal reflux should be treated with proton
rather than joint disease and erosive arthropathy is pump inhibitors and anti-reflux agents. Antibiotics
uncommon. Muscle weakness and wasting can occur may be required for bacterial overgrowth
due to myositis. syndromes, and metoclopramide or domperidone
may help patients with symptoms of
Gastrointestinal involvement pseudo-obstruction.
Smooth muscle atrophy and fibrosis in the lower two- • Hypertension should be treated aggressively
thirds of the oesophagus lead to reflux with erosive with ACE inhibitors, even if renal impairment is
oesophagitis. Dysphagia and odynophagia may also present.
occur. Involvement of the stomach causes early satiety • Joint involvement may be treated with analgesics
and occasionally outlet obstruction. Recurrent occult and/or NSAID. If synovitis is present,
upper gastrointestinal bleeding may indicate a ‘water- immunosuppressants such as methotrexate can also
melon’ stomach (antral vascular ectasia), which occurs be of value.
in up to 20% of patients. Small intestine involvement • Pulmonary hypertension may be treated with
may lead to malabsorption due to bacterial overgrowth bosentan. In selected patients, heart–lung
and intermittent bloating, pain or constipation. Dilata- transplantation may be considered. Corticosteroids
tion of large or small bowel due to autonomic neu- and cytotoxic drugs are indicated in patients who
ropathy may cause pseudo-obstruction with nausea, have coexisting myositis or fibrosing alveolitis.
vomiting, abdominal discomfort and distension, often
worse after food.
Mixed connective tissue disease
Pulmonary involvement
This is a major cause of morbidity and mortality. Pulmo- Mixed connective tissue disease (MCTD) is a condition
nary hypertension complicates long-standing disease in which the clinical features of SLE, systemic sclerosis
and is six times more prevalent in LCSS than in DCSS. and myositis may all occur in the same patient. It most
It presents with rapidly progressive dyspnoea (more commonly presents with synovitis and oedema of the
rapid than interstitial lung disease), right heart failure hands, in combination with Raynaud’s phenomenon
and angina, often in association with severe digital and muscle pain or weakness. Most patients have 1113
RHEUMATOLOGY AND BONE DISEASE
25 Behçet’s syndrome
Giant cell arteritis
Polyangiitis with
granulomatosis
Takayasu’s arteritis
Kawasaki disease
Churg–Strauss
syndrome
Microscopic
polyangiitis
Polyarteritis nodosa
Cryoglobulinaemic
vasculitis
Henoch-Schönlein
Behçet’s syndrome purpura
25 DISEASES OF BONE
differentiate into osteoblasts and an increase in their
ability to differentiate into adipocytes.
Peak bone mass and bone loss are regulated by
Osteoporosis both genetic and environmental factors. Genetic factors
account for up to 80% of the population variance in peak
Osteoporosis is the most common bone disease and bone mass and other determinants of fracture risk, such
affects millions of people worldwide. Fractures related as bone turnover and bone size. Polymorphisms have
to osteoporosis are estimated to affect around 30% of been identified in several genes that contribute to the
women and 12% of men in developed countries, and are pathogenesis of osteoporosis and many of these are in
a major public health problem. In the UK alone, fractures the RANK and Wnt signalling pathways, which play a
are sustained by over 250 000 individuals annually, with critical role in regulating bone turnover (see Fig. 25.2,
treatment costs of about £1.75 billion. Osteoporotic frac- p. 1061). However, these account for only a small propor-
tures can affect any bone, but the most common sites are tion of the genetic contribution to osteoporosis and many
the forearm (Colles fracture), spine (vertebral fracture) additional genetic variants remain to be discovered.
and hip (Fig. 25.51). Of these, hip fractures are the most Environmental factors, such as exercise and calcium
serious. Their immediate mortality is about 12% and intake during growth and adolescence, are important in
there is a continued increase in mortality of about 20% maximising peak bone mass and in regulating rates of
when compared with age-matched controls. Treatment post-menopausal bone loss. Smoking has a detrimental
of hip fracture accounts for the majority of the health- effect on bone mineral density (BMD) and is associated
care costs associated with osteoporosis. with an increased fracture risk, partly because female
The defining feature of osteoporosis is reduced bone smokers have an earlier menopause than non-smokers.
density, which causes a micro-architectural deteriora- Heavy alcohol intake is a recognised cause of osteoporo-
tion of bone tissue and leads to an increased risk of sis and fractures, but moderate intake does not substan-
fracture. The prevalence of osteoporosis increases tially alter risk.
with age, reflecting the fact that bone density declines
with age, especially in women (Fig. 25.52). The age- Post-menopausal osteoporosis
related decline in bone mass is accompanied by an This is the most common cause of osteoporosis because
increased risk of fractures (Fig. 25.53). This is due in of the effects of oestrogen deficiency, as described above.
part to the fall in bone density, but more importantly, Early menopause (below the age of 45 years) is a particu-
to the increased risk of falling, which increases with age larly important risk factor.
(p. 172).
Male osteoporosis
Pathophysiology Osteoporosis is less common in men and a secondary
Osteoporosis occurs because of a defect in attaining peak cause can be identified in about 50% of cases. The
bone mass and/or because of accelerated bone loss. In most common are hypogonadism, corticosteroid use
normal individuals, bone mass increases during skeletal (see below) and alcoholism. In hypogonadism, the
growth to reach a peak between the ages of 20 and pathogenesis is as described for post-menopausal osteo-
40 years but falls thereafter (see Fig. 25.52). In women porosis, as testosterone deficiency results in an increase
there is an accelerated phase of bone loss after the meno- in bone turnover and uncoupling of bone resorption
pause due to oestrogen deficiency, which causes uncou- from bone formation. Genetic factors are probably
pling of bone resorption and bone formation, such that important in the 50% of cases with no identifiable cause.
the amount of bone removed by osteoclasts exceeds the
rate of new bone formation by osteoblasts. Age-related Corticosteroid-induced osteoporosis
bone loss is a distinct process that accounts for the This is an important cause of osteoporosis that relates to
gradual bone loss that occurs with advancing age in both dose and duration of corticosteroid therapy. Although
genders. Bone resorption is not particularly increased there is no ‘safe’ dose of corticosteroid, the risk increases
but bone formation is reduced and fails to keep pace when the dose of prednisolone exceeds 7.5 mg daily and
with bone resorption. Accumulation of fat in the bone is continued for more than 3 months. Corticosteroids
marrow space also occurs because of an age-related have adverse effects on calcium metabolism and bone
decline in the ability of bone marrow stem cells to cell function. A key abnormality is reduced bone
A B C
1120 Fig. 25.51 Osteoporotic fractures: X-rays. A Wrist (Colles fracture). B Spine. C Hip.
Diseases of bone
A
+1.0
25.75 Secondary causes of osteoporosis and
osteoporotic fractures
Endocrine disease
Bone density T-score
0
Normal • Hypogonadism • Hyperparathyroidism
–1.0
• Hyperthyroidism • Cushing’s syndrome
Inflammatory disease
Osteopenia
–2.0 • Inflammatory bowel disease • RA
• Ankylosing spondylitis
–3.0 Osteoporosis Drugs
• Corticosteroids • Thiazolidinediones
• Gonadotrophin-releasing • Sedatives
0 20 40 60 80 hormone (GnRH) agonists • Anticonvulsants
• Aromatase inhibitors • Alcohol intake > 3 U/day
B • Thyroxine over-replacement • Heparin
Gastrointestinal disease
• Malabsorption • Chronic liver disease
Lung disease
• Chronic obstructive • Cystic fibrosis
pulmonary disease
Normal Osteoporosis Miscellaneous
Fig. 25.52 Changes in bone mass and microstructure with age. • Myeloma • Systemic mastocytosis
A Changes in bone mass with age in men (blue line) and women (red • Homocystinuria • Immobilisation
line). B Scanning electron micrographs of normal bone (left) and Body mass index < 18
25
• Anorexia nervosa* •
osteoporotic bone (right). • Highly trained athletes* • Heavy smokers
• HIV infection • Autoantibodies to
Women Men • Gaucher’s disease osteoprotegerin (OPG)
Fractures/100000 person-years
3000
Hip
Spine *Hypogonadism also plays a role in osteoporosis associated with these
Wrist conditions.
2000
25 Clinical features
Patients with osteoporosis are asymptomatic until a frac-
with an elevated 10-year fracture risk as defined by a
fracture risk assessment tool (websites listed on p. 1135).
Figure 25.54 provides an algorithm for the investigation
ture occurs. Osteoporotic spinal fracture may present
of patients with suspected osteoporosis based on clinical
with acute back pain or gradual onset of height loss and
risk factors, fracture risk assessment and DEXA.
kyphosis with chronic pain. The pain of acute vertebral
A history should be taken to identify any predispos-
fracture can occasionally radiate to the anterior chest or
ing causes, such as early menopause, excessive alcohol
abdominal wall and be mistaken for a myocardial infarc-
intake, smoking and corticosteroid therapy. Signs of
tion or intra-abdominal pathology, but worsening of
endocrine disease, neoplasia and inflammatory disease
pain by movement and local tenderness both suggest
should be sought on clinical examination. A falls history
vertebral fracture. Peripheral osteoporotic fractures
should be taken and a ‘get up and go’ test performed,
present with local pain, tenderness and deformity, often
especially in older patients (p. 167). Renal function, liver
after an episode of minimal trauma. In patients with hip
function, thyroid function, immunoglobulins and ESR,
fracture, the affected leg is shortened and externally
with screening for coeliac disease (anti-tissue trans-
rotated. Many patients present with incidental osteo-
glutaminase (tTG) antibodies), should be performed.
penia on an X-ray performed for other reasons.
Serum 25(OH) vitamin D and PTH measurements are
Investigations useful to exclude vitamin D deficiency and secondary
hyperparathyroidism. Primary hyperparathyroidism
The pivotal investigation is dual energy X-ray absorptio-
should be suspected if hypercalcaemia is present
metry (DEXA) at the lumbar spine and hip (see Fig. 25.8,
(p. 769). Levels of sex hormones and gonadotrophins
p. 1066). This should be considered in patients with clini-
should be measured in men with osteoporosis and
cal risk factors for osteoporosis (Box 25.76), and those
women under the age of 50. Transiliac bone biopsy is
sometimes required in early-onset osteoporosis of
unknown cause or when coexisting osteomalacia is
25.76 Indications for bone densitometry suspected.
Fig. 25.54 Algorithm for the investigation of patients with suspected osteoporosis. *Using FRAX® or QFracture (see Further information,
1122 p. 1135). (BMD = bone mineral density)
Diseases of bone
Drug treatment male osteoporosis but neither has been shown to prevent
Several drugs have been shown to reduce the risk of non-vertebral fractures in men. Ibandronate is some-
osteoporotic fractures in randomised controlled trials. times used but the evidence for prevention of non-
Their effects on vertebral and non-vertebral fracture are vertebral fractures is less robust. Zoledronic acid is
also summarised in Box 25.77. effective in the treatment of post-menopausal osteoporo-
Drug treatment should be considered in patients sis, corticosteroid-induced osteoporosis and osteoporo-
with BMD T-score values below −2.5 or below −1.5 in sis in men. It reduces the risk of vertebral fracture by
corticosteroid-induced osteoporosis, because there is about 75% with similar effects to alendronic acid on non-
evidence that fractures occur at a higher BMD value in vertebral fractures. It is especially useful for secondary
steroid users and that drugs prevent fracture in patients prevention of fractures in elderly patients with hip frac-
with T-scores at this level. Treatment should also be ture and reduces mortality in this group, being the only
considered in patients with vertebral fractures, irre- treatment that has been shown to modify this. Etidro-
spective of BMD, unless they resulted from significant nate reduces the risk of vertebral fracture but the effects
trauma. on non-vertebral fracture are less robust than those of
other bisphosphonates. It is now seldom used.
Oral bisphosphonates are poorly absorbed from the
Bisphosphonates gastrointestinal tract and should be taken on an empty
Bisphosphonates inhibit bone resorption by binding to stomach with plain water; no food should be eaten
hydroxyapatite crystals on the bone surface. When for 30–45 minutes after administration. Upper gastro-
osteoclasts attempt to resorb bone that contains bisphos- intestinal upset occurs in about 5% so oral bisphospho-
phonate, the drug is released within the cell, where it nates should be used with caution in patients with
inhibits key signalling pathways that are essential for existing gastro-oesophageal reflux disease. They should
osteoclast function. Although bisphosphonates prima- be avoided in patients with oesophageal stricture or
rily target the osteoclast, bone formation is also sup- achalasia, since tablets may stick in the oesophagus,
pressed because of coupling between bone formation causing ulceration and perforation. The most common
and bone resorption and an inhibitory effect on osteo- adverse effect with intravenous bisphosphonates is a
blasts. However, the balance of effect on bone turnover
is favourable, resulting in a gain in bone density due
transient influenza-like illness characterised by fever,
malaise, anorexia and generalised aches, which occurs
25
partly to increased mineralisation of bone. Bisphospho- 24–48 hours after administration. This is self-limiting but
nate treatment typically leads to an increase in spine can be treated with paracetamol or NSAID if necessary.
BMD of about 5–8% and in hip BMD of 2–4% during the It predominantly occurs after the first exposure and tol-
first 3 years of treatment and plateaus thereafter. erance develops thereafter. Other adverse effects are
Alendronic acid is the bisphosphonate used most fre- shown in Box 25.78. Osteonecrosis of the jaw (ONJ) is
quently. It reduces risk of vertebral fractures by 40% and characterised by the presence of necrotic bone in the
non-vertebral fractures by about 25% in postmenopausal mandible or maxilla, typically occurring after tooth
women with osteoporosis. Risedronate is an alternative extraction when the socket fails to heal. Most ONJ cases
with similar efficacy, but may be better tolerated in have occurred in cancer patients with coexisting mor-
patients with a history of gastrointestinal upset. Both bidity, such as infection and diabetes, who have received
drugs are effective in the treatment of corticosteroid- high doses of intravenous bisphosphonates; this compli-
induced osteoporosis. They can also be used to treat cation is very rare in patients who are treated with the
(+ effective, – not effective; +/– equivocal results, or efficacy based on post-hoc subgroup analysis of clinical trials.)
1123
RHEUMATOLOGY AND BONE DISEASE
modest increase in BMD (2%) and a 40% reduction in vertebral osteoporosis) and documenting the occurrence
vertebral fractures, but does not influence the risk of of clinical fractures.
non-vertebral fracture and can provoke muscle cramps
and worsen hot flushes. It increases the risk of VTE to a Surgery
similar extent as HRT but reduces the risk of breast Orthopaedic surgery is frequently required to reduce
cancer; it does not influence the risk of cardiovascular and stabilise osteoporotic fractures. Patients with intra-
disease. Bazedoxifene is a related SERM that has similar capsular fracture of the femoral neck generally require
effects to raloxifene. Tibolone is a steroid that has partial hemi-arthroplasty or total hip replacement in view of the
agonist activity at oestrogen, progestogen and androgen high risk of avascular necrosis.
receptors. It has similar effects on BMD to raloxifene and
has been found to prevent vertebral and non-vertebral Vertebroplasty and kyphoplasty
fractures in post-menopausal osteoporosis. Treatment is Vertebroplasty (VP) is sometimes used in the treatment
associated with a slightly increased risk of stroke but a of painful vertebral compression fractures. It involves
reduced risk of breast cancer. injecting methyl methacrylate (MMA) into the affected
vertebral body. Although VP has been found to give
Other drugs better pain relief than medical therapy in the short term,
Calcitonin is an osteoclast inhibitor that has weak anti- recent randomised controlled trials that compared VP
fracture efficacy but is no longer used in the treatment with a sham procedure showed no benefit (Box 25.80),
of osteoporosis because of concerns about an increased indicating that the reduction in pain may be a placebo
risk of cancer with long-term use. It is occasionally used response. Kyphoplasty (KP) is used under similar cir-
(unlicensed) in the short-term treatment of patients with cumstances but in this case a needle is introduced into
acute vertebral fracture, when it is given by subcutane- the affected vertebral body and a balloon is inflated,
ous or intramuscular injection (100–200 U daily). Calci- which is then filled with MMA. This procedure is more
triol (1,25(OH)2D3), the active metabolite of vitamin D, effective than medical treatment at relieving pain in the
is licensed for treatment of osteoporosis, but it is seldom short term, with results similar to VP. The effects of KP
used since the data on fracture prevention are less robust have not so far been compared with a sham procedure.
than for other agents. Both procedures are generally safe but serious adverse
effects include spinal cord compression, and fat embolus
25
Duration of therapy and may occur.
monitoring response
Oral bisphosphonates are usually given on a long-term 25.80 Vertebroplasty in painful vertebral
basis for osteoporosis with periodic review of the fractures
continued need for therapy at 5-yearly intervals. The ‘Meta-analysis of individual patient data from two placebo
evidence base on duration of treatment is limited. Alen- controlled trials of vertebroplasty showed no advantage of active
dronate and risedronate appear to be safe and effective treatment over a sham procedure.’
for up to 10 years in most patients, although one ran-
domised trial with alendronate showed that overall frac- • Staples MP, et al BMJ 2011; 343:d3952.
fragility and fractures. Rickets is the equivalent syn- orchestrated by the parathyroid glands. When vitamin
drome in children and is characterised by enlargement D levels fall – for example, as the result of reduced sun-
of the growth plate and bone deformity. The disease light exposure or dietary lack – 25(OH)D and 1,25(OH)2D
remains prevalent in frail older people who have a poor levels also fall, resulting in a reduction in calcium
diet and limited sunlight exposure, and in some Muslim absorption from the gut. This causes serum calcium
women who live in northern latitudes. There are four levels to fall, and this is detected by calcium-sensing
main causes of osteomalacia and rickets (Box 25.81). receptors on the parathyroid chief cells, which respond
by secreting parathyroid hormone (PTH). The raised
Vitamin D deficiency levels of PTH restore calcium levels to normal by stimu-
The most common cause of osteomalacia and rickets is lating production of 1,25(OH)2D, reducing renal calcium
vitamin D deficiency, which can result from either lack excretion and increasing bone resorption. Renal phos-
of sunlight exposure, from which the majority of vitamin phate excretion also increases, lowering serum phos-
D is derived; dietary deficiency (Fig. 25.55); or malab- phate levels. Initially, these changes are effective in
sorption of vitamin D in patients with gastrointestinal maintaining normal levels of serum calcium but, with
disease. prolonged vitamin D deficiency, reserves of 25(OH)D
become progressively depleted (through increased
Pathophysiology conversion of 25(OH)D to 1,25(OH)2D), leading to
The source of vitamin D and pathways involved in hypocalcaemia and hypocalcaemia with progressive
regulating its metabolism are shown in Figure 25.55. In demineralisation of the skeleton and the clinical syn-
normal individuals, vitamin D (also known as cholecal- dromes of osteomalacia and rickets.
ciferol) comes from two sources: about 70% is made in
the skin from 7-dehydrocholesterol under the influence Clinical features
of ultraviolet light, whereas the remaining 30% is Vitamin D deficiency in children causes delayed devel-
derived from the diet. On entering the circulation, opment, muscle hypotonia, craniotabes (small unossi-
vitamin D is hydroxylated in the liver to form 25(OH) fied areas in membranous bones of the skull that yield
vitamin D and this is further hydroxylated in the kidney to finger pressure with a cracking feeling), bossing of the
to form 1,25(OH)2D, the biologically active metabolite. frontal and parietal bones and delayed anterior fonta-
The 1,25(OH)2D primarily acts on the gut to increase nelle closure, enlargement of epiphyses at the lower end
intestinal calcium absorption but also acts on the of the radius, and swelling of the rib costochondral junc-
skeleton to stimulate bone remodelling. Synthesis of tions (‘rickety rosary’). Osteomalacia in adults presents
1126 1,25(OH)2D is regulated by a negative feedback loop insidiously. Mild osteomalacia can be asymptomatic or
Diseases of bone
Sunlight
Calcium-sensing Parathyroids
Oral Parathyroid receptor
intake chief cell
Ca2+
–ve Ca2+
Ca2+ –ve feedback
PTH
Skin secretory
granules PTH
~30% ~70%
PTH
Vitamin D Kidney Bone
Liver
Vitamin D 25(OH)
25-hydroxylase 25(OH) 1,25(OH) 2
vitamin D vitamin D vitamin D
(inactive) 1α-hydroxylase (active)
Gut
Serum Serum
phosphate↓ calcium↑
Fig. 25.55 Vitamin D metabolism. There is close interaction between vitamin D, serum calcium and parathyroid hormone (PTH). See text for details. 25
present with fractures and mimic osteoporosis. More A
severe osteomalacia presents with muscle and bone
pain, general malaise and fragility fractures. Proximal
muscle weakness is prominent and the patient may walk
with a waddling gait and struggle to climb stairs or get
out of a chair. There may be bone and muscle tenderness
on pressure and focal bone pain can occur due to fissure
fractures of the ribs and pelvis.
Investigations
The diagnosis can usually be made on a biochemical
screen with measurement of serum 25(OH)D and PTH.
Typically, serum ALP levels are raised, 25(OH)D levels
are low or undetectable, and PTH is elevated. Serum
B
calcium and phosphate levels may also be low but
normal values do not exclude the diagnosis. X-rays are
normal until advanced disease, when focal radiolucent
areas (pseudofractures or Looser’s zones) may be seen
in ribs, pelvis and long bones (Fig. 25.56A). Radiographic
osteopenia is common and the presence of vertebral
crush fractures may cause confusion with osteoporosis.
In children, there is thickening and widening of the
epiphyseal plate. Radionuclide bone scan can show
multiple hot spots in the ribs and pelvis at the site of
fractures and the appearance may be mistaken for Fig. 25.56 Osteomalacia. A X-ray of the pelvis showing Looser’s
metastases. Where there is doubt, the diagnosis can be zones (arrow). B Photomicrograph of bone biopsy from osteomalacic
confirmed by bone biopsy, which shows the pathogno- patient showing thick osteoid seams (stained light blue) that cover almost
monic features of increased thickness and extent of all of the bone surface. Calcified bone is stained dark blue.
osteoid seams (Fig. 25.56B).
Management fall to within the reference range as the bone disease
Osteomalacia and rickets respond promptly to treatment heals. After 3–4 months, treatment can generally be
with vitamin D (250–1000 μg daily), with rapid clinical stopped or the dose of vitamin D reduced to a mainte-
improvement, an elevation in serum 25(OH)D and a nance level of 10–20 μg of cholecalciferol daily, except in
reduction in PTH. Serum ALP levels sometimes rise ini- patients with underlying disease such as malabsorption,
tially as mineralisation of bone increases, but eventually in whom higher doses may be required. 1127
RHEUMATOLOGY AND BONE DISEASE
A B
Fig. 25.57 Paget’s disease. A Isotope bone scan from a patient with Paget’s disease, illustrating the intense tracer uptake and deformity of the
affected femur. B The typical radiographic features with expansion of the femur, alternating areas of osteosclerosis and radiolucency of the trochanter,
and pseudofractures breaching the bone cortex (arrows). 1129
RHEUMATOLOGY AND BONE DISEASE
secondary OA, which may cause back pain. Occasion- thrive, delayed dentition, cranial nerve palsies (due to
ally, the vertebral deformity and kyphosis can be mis- absent cranial foramina), blindness, anaemia and recur-
taken for osteoporotic vertebral fractures during adult rent infections due to bone marrow failure. The adult-
life, but this can be excluded by DEXA examination, onset type (Albers–Schönberg disease) shows autosomal
which typically shows normal or raised BMD values in dominant inheritance and presents with bone pain,
Scheuermann’s disease. cranial nerve palsies, osteomyelitis, OA or fracture, or
is sometimes detected as an incidental radiographic
Polyostotic fibrous dysplasia finding. The responsible mutations either affect the
This is an acquired disorder caused by mutations in the genes that regulate osteoclast differentiation (RANK,
GNAS1 gene, characterised by focal or multifocal bone RANKL), causing ‘osteoclast-poor’ osteopetrosis, or
pain, bone deformity and expansion, and pathological affect the genes involved in bone resorption, causing
fractures. Associated features include endocrine dys- ‘osteoclast-rich’ osteopetrosis. These include mutations
function, especially precocious puberty, and café-au-lait in the TCIRG1 gene, which encodes a component of the
skin pigmentation (McCune–Albright syndrome). The osteoclast proton pump, and mutations in the CLCN7
diagnosis is made by imaging, which shows focal, pre- gene, which encodes the osteoclast chloride pump.
dominantly osteolytic lesions and bone expansion Management is difficult. IFN-γ treatment can improve
on X-ray, and focal increased uptake on bone scan. blood counts and reduce frequency of infections, but in
The condition can resemble Paget’s disease of bone but severe cases haematopoietic stem cell transplantation is
the earlier age of onset and pattern of involvement required to provide a source of osteoclasts that resorb
are usually distinctive. Management is symptomatic. bone normally.
Surgery is sometimes required for treatment of fracture
and deformity. Very rarely, malignant change can occur Sclerosing bone dysplasias
and should be suspected if there is a sudden increase in These are rare diseases characterised by osteosclerosis
pain and swelling. There is limited evidence that intra- and increased bone formation. Van Buchem’s disease
venous pamidronate may help bone pain and promote and sclerosteosis are recessive disorders caused by loss-
healing of lytic lesions. of-function mutations in the SOST gene (see Fig. 25.2,
Osteogenesis imperfecta
p. 1061). The resulting lack of sclerostin causes increased
bone formation and bone overgrowth, leading to
25
Osteogenesis imperfecta (OI) is the name given to a enlargement of the cranium and jaw, tall stature and
group of disorders characterised by severe osteoporosis cranial nerve palsies. There is no effective treatment.
and multiple fractures in infancy and childhood. Most High bone mass syndrome is a benign disorder charac-
cases are caused by mutations in the COL1A1 and terised by unusually high bone density. Most patients
COL1A2 genes, which encode the proteins that make up are asymptomatic but bone overgrowth in the palate can
type I collagen. This results either in reduced collagen occur. Treatment is not usually required. Camurati–
production (in mild OI) or in formation of abnormal Engelmann disease is an autosomal dominant condition
collagen chains that are rapidly degraded (in severe OI). caused by gain of function in the TGFB1 gene. It presents
Most patients have dominant inheritance but recessive with bone pain, muscle weakness and osteosclerosis
forms have been described, caused by mutations in the mainly affecting the diaphysis of long bones. Cortico-
CRTAP and LEPRE genes, which are involved in post- steroids can help the bone pain, although analgesics are
translational modification of collagen. Many patients also usually required.
have no family history and are presumed to have new
mutations. Severity varies from neonatal lethal (type II),
through very severe with multiple fractures in infancy BONE AND JOINT TUMOURS
and childhood (types III and IV), to mild (type I), in
which affected patients typically have blue sclerae. The Primary tumours of bones and joints are rare, have a
diagnosis of OI is usually obvious clinically. In child- peak incidence in childhood and adolescence, and can
hood, the disease can be mistaken for non-accidental be benign or malignant (Box 25.83). Paget’s disease of
injury and in adulthood for osteoporosis. In such cases,
genetic testing can be of diagnostic value. Treatment is
multidisciplinary, involving surgical reduction and fixa-
tion of fractures and correction of limb deformities, and
physiotherapy and occupational therapy for rehabilita- 25.83 Primary tumours of the
tion of patients with bone deformity. Bisphosphonates
musculoskeletal system
are widely used in the treatment of OI, especially intra- Cell type Benign Malignant
venous pamidronate in children, but there is limited Osteoblast Osteoid osteoma Osteosarcoma
evidence that this prevents fractures or deformity. Chondrocyte Chondroma Chondrosarcoma
Osteochondroma
Osteopetrosis
Fibroblast Fibroma Fibrosarcoma
Osteopetrosis is a rare group of inherited diseases
caused by failure of osteoclast function. Presentation is Bone marrow cell Eosinophilic Ewing’s sarcoma
highly variable, ranging from a lethal disorder that granuloma
presents with bone marrow failure in infancy to a milder Endothelial cell Haemangioma Angiosarcoma
and sometimes asymptomatic form that presents in
Osteoclast precursor Giant cell tumour Malignant giant
adulthood. Severe osteopetrosis is inherited in an auto- cell tumour
somal recessive manner and presents with failure to 1131
RHEUMATOLOGY AND BONE DISEASE
Joint hypermobility
Trigger finger
Hypermobility is a relatively uncommon disorder asso-
ciated with joint laxity. It may be primary or secondary This occurs as the result of stenosing tenosynovitis in the
to inherited diseases, such as Marfan’s syndrome flexor tendon sheath, with intermittent locking of the
(p. 603), Ehlers–Danlos syndrome (p. 1050) and osteo- finger in flexion. It can arise spontaneously or in associa-
genesis imperfecta (p. 1131). Benign joint hypermobility tion with inflammatory diseases like RA. Symptoms
syndrome is diagnosed clinically when the modified usually respond to local steroid injections but surgical
1134 Beighton score is 4 or above in the presence of arthralgia decompression is occasionally required.
Further information
1135
J.P. Leach
R.J. Davenport
26
Neurological disease
Clinical examination of the nervous Functional symptoms 1175 Intracranial mass lesions and raised
system 1138 intracranial pressure 1211
Headache syndromes 1176
Functional anatomy and physiology 1140 Raised intracranial pressure 1212
Epilepsy 1178 Brain tumours 1213
Functional anatomy of the nervous
system 1141 Vestibular disorders 1186 Paraneoplastic neurological disease 1216
Localising lesions in the brainstem 1148 Hydrocephalus 1216
Disorders of sleep 1187
Idiopathic intracranial hypertension 1217
Investigation of neurological disease 1149 Excessive daytime sleepiness Head injury 1218
Neuroimaging 1149 (hypersomnolence) 1187
Neurophysiological testing 1151 Parasomnias 1187 Disorders of cerebellar function 1218
Presenting problems in neurological Neuro-inflammatory diseases 1188 Disorders of the spine and spinal cord 1218
disease 1155 Multiple sclerosis 1188 Cervical spondylosis 1218
Headache and facial pain 1156 Acute disseminated encephalomyelitis 1192 Lumbar spondylosis 1219
Dizziness, blackouts and ‘funny turns’ 1157 Transverse myelitis 1193 Spinal cord compression 1220
Status epilepticus 1159 Neuromyelitis optica 1193 Intrinsic diseases of the spinal cord 1222
Coma 1159 Diseases of peripheral nerves 1223
Paraneoplastic neurological disorders 1193
Delirium 1161 Entrapment neuropathy 1224
Amnesia 1161 Neurodegenerative diseases 1194
Multifocal neuropathy 1224
Weakness 1162 Movement disorders 1194
Polyneuropathy 1224
Sensory disturbance 1164 Ataxias 1198
Guillain–Barré syndrome 1224
Abnormal movements 1165 Tremor disorders 1199
Chronic polyneuropathy 1225
Abnormal perception 1167 Dystonia 1200
Brachial plexopathy 1225
Altered balance and vertigo 1167 Hemifacial spasm 1200
Lumbosacral plexopathy 1226
Abnormal gait 1168 Motor neuron disease 1200
Spinal root lesions 1226
Abnormal speech and language 1168 Spinal muscular atrophy 1201
Diseases of the neuromuscular
Disturbance of smell 1169 Infections of the nervous system 1201 junction 1226
Visual disturbance and ocular Meningitis 1201 Myasthenia gravis 1226
abnormalities 1169 Parenchymal viral infections 1205 Other myasthenic syndromes 1227
Hearing disturbance 1173 Parenchymal bacterial infections 1208
Bulbar symptoms – dysphagia and Diseases of muscle 1228
Diseases caused by bacterial toxins 1209
dysarthria 1173
Transmissible spongiform
Bladder, bowel and sexual disturbance 1174 encephalopathies 1211
Personality change 1175
Sleep disturbance 1175
Psychiatric disorders 1175
1137
NEUROLOGICAL DISEASE
Cranial nerves 4
5 Optic fundi
Papilloedema
Optic atrophy
Cupping of disc (glaucoma)
Hypertensive changes
Signs of diabetes
7 Sensory
Stance and gait 1
Pin-prick, temperature
Posture
Joint position, vibration
Romberg’s test
Two-point discrimination
Arm swing
Pattern of gait
Tandem (heel-toe) gait
Observation
• General appearance
• Mood (e.g. anxious, depressed) 8 Higher cerebral function
• Facial expression (or lack thereof) Orientation
• Handedness Memory
• Nutritional status Speech and language
• Blood pressure Localised cortical functions
1138
Clinical examination of the nervous system
1139
NEUROLOGICAL DISEASE
Sensory cell
Spinal cord body in dorsal
Ependymal cell Oligodendrocyte Astrocyte foot processes grey matter root ganglion
surround the brain capillary
Astrocyte Synapse (site of blood–brain barrier) Motor neuron
cell body in
CSF Neuron anterior horn
Schwann cell
Axon Capillary Capillary Tight Sensory Vas
endothelial junction axon nervorum
cell Red blood
cell in capillary Motor axon Node of Ranvier
1140 Fig. 26.1 Cells of the nervous system. (CSF = cerebrospinal fluid)
Functional anatomy and physiology
form the structural framework for neurons and control in internal conditions. Each neuron receives input by
their biochemical environment. Astrocyte foot processes synaptic transmission from dendrites (branched projec-
are intimately associated with blood vessels, forming the tions of other neurons), which may sum to produce
blood–brain barrier (Fig. 26.1). Oligodendrocytes are output in the form of an action potential. This is con-
responsible for the formation and maintenance of the ducted down axons, with synaptic transmission to other
myelin sheath, which surrounds axons and is essential neurons or, in the motor system, to muscle cells. These
for the rapid transmission of action potentials by salta- processes require the maintenance of an electrochemical
tory conduction. Microglial cells derive from monocytes/ gradient across neuron cell membranes by specialised
macrophages and play a role in fighting infection and membrane ion channels. Synaptic transmission involves
removing damaged cells. Peripheral neurons have axons the release of neurotransmitters that modulate the func-
invested in myelin made by Schwann cells. Ependymal tion of the target cell by interacting with structures on
cells line the cerebral ventricles. the cell surface, including ion channels and other cell
surface receptors (Fig. 26.2). At least 20 different neuro-
Generation and transmission of transmitters are known to act at different sites in the
the nervous impulse nervous system, and all are potentially amenable to
pharmacological manipulation.
The role of the central nervous system (CNS) is to gener-
The neuronal cell bodies may receive synaptic input
ate outputs in response to external stimuli and changes
from thousands of other neurons. The synapsing neuron
terminals are also subject to feedback regulation via
Microtubules in receptor sites on the pre-synaptic membrane, modifying
axon down which the release of transmitter across the synaptic cleft. In
neurotransmitters addition to such acute effects, some neurotransmitters
and/or precursors
are transported produce long-term modulation of metabolic function or
gene expression. This effect probably underlies more
Action complex processes in, for example, long-term memory.
potential
Ca2+
2 Anterior Posterior
B Ions Cerebral
3
hemispheres
G-protein Sensation
Ions 3 4 Behaviour and
and perception
A motor
Second
messengers New ion channel
e.g. cAMP or modulating
enzyme Cerebellum
Transcription
factor Brainstem
Translation
Heart and
Autonomic
circulation
mRNA Spinal cord
Cell
DNA nucleus GI tract
Bladder
depolarise the membrane and initiate an action potential (4), or (B) to bind to
metabotrophic receptors that activate an effector enzyme (e.g. adenylyl
cyclase) and thus modulate gene transcription via the intracellular second Reproductive
messenger system, leading to changes in synthesis of ion channels or organs Neuromuscular
modulating enzymes. (5) Neurotransmitters are taken up at the pre-synaptic junction
membrane and/or metabolised. (cAMP = cyclic adenosine monophosphate; Fig. 26.3 The major anatomical components of the nervous
DNA = deoxyribonucleic acid; mRNA = messenger ribonucleic acid) system. 1141
NEUROLOGICAL DISEASE
26 Cerebral hemispheres
The parietal lobes integrate sensory perception. The
primary sensory cortex lies in the post-central gyrus
The cerebral hemispheres coordinate the highest level of the parietal lobe. Much of the remainder is devoted
of nervous function, the anterior half dealing with exec- to ‘association’ cortex, which processes and interprets
utive (‘doing’) functions and the posterior half con- input from the various sensory modalities. The supra-
structing a perception of the environment. Each cerebral marginal and angular gyri of the dominant parietal lobe
hemisphere has four functionally specialised lobes (Fig. form part of the language area (p. 1169). Close to these
26.4 and Box 26.2), but some functions are lateralised, are regions dealing with numerical function. The non-
and this depends on cerebral dominance (i.e. the hemi- dominant parietal lobe is concerned with spatial aware-
sphere in which language is represented). Cerebral ness and orientation.
dominance aligns limb dominance with language func- The temporal lobes contain the primary auditory
tion: in right-handed individuals the left hemisphere is cortex and primary vestibular cortex. On the inner
almost always dominant, while around half of left- medial sides lie the olfactory cortex and the para-
handers have a dominant right hemisphere. hippocampal cortex, which is involved in memory
The frontal lobes are concerned with executive func- function. The temporal lobes also contain much of the
tion, movement, behaviour and planning. In addition to limbic system, including the hippocampus and the
the primary and supplementary motor cortex, there are amygdala, which are involved in memory and emo-
specialised areas for the control of eye movements, tional processing. The dominant temporal lobe also
speech (Broca’s area) and micturition. participates in language functions, particularly verbal
Central sulcus
Leg Primary sensory cortex
Frontal eye field Supramarginal gyrus
Primary motor cortex Angular gyrus
Parietal lobe
Frontal lobe
Face
Inferior frontal gyrus Wernicke’s area
Temporal lobe
Supplementary motor area
Foot
Corpus callosum
Parahippocampal cortex
26
Fig. 26.4 The anatomy of the cerebral cortex.
therefore imply chronic partial denervation with (bradykinesia), which characteristically reduce in size
re-innervation. with repetition, as well as postural instability, which can
precipitate falls.
Upper motor neurons
Upper motor neurons have both inhibitory and excita- The cerebellum
tory influence on the function of anterior horn motor The cerebellum fine-tunes and coordinates movements
neurons. Lesions affecting the upper motor neuron initiated by the motor cortex. It also participates in the
result in increased tone, most evident in the strongest planning and learning of skilled movements through
muscle groups (i.e. the extensors of the lower limbs and reciprocal connections with the thalamus and cortex,
the flexors of the upper limbs). The weakness of upper and in articulation of speech. A lesion in a cerebellar
motor neuron lesions is conversely more pronounced in hemisphere causes lack of coordination on the same side
the opposing muscle groups. Loss of inhibition will also of the body. Cerebellar dysfunction impairs the smooth-
lead to brisk reflexes and enhanced reflex patterns of ness of eye movements, causing nystagmus and renders
movement, such as flexion withdrawal to noxious speech dysarthric. In the limbs, the initial movement is
stimuli and spasms of extension. The increased tone is normal, but as the target is approached, the accuracy of
more apparent during rapid stretching (‘spastic catch’), the movement deteriorates, producing an ‘intention
but may suddenly give way with sustained tension (the tremor’. The distances of targets are misjudged (dys-
‘clasp-knife’ phenomenon). More primitive reflexes are metria), resulting in ‘past-pointing’. The ability to
also released, manifest as extensor plantar responses. produce rapid, accurate, regularly alternating move-
Spasticity may not be present until some weeks after the ments is also impaired (dysdiadochokinesis). The central
onset of an upper motor neuron lesion. Chronic spas- vermis of the cerebellum is concerned with the coordina-
ticity in a patient with a spinal cord lesion may also be tion of gait and posture. Disorders of this therefore
exacerbated by increased sensory input – for example, produce a characteristic ataxic gait (see below).
from a pressure sore or urinary tract infection.
Vision
The extrapyramidal system The neurological organisation of visual pathways is
26
Circuits between the basal ganglia and the motor cortex shown in Figure 26.7. Fibres from ganglion cells in the
constitute the extrapyramidal system, which controls retina pass to the optic disc and then backwards through
muscle tone, body posture and the initiation of move- the lamina cribrosa to the optic nerve. Nasal optic nerve
ment (see Fig. 26.6). Lesions of the extrapyramidal fibres (subserving the temporal visual field) cross at
system produce an increase in tone that, unlike spas- the chiasm, but temporal fibres do not. Hence, fibres in
ticity, is continuous throughout the range of movement each optic tract and further posteriorly carry representa-
at any speed of stretch (‘lead pipe’ rigidity). Involuntary tion of contralateral visual space. From the lateral geni-
movements are also a feature of extrapyramidal lesions culate nucleus, lower fibres pass through the temporal
(p. 1165), and tremor in combination with rigidity lobes on their way to the primary visual area in the
produces typical ‘cogwheel’ rigidity. Extrapyramidal occipital cortex, while the upper fibres pass through the
lesions also cause slowed and clumsy movements parietal lobe.
2
Retina
1
3
Optic nerve
2
Optic chiasm
4 3
Optic tract
4 Lateral geniculate body
5
5 Lower fibres in
temporal lobe
3rd
4th A
MLF
Verbal
6th memory
B Auditory
Corticobulbar
C tract cortex
8th Pontine
lateral gaze Bulbar
centre muscles
Fig. 26.9 Areas of the cerebral cortex involved in the generation
Fig. 26.8 Control of conjugate eye movements. Downward of spoken language.
projections pass from the cortex to the pontine lateral gaze centre
(A). The pontine gaze centre projects to the 6th cranial nerve nucleus
(B), which innervates the ipsilateral lateral rectus and projects to the
contralateral 3rd nerve nucleus (and hence medial rectus) via the medial
longitudinal fasciculus (MLF). Tonic inputs from the vestibular apparatus concepts, occurs predominantly in the lower parts of the
(C) project to the contralateral 6th nerve nucleus via the vestibular nuclei. anterior parietal lobe (the angular and supramarginal
gyri). The temporal speech comprehension region is
referred to as Wernicke’s area (Fig. 26.9). Other parts of
the temporal lobe contribute to verbal memory, where
Normally, the eyes move conjugately (in unison), lexicons of meaningful words are ‘stored’. Parts of the
though horizontal convergence allows visual fusion of non-dominant parietal lobe appear to contribute to non-
objects at different distances. The control of eye move- verbal aspects of language in recognising meaningful
ments begins in the cerebral hemispheres, particularly intonation patterns (prosody).
within the frontal eye fields, and the pathway then The frontal language area is in the posterior end of
descends to the brainstem with input from the visual the dominant inferior frontal gyrus known as Broca’s
cortex, superior colliculus and cerebellum. Horizontal area. This receives input from the temporal and parietal
and vertical gaze centres in the pons and mid-brain, lobes via the arcuate fasciculus. The motor commands
respectively, coordinate output to the ocular motor generated in Broca’s area pass to the cranial nerve nuclei
nerve nuclei (3, 4 and 6), which are connected to each in the pons and medulla, as well as to the anterior horn
other by the medial longitudinal fasciculus (MLF) (Fig. cells in the spinal cord. Nerve impulses to the lips,
26.8). The MLF is particularly important in coordinating tongue, palate, pharynx, larynx and respiratory muscles
horizontal movements of the eyes. The extraocular result in the series of ordered sounds recognised as
muscles are then supplied by the oculomotor (3rd), speech. The cerebellum also plays an important role in
trochlear (4th) and abducens (6th) cranial nerves. coordinating speech, and lesions of the cerebellum lead
The pupillary response to light is due to a combina- to dysarthria, where the problem lies in motor articula-
tion of parasympathetic and sympathetic activity. Para- tion of speech.
sympathetic fibres originate in the Edinger–Westphal
subnucleus of the 3rd nerve, and pass with the 3rd nerve
to synapse in the ciliary ganglion before supplying the
The somatosensory system
constrictor pupillae of the iris. Sympathetic fibres origi- Sensory information from the limbs ascends the nervous
nate in the hypothalamus, pass down the brainstem and system in two anatomically discrete systems (Fig. 26.10).
cervical spinal cord to emerge at T1, return up to the Fibres from proprioceptive organs and those mediating
eye in association with the internal carotid artery, and well-localised touch (including vibration) enter the
supply the dilator pupillae. spinal cord at the posterior horn and pass without syn-
apsing into the ipsilateral posterior columns. Neural
fibres conveying pain and temperature sensory informa-
Speech tion (nociceptive neurons) synapse with second-order
Much of the cerebral cortex is involved in the process of neurons that cross the midline in the spinal cord before
forming and interpreting communicating sounds, espe- ascending in the contralateral anterolateral spino-
cially in the dominant hemisphere (see Box 26.2, p. 1142). thalamic tract to the brainstem.
Decoding of speech sounds (phonemes) is carried out in The second-order neurons of the dorsal column
the upper part of the posterior temporal lobe. The attri- sensory system cross the midline in the upper medulla
bution of meaning, as well as the formulation of the to ascend through the brainstem. Here they lie just
1146 language required for the expression of ideas and medial to the (already crossed) spinothalamic pathway.
Functional anatomy and physiology
Brainstem lesions can therefore cause sensory loss affect- (near the ears) descend within the brainstem to the
ing all modalities of the contralateral side of the body. upper part of the spinal cord before synapsing, the
Sensory loss on the face due to brainstem lesions is second-order neurons crossing the midline and then
dependent on the anatomy of the trigeminal fibres ascending with the spinothalamic fibres. Fibres convey-
within the brainstem. Fibres from the back of the face ing sensation from progressively more forward areas of
the face descend a shorter distance in the brainstem.
Thus, sensory loss in the face from low brainstem lesions
is in a ‘balaclava helmet’ distribution, as the longer
Parietal descending trigeminal fibres are affected. Both the dorsal
cortex
column and spinothalamic tracts end in the thalamus,
relaying from there to the parietal cortex.
Thalamus Pain
Pain is a complex percept that is only partly related
Gracile and to activity in nociceptor neurons (Fig. 26.11). In the pos-
cuneate nuclei terior horn of the spinal cord, the second-order neuron
of the spinothalamic tract is affected by a number of
influences in addition to its synapse with the fibres
from nociceptors. Branches from the larger mechanocep-
Joint position, tor fibres destined for the posterior column also synapse
vibration
and accurate Dorsal with the second-order spinothalamic neurons and with
touch column interneurons of the grey matter of the posterior horn.
The nociceptor neurons release neurotransmitters (such
as substance P), in addition to excitatory transmitters,
which influence the excitability of the spinothalamic
neurons. Activity in the posterior horn neurons is modu-
lated by fibres descending from the peri-aqueductal
grey matter of the mid-brain and raphe nuclei of the
26
medulla. Neurons of this ‘descending analgesia system’
Pain, are activated by endogenous opiate (endorphin) pep-
temperature tides. The spinal cord’s posterior horn is therefore
and poorly
localised touch much more than a relay station in pain transmission; its
Vestibulospinal complexity allows it to ‘gate’ and modulate painful sen-
tract sation before it ascends in the spinothalamic tract. In the
Lateral
spinothalamic diencephalon, the perception of pain is further influ-
tract enced by the rich interconnections of the thalamus with
Fig. 26.10 The main somatic sensory pathways. the limbic system.
Peri-aqueductal
grey matter
Raphe nuclei
of medulla
Descending
pain perception
modulation
Dorsal
column
Posterior
Spinothalamic horn
tract
Crossing Mechanoceptor
spinothalamic (mechanical stimuli)
tract neuron
26 Sphincter control
The sympathetic supply to the bladder leaves from
on the slow wave. REM sleep persists for a short spell
before another slow-wave spell starts, the cycle repeat-
T11–L2 to synapse in the inferior hypogastric plexus, ing several times throughout the night. REM periods
while the parasympathetic supply leaves from S2–4. In become longer as the sleep period progresses. REM
addition, a somatic supply to the external (voluntary) sleep seems to be the most important part of the sleep
sphincter arises from S2–4, travelling via the pudendal cycle for refreshing cognitive processes, and REM sleep
nerves. deprivation causes tiredness, irritability and impaired
Storage of urine is maintained by inhibiting para- judgement.
sympathetic activity and thus relaxing the detrusor
muscle of the bladder wall. Continence is maintained by
simultaneous sympathetic and somatic (via the puden-
dal nerve) mediated tonic contraction of the urethral
Localising lesions in the brainstem
sphincters. Voiding is usually under conscious control,
After taking a history and examining the patient, the
and triggered by relaxation of tonic inhibition on the
clinician should have an idea of the nature and site of
pontine micturition centre from higher centres, leading
any pathology. Given the density of tracts and nuclei in
to relaxation of the pelvic floor muscles and external and
the brainstem (see Fig. 26.5), detailed localisation may
internal urethral sphincters, along with parasympathetic-
be possible on the basis of history and examination
mediated detrusor contraction.
alone, to be confirmed or refuted by investigation.
Brainstem lesions typically present with symptoms
Personality and mood due to cranial nerve, cerebellar and upper motor neuron
The physiology and pathology of mood disorders are dysfunction and are most commonly caused by vascular
discussed elsewhere (Ch. 10) but it is important to disease. Since the anatomy of the brainstem is very pre-
remember that any process affecting brain function will cisely organised, it is usually possible to localise the site
have some effect on mood and affect. Conversely, mood of a lesion on the basis of careful history and examina-
disorder will have a significant effect on perception and tion in order to determine exactly which tracts/nuclei
function. It can be difficult to disentangle whether psy- are affected, usually invoking the fewest number of
chological and psychiatric changes are the cause or the lesions.
effect of any neurological symptoms. For example, in a patient presenting with sudden
onset of upper motor neuron features affecting the right
Sleep face, arm and leg in association with a left 3rd nerve
The function of sleep is unknown but it is required for palsy, the lesion will be in the left cerebral peduncle in
good health. Sleep is controlled by the reticular activat- the brainstem and the pathology is likely to have been a
ing system in the upper brainstem and diencephalon. It small stroke, as the onset was sudden. This combination
is composed of different stages that can be visualised on of signs is known as Weber’s syndrome, and is one of
electroencephalography (EEG). As drowsiness occurs, several well-described brainstem syndromes, which are
normal EEG background alpha rhythm disappears and listed in Box 26.3. The effects of individual cranial nerve
activity becomes dominated by deepening slow-wave deficits are discussed in the sections on eye movements
activity. As sleep deepens and dreaming begins, the (p. 1169) and on facial weakness, sensory loss in brain-
limbs become flaccid, movements are ‘blocked’ and EEG stem lesions, dysphonia and dysarthria, and bulbar
signs of rapid eye movements (REM) are superimposed symptoms (pp. 1163, 1165, 1168 and 1173).
(CT = computed tomography; CTA = computed tomographic angiography; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging;
PET = positron emission tomography; SPECT = single photon emission clinical tomography)
1149
NEUROLOGICAL DISEASE
26 A B
C D
Fig. 26.12 Different techniques of imaging the head and brain. A Skull X-ray showing lytic skull lesion (eosinophilic granuloma – arrow). B CT
showing complete middle cerebral artery infarct (arrows). C MRI showing widespread areas of high signal in multiple sclerosis (arrows). D SPECT after
caudate infarct showing relative hypoperfusion of overlying right cerebral cortex (arrows).
Different MRI techniques will increase sensitivity to intervertebral discs, but also about their effects on the
acute ischaemic stroke and may allow detection of spinal cord and nerve roots. Myelography is an invasive
abnormalities by filtering signals from other tissues (e.g. technique involving injection of contrast into the lumbar
adipose tissues in the orbits). theca. While the outline of the nerve roots and spinal
Examples of brain imaged by the various techniques cord provides information about abnormal structure,
are shown in Figure 26.12. the accuracy and wide availability of MRI have reduced
the need for this. Myelography may still be used for
Cervical, thoracic and technical reasons or where MRI is unavailable, contra-
lumbar spine indicated, or precluded by the patient’s claustrophobia.
Plain X-rays are useful in the investigation of trauma to Examples of the cervical spine imaged by plain X-rays,
vertebrae, but their value in providing information myelography and MRI are shown in Figure 26.13.
about non-bony tissues is limited, which makes them
far less helpful in the assessment of inflammatory and Blood vessels
degenerative conditions of the spine. MRI has trans- Imaging of the extra- and intracranial blood vessels and
formed the investigation of these areas, since it can disturbance of arterial or venous blood flow is described
give information not only about the vertebrae and in Chapter 27.
1150
Investigation of neurological disease
A B C
C6
C7
Fig. 26.13 Different techniques of imaging the cervical spine. A Lateral X-ray showing bilateral C6/7 facet dislocation. B Myelogram showing
widening of cervical cord due to astrocytoma (arrows). C MRI showing posterior epidural compression from adenocarcinomatous metastasis to the
posterior arch of T1 (arrows).
26
certain dementias such as Creutzfeldt–Jakob disease
Neurophysiological testing (p. 1211).
Since sleep induces marked changes in cerebral activ-
Electroencephalography ity, EEG can be useful in characterising those conditions
The electroencephalogram (EEG) is used to detect elec- where sleep patterns are disturbed. In paroxysmal dis-
trical activity arising in the cerebral cortex. The EEG orders such as epilepsy, EEG is at its most useful when
involves placing electrodes on the scalp to record the it captures activity during one of the events in question.
amplitude and frequency of the resulting waveforms. Up to 5% of some normal populations may demonstrate
With closed eyes, the normal background activity is epileptiform discharges on EEG which prevent its use as
8–13 Hz (known as alpha rhythm), most prominent a screening test for epilepsy. Over 50% of patients with
occipitally and suppressed on eye opening. Other fre- proven epilepsy will have a normal ‘routine’ EEG, and,
quency bands seen over different parts of the brain conversely, the presence of epileptiform features does
in different circumstances are beta (faster than 13/s), not of itself make a diagnosis (most notably in younger
theta (4–8/s) and delta (slower than 4/s). Normal patients with a family history of epilepsy). In view of
EEG changes evolve with age and with alertness; this, the EEG should not be used where epilepsy is
lower frequencies predominate in the very young and merely ‘suspected’.
during sleep. The EEG in epilepsy is predominantly used in its
In recent years, digital technology has allowed longer, classification and prognosis, and in some patients to
cleaner EEG recordings that can be analysed in a number localise the seat of epileptiform discharges when surgery
of ways and recorded alongside contemporaneous video is being considered. During an epileptic seizure, high-
of any clinical ‘event’. Meanwhile, the development of voltage disturbances of background activity (‘dis-
intracranial recording allows more sensitive monitoring charges’) will often be noted. These may be generalised,
via surgically placed electrodes in and around lesions to as in the 3-Hz ‘spike and wave’ of childhood absence
help increase the efficacy and improve the safety of epi- epilepsy, or more focal, as in localisation-related epilep-
lepsy surgery. sies (Fig. 26.14). Techniques such as hyperventilation or
Abnormalities in the EEG result from a number of photic stimulation can be used to increase the yield of
conditions. Examples include an increase in fast fre- epileptiform changes, particularly in the generalised epi-
quencies (beta) seen with sedating drugs such as ben- lepsy syndromes. While some argue that it is possible to
zodiazepines, or marked focal slowing noted over a detect ‘spikes’ and ‘sharp waves’ to lend support to a
structural lesion such as a tumour or an infarct. Improved clinical diagnosis, these are non-specific and therefore
quality and accessibility of imaging have made EEG not diagnostic.
redundant in lesion localisation, except in the specialist
investigation of epilepsy (p. 1182). EEG remains useful Nerve conduction studies
in progressive and continuous disorders such as reduced Electrical stimulation of a nerve causes an impulse
consciousness (p. 1159), in encephalitis (p. 1205), and in to travel both efferently and afferently along the
1151
NEUROLOGICAL DISEASE
26 A B
2
5 4 3 2
11 10 9 8 7 6
3
15 14 13 12 4
16
5
7
8
10
11
Secondary generalised
seizure
Fig. 26.14 EEGs in epilepsy. A Generalised epileptic discharge, as seen in epilepsy syndromes such as childhood absence or juvenile myoclonic
epilepsy. B Focal sharp waves over the right parietal region (circled), with spread of discharge to cause a generalised tonic–clonic seizure.
underlying axons. Nerve conduction studies (NCS) increasing CMAP with high-frequency RNS is seen in
make use of this, recording action potentials as they pass Lambert–Eaton myasthenic syndrome (p. 1227).
along peripheral nerves and (with motor nerves) as they
pass into the muscle belly. Digital recording has Electromyography
enhanced sensitivity and reproducibility of these tiny
Electromyography (EMG) is usually performed with
potentials. By measuring the time taken to traverse a
NCS, and involves needle recording of muscle electrical
known distance, it is possible to calculate nerve conduc-
potential during rest and contraction. At rest, muscle is
tion velocities (NCVs). Healthy nerves at room tempera-
electrically silent but loss of nerve supply causes muscle
ture will conduct at a speed of 40–50 m/s. If the recorded
membrane to become unstable, manifest as fibrillations,
potential is smaller than expected, this provides evi-
positive sharp waves (‘spontaneous activity’) or fascicu-
dence of a reduction in the overall number of function-
lations. During muscle contraction, motor unit action
ing axons. Significant slowing of conduction velocity,
potentials are recorded. Axonal loss or destruction will
in contrast, suggests impaired saltatory conduction
result in fewer motor units. Resultant sprouting of
due to peripheral nerve demyelination. Such changes in
remaining units will lead to increasing size of each indi-
NCS may be diffuse (as in a hereditary demyelinating
vidual unit on EMG. Myopathy, in contrast, will cause
peripheral neuropathy, p. 1223), focal (as in pressure
muscle fibre splitting, which will result in a large number
palsies, p. 1224) or multifocal (e.g. Guillain–Barré syn-
of smaller units on EMG. Other abnormal activity, such
drome, p. 1224; mononeuritis multiplex, p. 1224). The
as myotonic discharges, may signify abnormal ion
information gained can allow the disease responsible for
channel conduction, as in myotonic dystrophy or myo-
peripheral nerve dysfunction to be better deduced (see
tonia congenita.
Box 26.99, p. 1223).
Specialised single fibre EMG (SFEMG) can be used to
Stimulation of motor nerves allows for the recording
investigate neuromuscular junction transmission. Meas-
of compound muscle action potentials (CMAPs) over
uring ‘jitter’ and ‘blocking’ can identify the effect of anti-
muscles (Fig. 26.15). These are around 500 times
bodies in reducing the action of acetylcholine on the
larger than sensory nerve potentials, typically around
receptor.
1–20 millivolts. Since a proportion of stimulated impulses
in motor nerves will ‘reflect’ back to the anterior horn
cell body (forming the ‘F’ wave), it is also possible to Evoked potentials
obtain some information about the condition of nerve The cortical response to visual, auditory or electrical
roots. stimulation can be measured on an EEG as an evoked
Repetitive nerve stimulation (RNS) at 3–15/s pro- potential (EP). If a stimulus is provided – for example,
vides consistent CMAPs in healthy muscle. In myasthe- to the eye – the tiny EEG response can be discerned
nia gravis (p. 1226), where there is partial blockage of when averaging 100–1000 repeated stimuli. Assessing
acetylcholine receptors, however, there is a diagnostic the latency (the time delay) and amplitude can give
1152 fall (decrement) in CMAP amplitude. In contrast, an information about the integrity of the relevant pathway.
Investigation of neurological disease
CMAP
Amplitude
L2 F wave
P100
Immunological tests
5uV 5uV Recent developments have seen a host of new immune-
P100
mediated conditions emerge in clinical neurology, with
effects ranging from muscle and neuromuscular junction
disturbance (causing weakness and muscle pain) to spe-
5uV 5uV cific neuronal ion channels (causing cognitive decline,
epilepsy and psychiatric changes). The last decade has
seen the identification of many causative antibodies (see
100 200 300 100 200 300 Boxes 26.62 and 26.63, p. 1194), and it is likely that further
conditions will turn out to have an immune basis.
L ms R ms
Fig. 26.16 Visual evoked responses (VER) recording. The Genetic testing
abnormality is in the left hemisphere, with delay in latency and a reduction An increasing number of inherited neurological condi-
in signal of the P100. tions can now be diagnosed by DNA analysis (p. 60).
These include diseases caused by increased numbers
MRI now provides more information about CNS path- of trinucleotide repeats, such as Huntington’s disease
ways, thus reducing reliance on EPs. In practice, visual (p. 1198), myotonic dystrophy (p. 1228) and some types
evoked potentials (VEPs) are most commonly used to of spinocerebellar ataxia (p. 1199). Mitochondrial DNA
help differentiate CNS demyelination from small-vessel can also be sequenced to diagnose relevant disorders
white-matter changes (Fig. 26.16). (p. 60).
Magnetic stimulation
Central conduction times can also be measured using Lumbar puncture
electromagnetic induction of action potentials in the Lumbar puncture (LP) is the technique used to obtain
cortex or spinal cord by the local application of special- a CSF sample and provides an indirect measure of
ised coils. Again, MRI has made this largely redundant, intracranial pressure. After local anaesthetic injection, a
other than for research. needle is inserted between lumbar spinous processes 1153
NEUROLOGICAL DISEASE
(usually between L3 and L4) through the dura and into intravascular coagulation or anticoagulant treatment),
the spinal canal. Intracranial pressure can be deduced (if then caution should be exercised or specific measures
patients are lying on their side) and CSF removed for should be taken. LP can be safely performed in patients
analysis. CSF pressure measurement is important in the on antiplatelet drugs or low-dose heparin, but may be
diagnosis and monitoring of idiopathic intracranial unsafe in patients who are fully anticoagulated due to
hypertension (p. 1217). In this condition, the LP itself is the increased risk of epidural haematoma.
therapeutic. About 30% of LPs are followed by a postural head-
CSF is normally clear and colourless, and the tests ache, due to reduced CSF pressure. The frequency of
that are usually performed include a naked eye exami- headache can be reduced by using smaller or atraumatic
nation of the CSF and centrifugation to determine the needles. Other rarer complications involve transient
colour of the supernatant (yellow, or xanthochromic, radicular pain, and pain over the lumbar region during
some hours after subarachnoid haemorrhage (p. 1246). the procedure. Aseptic technique renders secondary
Routine analysis will involve a cell count, as well as infections such as meningitis extremely rare.
assay of glucose and protein.
CSF assessment is important in investigating infec- Biopsy
tions (meningitis or encephalitis), subarachnoid haemor- Biopsies of nervous tissue (peripheral nerve, muscle,
rhage and inflammatory conditions (multiple sclerosis, meninges or brain) are occasionally required for
sarcoidosis and cerebral lupus). Normal values and diagnosis.
abnormalities found in specific conditions are shown in Nerve biopsy can help in the investigation of periph-
Box 26.5. eral neuropathy. Usually, a distal sensory nerve (sural
More sophisticated analysis allows measurement of or radial) is targeted. Histological examination can help
antibody formation solely within the CNS (oligoclonal identify underlying causes, such as vasculitides or infil-
bands), genetic analysis (e.g. polymerase chain reaction trative disorders like amyloid. Nerve biopsy should not
(PCR) for herpes simplex or tuberculosis), immunologi- be undertaken lightly since there is an appreciable mor-
cal tests (paraneoplastic antibodies) and cytology (to bidity; it should be reserved for cases where the diagno-
detect malignant cells). sis is in doubt after routine investigations and where it
If there is a cranial space-occupying lesion causing will influence management.
raised intracranial pressure, LP presents a theoretical Muscle biopsy is performed more frequently and is
risk of downward shift of intracerebral contents, a indicated for the differentiation of myositis and myo-
potentially fatal process known as coning (p. 1212). pathies. These conditions can usually be distinguished
Consequently, LP is contraindicated if there is any by histological examination, and enzyme histochemistry
clinical suggestion of raised intracranial pressure can be useful when mitochondrial diseases and storage
(papilloedema), depressed level of consciousness, or diseases are suspected. The quadriceps muscle is most
focal neurological signs suggesting a cerebral lesion, commonly biopsied but other muscles may also be
until imaging (by CT or MRI) has excluded a space- sampled if they are involved clinically. Although pain
occupying lesion or hydrocephalus. When there is a risk and infection can follow the procedure, these are less of
1154 of local haemorrhage (thrombocytopenia, disseminated a problem than after nerve biopsy.
Presenting problems in neurological disease
Brain biopsy is required when imaging fails to clarify called ‘numbness’, while there are many possible inter-
the nature of intracerebral lesions: for example, in unex- pretations of ‘dizziness’. These must be clarified; even in
plained degenerative diseases such as unusual cases of emergency situations, a clear, accurate history is the
dementia and in patients with brain tumour. Most biop- foundation of any management plan. While the story
sies are performed stereotactically through a burr-hole should come primarily from the patient, input from
in the skull, which lowers complication rates. Neverthe- eye-witnesses and family members is crucial if the
less, haemorrhage, infection and death still occur and patient is unable to provide details or if there has been
brain biopsy should only be considered if a diagnosis is loss of consciousness. This need for corroboration and
otherwise elusive. clarification means the telephone is as important as any
investigation.
The aim of the history is to answer two key issues:
where is the lesion and what is the lesion (Box 26.7)?
PRESENTING PROBLEMS IN These should remain uppermost in the doctor’s mind
NEUROLOGICAL DISEASE whilst eliciting the history. Some common combina-
tions of symptoms may suggest particular locations
While history is important in all medical specialties, it is for a lesion (Box 26.8). Enquiry about handedness is
especially key in neurology, where many neurological important; lateralisation of the dominant hand helps
diagnoses have no confirmatory test. History-taking designate the dominant hemisphere, which in turn may
allows doctor and patient to get to know one another – help to localise any pathologies, or to plan rehabilitation
many neurological diseases follow chronic paths, and or treatment strategies in asymmetrical disorders such
this may be the first of many such consultations. It also as stroke or Parkinson’s disease.
allows the clinician to obtain information about the Epidemiology must be borne in mind; how likely is
patient’s affect, cognition and psychiatric state. it that this particular patient has any specific condition
History-taking is a highly active process and, whilst under consideration? For example, a 20-year-old with
there are generic templates (Box 26.6), each indi- right-sided headache and tenderness will not have tem-
vidual story will follow its own course, and diagnostic poral arteritis, but this is an important possibility if such
symptoms present in a 78-year-old female.
considerations during the history will guide further
questioning. Determining the evolution and speed of onset and
progression of a disease is important (Box 26.9). For
26
It is important to be clear about what patients mean
by certain words. Patients may find it difficult to example, if right-hand weakness occurred overnight, it
describe symptoms – for instance, weakness may be would suggest a stroke in an older person or an acute
entrapment neuropathy in a younger one. Evolution
over several days, however, might make demyelination
(multiple sclerosis) a possible diagnosis, or perhaps a
subdural haematoma if the weakness was preceded by
26.6 How to take a neurological history a head injury in an older person taking warfarin. Pro-
gression over weeks might bring an intracranial mass
Introduction
lesion or motor neuron disease into the differential. Slow
• Age and sex progression over a year or so, with difficulty in using the
• Handedness hand, could suggest a degenerative process such as
Presenting complaint Parkinson’s disease. The impact on day-to-day activities,
• Symptoms (clarify: see text) such as walking, climbing stairs and carrying out fine
• Overall pattern: intermittent or persistent? hand movements, should also be established in order to
If intermittent, how often do symptoms occur and how gauge the level of associated disability.
long do they last?
• Speed of onset: seconds, minutes, hours, days, weeks,
months, years, decades?
• Better, worse or the same over time?
• Associated symptoms (including non-neurological) 26.7 The key diagnostic questions
• Disability caused by symptoms
Change in walking Where is the lesion?
Difficulty with fine hand movements, e.g. writing, fastening • Is it neurological?
buttons, using cutlery • If so, to which part of the nervous system does it localise?
• Effect on work, family life and leisure Central versus peripheral
Background Sensory versus motor versus both
• Previous neurological symptoms and whether similar to What is the lesion?
current symptoms • Hereditary or congenital
• Previous medical history • Acquired
• Domestic situation Traumatic
• Driving licence status Infective
• Medications (current and at time of symptom onset) Neoplastic
• Alcohol/smoking habits Degenerative
• Recreational drug and other toxin exposure Inflammatory or immune-mediated
• Family history and developmental history Vascular
• What are patient’s thoughts/fears/concerns? Functional
1155
NEUROLOGICAL DISEASE
Presyncope
(reduced cerebral
perfusion)
Fig. 26.17 A diagnostic approach to the patient with dizziness, funny turns or blackouts. (Neurological causes are shown in green.)
26.12 Dizziness in old age 26.13 How to differentiate seizures from syncope
• Prevalence: common, affecting up to 30% of people aged Seizure Syncope
> 65 yrs. Aura (e.g. olfactory) + –
• Symptoms: most frequently described as a combination of
unsteadiness and lightheadedness. Cyanosis + –
• Most common causes: postural hypotension, cardiovascular Tongue-biting + –/+
disease, cervical spondylosis. Many patients have more than Post-ictal confusion + –
one underlying cause.
• Arrhythmia: can present with lightheadedness either at rest Post-ictal amnesia + –
or on activity. Post-ictal headache + –
• Anxiety: frequently associated with dizziness but rarely the
Rapid recovery – +
only cause.
• Falls: multidisciplinary workup is required if dizziness is
associated with falls.
Syncope
26.14 Management of status epilepticus
Typically, syncope is preceded by a brief feeling of light-
headedness. Neurocardiogenic syncope (p. 555) is more Initial
likely on standing, and may be provoked by pain or
• Ensure airway is patent; give oxygen to prevent cerebral
emotion. There may be darkening of vision, ringing in hypoxia
the ears, symptoms of hyperventilation, distal tingling, • Check pulse, blood pressure, BM stix® and respiratory rate
feelings of nausea, clamminess or sweating. The LOC is • Secure intravenous access
gradual and brief, and the patient recovers quickly • Send blood for:
without confusion as long as he or she has assumed a Glucose, urea and electrolytes, calcium and magnesium,
horizontal position. There is often some brief stiffening liver function, anti-epileptic drug levels
and limb twitching, which requires differentiation from Full blood count and clotting screen
seizure-like movements. It is rare for syncope to cause Storing a sample for future analysis (e.g. drug misuse)
injury or to cause amnesia after regaining awareness. • If seizures continue for > 5 mins: give diazepam 10 mg IV
During a syncopal attack, incontinence of urine can (or rectally) or lorazepam 4 mg IV; repeat once only after
occur. Tongue-biting is less common in syncope and, if 15 mins
present, usually involves little trauma. • Correct any metabolic trigger, e.g. hypoglycaemia
Cardiac syncope (p. 555), caused by a sudden drop in Ongoing
cardiac output, may be provoked by exertion in those
If seizures continue after 30 mins
with severe aortic stenosis, ischaemia or hypertrophic
• IV infusion (with cardiac monitoring) with one of:
obstructive cardiomyopathy, or without warning in
Phenytoin: 15 mg/kg at 50 mg/min
patients with cardiac arrhythmia.
Fosphenytoin: 15 mg/kg at 100 mg/min
Seizures Phenobarbital: 10 mg/kg at 100 mg/min
• Cardiac monitor and pulse oximetry
The diagnosis of generalised tonic–clonic seizures, in Monitor neurological condition, blood pressure, respiration;
which there is loss of consciousness, falling to the ground check blood gases
and clonic movements (p. 1180), is easy but lack of eye-
If seizures still continue after 30–60 mins
witness accounts can leave uncertainty. Less dramatic
seizures, such as absences (p. 1181) or some focal sei-
• Transfer to intensive care
Start treatment for refractory status with intubation,
26
zures (p. 1180), which cause alteration of consciousness ventilation and general anaesthesia using propofol or
without the patient falling to the ground, may merely be thiopental
experienced as ‘lost time’. Since epileptic seizures are the EEG monitor
result of specific processes that vary from patient to Once status controlled
patient, their manifestation tends to be intermittent and • Commence longer-term anticonvulsant medication with
stereotyped and often clusters in time, for reasons one of:
incompletely understood. Sodium valproate 10 mg/kg IV over 3–5 mins, then
800–2000 mg/day
Non-epileptic attack disorder, psychogenic Phenytoin: give loading dose (if not already used as above)
seizures, pseudoseizures, psychogenic of 15 mg/kg, infuse at < 50 mg/min, then 300 mg/day
non-epileptic seizures Carbamazepine 400 mg by nasogastric tube, then
This disorder is recognised in all cultures but nomencla- 400–1200 mg/day
ture has yet to be standardised. Around 10% of patients • Investigate cause
referred to a first seizure clinic will have LOC resulting
from psychological reactions to circumstances or trau-
matic life events. Clinical pointers to the diagnosis
include specific emotional triggers, partially retained more subtle. Cyanosis, pyrexia, acidosis and sweating
awareness, dramatic movements or vocalisation, very may occur, and complications include aspiration, hypo-
prolonged duration (up to hours), rapid recovery or tension, cardiac arrhythmias and renal or hepatic failure.
subsequent emotional distress. Diagnosis is important, In patients with pre-existing epilepsy, the most likely
as such patients are at significant risk of being harmed cause is a fall in anti-epileptic drug levels. In de novo
by inappropriate treatment if they are assumed to have status epilepticus, it is essential to exclude precipitants
epilepsy. Conversely, a hasty diagnosis may lead to such as infection (meningitis, encephalitis), neoplasia
treatment being withheld in atypical or prolonged sei- and metabolic derangement (hypoglycaemia, hypo-
zures. Specialist help is necessary to plan management. natraemia, hypocalcaemia). Treatment and investigation
are outlined in Box 26.14.
Status epilepticus
Coma
Status epilepticus is seizure activity not resolving spon-
taneously, or recurrent seizure with no recovery of con- Conscious level should be measured using the Glasgow
sciousness in between. Persisting seizure activity has a Coma Scale (GCS, Box 26.15). Although developed
recognised mortality and is a medical emergency. for use in head injury, GCS is widely used in medical
Diagnosis is usually clinical and can be made on the coma, but disorders that affect language or limb func-
basis of the description of prolonged rigidity and/or tion (e.g. left hemisphere stroke, locked-in syndrome)
clonic movements with loss of awareness. As seizure may reduce its usefulness. Nevertheless, it provides
activity becomes prolonged, movements may become useful prognostic information, and serial recordings 1159
NEUROLOGICAL DISEASE
Cerebral
hemispheres
Contralateral
hemiplegia
Upper
motor
neuron Tetraplegia
lesion Spinal cord
Upper limbs
Lower limbs
Fig. 26.18 Patterns of motor loss according to the anatomical site of the lesion.
26
26 Sensory disturbance
nor fit with any organic disease. Care must be taken in
diagnosing non-organic sensory problems; a careful
history and examination will ensure there is no other
Sensory symptoms are common and are frequently objective neurological deficit.
benign. Patients often find sensory symptoms difficult Sensory neurological examination needs to be under-
to describe, and sensory examination is difficult for taken and interpreted with care since the findings
both doctor and patient. While neurological disease depend, by definition, on subjective reports. However,
can cause sensory symptoms, systemic disorders can the reported distribution of sensory loss can be useful
also be responsible. Tingling in both hands and around when combined with the coexisting deficits of motor
the mouth can occur as the result of hyperventilation and/or cranial nerve function (Fig. 26.19).
(p. 657) or hypocalcaemia (p. 768). When there is dys-
function of the relevant cerebral cortex, the patient’s Sensory loss in peripheral nerve lesions
perception of the wholeness or actual presence of the
relevant part of the body may be distorted. Here the symptoms are usually of sensory loss and par-
aesthesia. Single nerve lesions cause disturbance in the
Numbness and paraesthesia sensory distribution of the nerve, whereas in diffuse
neuropathies the longest neurons are affected first,
The history may give the best clues to localisation and
giving a characteristic ‘glove and stocking’ distribution.
pathology. Certain common patterns are recognised:
If smaller nerve fibres are preferentially affected (e.g. in
in migraine, the aura may consist of spreading tingling
diabetic neuropathy), temperature and pin-prick (pain)
or paraesthesia, followed by numbness evolving over
are reduced, whilst vibration sense and proprioception
20–30 minutes over one half of the body, often splitting
(modalities served by the larger, well-myelinated,
the tongue. Sensory loss caused by a stroke or transient
sensory nerves) may be spared. In contrast, vibration
ischaemic attack (TIA) occurs much more rapidly and
and proprioception are particularly affected if the neu-
is typically negative (numbness) rather than positive
ropathy is demyelinating in character (p. 1224), produc-
(tingling). Rarely, unpleasant paraesthesia of sensory
ing symptoms of tightness and swelling with impairment
epilepsy spreads within seconds. The sensory alteration
of proprioception and vibration sensation.
of inflammatory spinal cord lesions often ascends from
one or both lower limbs to a distinct level on the trunk
over hours to days. Psychogenic sensory change can Sensory loss in nerve root lesions
occur as a manifestation of anxiety or as part of a conver- These typically present with pain as a prominent feature,
sion disorder (p. 246). In such cases, the distribution either within the spine or in the limb plexuses. It is often
usually does not conform to a known anatomical pattern felt in the myotome rather than the dermatome. The
C5
C7
L5
E Unilateral cord lesion F Central cord lesion G Mid-brainstem lesion H Hemisphere (thalamic)
(Brown–Séquard) lesion
Fig. 26.19 Patterns of sensory loss. A Generalised peripheral neuropathy. B Sensory roots: some common examples. C Single dorsal column
lesion (proprioception and some touch loss). D Transverse thoracic spinal cord lesion. E Unilateral cord lesion (Brown–Séquard): ipsilateral dorsal
column (and motor) deficit and contralateral spinothalamic deficit. F Central cord lesion: ‘cape’ distribution of spinothalamic loss. G Mid-brainstem
lesion: ipsilateral facial sensory loss and contralateral loss on body below the vertex. H Hemisphere (thalamic) lesion: contralateral loss on one side of
1164 face and body.
Presenting problems in neurological disease
nerve root involved may be deduced from the der- Cortical lesions are more likely to cause a mixed
matomal pattern of sensory loss, although overlap may motor and sensory loss. Substantial lesions of the pari-
lead to this being smaller than expected. etal cortex (as in large strokes) can cause severe loss of
proprioception and may even abolish conscious aware-
Sensory loss in spinal cord lesions ness of the existence of the affected limb(s). The resulting
Transverse lesions of the spinal cord produce loss of all loss of function in the limb may be impossible to distin-
sensory modalities below that segmental level, although guish from paralysis. Pathways are so tightly packed in
the clinical level may only be manifest 2–3 segments the thalamus that even small lacunar strokes can cause
lower than the anatomical site of the lesion. Very often, isolated contralateral hemisensory loss.
there is a band of paraesthesia or hyperaesthesia at the
top of the area of sensory loss. Clinical examination may Neuropathic pain
reveal dissociated sensory loss, i.e. different patterns in Neuropathic pain is a positive neurological symptom
the spinothalamic and dorsal columnar pathways. If the caused by dysfunction of the pain perception apparatus,
transverse lesion is vascular due to anterior spinal artery in contrast to nociceptive pain, which is secondary to
thrombosis, the spinothalamic pathways may be affected pathological processes such as inflammation. Neuro-
while the posterior one-third of the spinal cord (the pathic pain has distinctive features and typically pro-
dorsal column modalities) may be spared. vokes a very unpleasant, persistent, burning sensation.
Lesions damaging one side of the spinal cord will There is often increased sensitivity to touch, so that light
produce loss of spinothalamic modalities (pain and tem- brushing of the affected area causes exquisite pain (allo-
perature) on the opposite side, and of dorsal column dynia). Painful stimuli are felt as though they arise from
modalities (joint position and vibration sense) on the a larger area than that touched, and spontaneous bursts
same side of the body – the Brown–Séquard syndrome of pain may also occur. Pain may be elicited by other
(p. 1221). modalities (allodynia) and is considerably affected by
Lesions in the centre of the spinal cord (such as emotional influences. The most common causes of neu-
syringomyelia: see Box 26.98 and Fig. 26.46, p. 1222) ropathic pain are diabetic neuropathies, trigeminal and
spare the dorsal columns but involve the spino- post-herpetic neuralgias, and trauma to a peripheral
26
thalamic fibres crossing the cord from both sides over nerve. Treatment of these syndromes can be difficult.
the length of the lesion. There is no sensory loss in seg- Drugs that modulate various parts of the nociceptive
ments above and below the lesion; this is described as system, such as gabapentin, carbamazepine or tricyclic
‘suspended’ sensory loss. There is sometimes reflex loss antidepressants, may help. Localised treatment (topical
at the level of the lesion if afferent fibres of the reflex arc treatment or nerve blocks) sometimes succeeds but may
are affected. increase the sensory deficit and worsen the situation.
An isolated lesion of the dorsal columns is not uncom- Electrical stimulation has occasionally proved success-
mon in multiple sclerosis. This produces a characteristic ful. For further information, see Chapter 12.
unpleasant, tight feeling over the limb(s) involved and,
while there is no loss of pin-prick or temperature sensa-
tion, the associated loss of proprioception may severely
limit function of the affected limb(s). Abnormal movements
Sensory loss in brainstem lesions Disorders of movement lead to either extra, unwanted
movement (hyperkinetic disorders) or too little move-
Lesions in the brainstem can be associated with sensory
ment (hypokinetic disorders) (Box 26.21). In either case,
loss, but the distribution depends on the site of the
the lesion often localises to the basal ganglia, although
lesion. A lesion limited to the trigeminal nucleus or its
some tremors are related to cerebellar or brainstem dis-
sensory projections will cause ipsilateral facial sensory
turbance. Functional movement disorders are common,
disturbance. For example, pain resembling trigeminal
and may mimic all of the organic syndromes below. The
neuralgia can be seen in patients with multiple sclerosis.
most important hypokinetic disorder is Parkinson’s
The anatomy of the trigeminal connections means that
disease (p. 1194). Parkinsonism is a clinical description
lesions in the medulla or spinal cord can give rise to
of a collection of symptoms, including tremor, brady-
‘balaclava’ patterns of sensory loss (p. 1147). Sensory
kinesia and rigidity. Whilst the history is always impor-
pathways running up from the spinal cord can also be
tant, observation is clearly vital; much of the skill in
damaged in the brainstem, resulting in simultaneous
diagnosing movement disorders lies in pattern recogni-
sensory loss in arm(s) and/or leg(s).
tion. Once it is established whether the problem is
Sensory loss in hemispheric lesions hypo- or hyperkinetic, the next task is to categorise the
movements further, accepting that there is often overlap.
The temporal, parietal and occipital lobes receive sensory
Videoing the movements (with the patient’s permis-
information regarding the various modalities of touch,
sion), so that they can be shown to a movement disorder
vision, hearing and balance (see Box 26.2, p. 1142). The
expert, may provide a quick diagnosis in cases of
initial points of entry into the cortex are the respective
uncertainty.
primary cortical areas (see Fig. 26.4, p. 1143). Damage
to any of these primary areas will result in reduction or
loss of the ability to perceive that particular modality: Tremor
‘negative’ symptomatology. Abnormal excitation of Tremor is caused by alternating agonist/antagonist
these areas can result in a false perception (‘positive’ muscle contractions and produces a rhythmical oscilla-
symptoms), the most common of which is migrainous tion of the body part affected. In the assessment of
visual aura (flashing lights or teichopsiae). tremor, the position, body part affected, frequency and 1165
NEUROLOGICAL DISEASE
amplitude should be considered, as these provide diag- prolonged levodopa treatment for Parkinson’s
nostic clues (Box 26.22). disease. Other causes are shown in Box 26.23.
• Athetosis: slower, writhing movement of the limbs,
Other hyperkinetic syndromes often combined with chorea and having similar
Non-rhythmic involuntary movements include chorea, causes.
athetosis, ballism, dystonia, myoclonus and tics. They • Ballism: a more dramatic form of chorea, causing
are categorised by clinical appearance, and coexistence often-violent flinging movements of one limb
and overlap are common, such as in choreoathetosis. (monoballism) or one side of the body
• Chorea: jerky, brief, purposeless involuntary (hemiballism). The lesion localises to the
movements, appearing as fidgety movements contralateral subthalamic nucleus and the most
affecting different areas; they suggest disease in common cause is stroke.
the caudate nucleus (as in Huntington’s disease, • Dystonia: sustained involuntary muscle contraction
1166 p. 1198) and are a common complication of that causes abnormal postures or movement. It may
Presenting problems in neurological disease
difficult to distinguish the different types clinically (Box (non-existent words). Examples include Wernicke’s
26.24). Dysarthria is discussed further in the section on aphasia (which localises to the superior posterior tem-
bulbar symptoms (p. 1173). poral lobe), transcortical sensory aphasia, conduction
aphasia and anomic aphasia.
Dysphasia Non-fluent aphasias, also called expressive apha-
sias, are difficulties in articulating, but in most cases
Dysphasia (or aphasia) is a disorder of the language
there is relatively good auditory verbal comprehension.
content of speech. It can occur with lesions over a
26
Examples include Broca’s aphasia (associated with
wide area of the dominant hemisphere (Fig. 26.20). Dys-
pathologies in the inferior frontal region), transcortical
phasia may be categorised according to whether the
motor aphasia and global aphasia.
speech output is fluent or non-fluent. Fluent aphasias,
‘Pure’ aphasias are selective impairments in reading,
also called receptive aphasias, are impairments related
writing or the recognition of words. These disorders
mostly to the input or reception of language, with dif-
may be quite selective. For example, a person is able
ficulties either in auditory verbal comprehension or in
to read but not write, or is able to write but not read.
the repetition of words, phrases or sentences spoken by
Examples include pure alexia, agraphia and pure
others. Speech is easy and fluent, but there are difficul-
word deafness.
ties related to the output of language as well, such as
Dysphasia (a focal symptom) is frequently misinter-
paraphasia (either substitution of similar-sounding
preted as confusion (which is non-focal). Dysphasia can
non-words, or incorrect words) and neologisms
be misheard/misspelt as dysphagia, and for this reason
some prefer to use ‘aphasia’ to avoid confusion.
Central
sulcus
3 5 2 1 4
Disturbance of smell
Symptomatic olfactory loss almost always is due to local
causes (nasal obstruction), follows head injury or is idio-
pathic. Hyposmia may occur early in Parkinson’s
disease. Frontal lobe lesions are a rare cause. Positive
olfactory symptoms may arise from Alzheimer’s disease
or epilepsy.
visual field loss are explained by the anatomy of the the headache. Simple flashes of light (phosphenes) may
visual pathways (see Fig. 26.7, p. 1145). Associated clini- indicate damage to the retina (e.g. detachment) or to
cal manifestations are described in Box 26.25. Visual the primary visual cortex. Formed visual hallucinations
symptoms affecting one eye only are liable to be due to may be caused by drugs, or may be due to epilepsy or
lesions anterior to the optic chiasm. ‘release phenomena’ in a blind visual field (Charles
Transient visual loss is quite common and sudden- Bonnet’s syndrome).
onset visual loss lasting less than 15 minutes is likely to
have a vascular origin. It may be difficult to know Double vision
whether the visual loss was monocular (carotid circula-
tion) or binocular (vertebrobasilar circulation), and it can Subtle double vision (diplopia) may be reported as
help to ask if the patient tried closing each eye in turn blurred rather than double vision and most commonly
to see whether the symptom affected one eye or both. arises from misalignment of the eyes. Monocular diplo-
Visual field testing is an important part of the examina- pia is rare and indicates ocular disease, while binocular
tion, either at the bedside or formally with perimetry. diplopia suggests a probable neurological cause. Closing
Field defects become more symmetrical (congruous), the either eye in turn will abort binocular diplopia. Once
closer the lesion comes to the visual cortex. the presence of binocular diplopia is confirmed, it should
Migrainous visual symptoms are very common and, be established whether the diplopia is maximal in any
when associated with typical headache and other particular direction of gaze, whether the images are
migraine features, rarely pose a diagnostic challenge. separated horizontally or vertically, and whether there
However, they may occur in isolation, making distinc- are any associated symptoms or signs, such as ptosis or
tion from TIA difficult, but TIAs typically cause negative pupillary disturbance.
(transient blindness) symptoms, whereas migraine Binocular diplopia occurs when eye movement is
causes positive phenomena (see below). TIAs often last impaired, so that the image is not projected to the same
for a shorter time (a few minutes), compared to the 10– points on the two retinae. It may result from central
60-minute duration of migraine aura, and will have an disorders or from disturbance of the ocular motor
abrupt onset and end, unlike the gradual evolution of a nerves, muscles or the neuromuscular junction (see Fig.
migraine aura. 26.8, p. 1146). The pattern of double vision, along with
any associated features, usually allows inference of
which nerves/muscles are affected, whilst the mode of
Positive visual phenomena onset and other features (e.g. fatigability in myasthenia)
The most common cause is migraine; patients may provide further clues about the cause.
describe silvery zigzag lines (fortification spectra) or The causes of ocular motor nerve palsies are listed in
1170 flashing coloured lights (teichopsia), usually preceding Box 26.26.
Presenting problems in neurological disease
26
Orbit Vascular (e.g. diabetes, vasculitis) 3, 4 and/or 6 Pain
Infections Pupil often spared in vascular 3rd
Tumour nerve palsy
Granuloma
Trauma
Optic Optic
nerve Swollen nerve
optic disc
Retinal
veins Central retinal vein Axonal transport
block
Meningeal sheath
Swollen axons
Fig. 26.22 Mechanism of optic disc oedema (papilloedema). A Normal. B Disc oedema (e.g. due to cerebral tumour). C Fundus photograph
of the left eye showing optic disc oedema with a small haemorrhage on the nasal side of the disc.
Hearing disturbance
Papilloedema
Each cochlear organ has bilateral cortical representation,
There are several causes of swelling of the optic disc, but
so unilateral hearing loss is a result of peripheral organ
the term ‘papilloedema’ is reserved for swelling second-
damage. Bilateral hearing dysfunction is usual, and is
ary to raised intracranial pressure, when obstructed axo-
most commonly due to age-related degeneration or
plasmic flow from retinal ganglion cells results in
noise damage, although infection and drugs (particu-
swollen nerve fibres, which in turn cause capillary and
larly diuretics and aminoglycoside antibiotics) can be a
venous congestion, producing papilloedema. The earli-
primary cause. Prominent deafness may suggest a mito-
est sign is the cessation of venous pulsation seen at the
chondrial disorder (see Box 26.109, p. 1229).
disc, progression causing the disc margins to become
red (hyperaemic). Disc margins become indistinct and
haemorrhages may occur in the retina (Fig. 26.22). Lack Bulbar symptoms – dysphagia
of papilloedema never excludes raised intracranial pres-
sure. Other causes of optic disc swelling are listed in Box and dysarthria
26.29. Some normal variations of disc appearance (e.g.
optic nerve drusen) can mimic disc swelling. Swallowing is a complex activity involving the coordi-
nated action of lips, tongue, soft palate, pharynx and
larynx, which are innervated by cranial nerves 7, 9, 10,
Optic atrophy 11 and 12. Structural causes of dysphagia are considered
Loss of nerve fibres causes the optic disc to appear pale, on page 851. Neurological mechanisms are vulnerable to
as the choroid becomes visible (Fig. 26.23). A pale disc damage at different points, resulting in dysphagia that
(optic atrophy) follows optic nerve damage, and causes is usually accompanied by dysarthria. Tempo is again
include previous optic neuritis or ischaemic damage, crucial: acute onset of dysphagia may occur as a result
long-standing papilloedema, optic nerve compression, of brainstem stroke or a rapidly developing neuropathy, 1173
NEUROLOGICAL DISEASE
such as Guillain–Barré syndrome or diphtheria. Inter- evokes reflex detrusor contraction (analogous to the
mittent fatigable muscle weakness (including dys- muscle stretch reflex), and reciprocal changes in sympa-
phagia) would suggest myasthenia gravis. Dysphagia thetic activation and relaxation of the distal sphincter
developing over weeks or months may be seen in motor result in coordinated bladder emptying.
neuron disease, polymyositis, basal meningitis and Damage to the lower motor neuron pathways (the
inflammatory brainstem disease. More slowly develop- pelvic and pudendal nerves) produces a flaccid bladder
ing dysphagia suggests a myopathy or possibly a brain- and sphincter with overflow incontinence, often accom-
stem or skull-base tumour. panied by loss of pudendal sensation. Such damage may
Pathologies affecting lower cranial nerves (9, 10, 11 be due to disease of the conus medullaris or sacral nerve
and 12) frequently manifest bilaterally, producing roots, either within the dura (as in inflammatory or car-
dysphagia and dysarthria. The term ‘bulbar palsy’ is cinomatous meningitis) or as they pass through the
used to describe lower motor neuron lesions, either sacrum (trauma or malignancy), or due to damage to the
within the medulla or outside the brainstem. The tongue nerves themselves in the pelvis (infection, haematoma,
is wasted and fasciculating, and palatal movement is trauma or malignancy).
reduced. Damage to the pons or spinal cord results in an
Upper motor neuron innervation of swallowing is ‘upper motor neuron’ pattern of bladder dysfunction
bilateral, so persistent dysphagia is unusual with a uni- due to uncontrolled over-activity of the parasympathetic
lateral upper motor lesion (the exception being in the supply. The bladder is small and highly sensitive to
acute stages of, for example, a hemispheric stroke). being stretched. This results in frequency, urgency and
Widespread lesions above the medulla will cause upper urge incontinence. Loss of the coordinating control of
motor neuron bulbar paralysis, known as ‘pseudobulbar the pontine micturition centre will also result in the phe-
palsy’. Here the tongue is small and contracted, and nomenon of detrusor–sphincter dyssynergia, in which
moves slowly; the jaw jerk is brisk. Causes of bulbar and detrusor contraction and sphincter relaxation are not
pseudobulbar palsies are shown in Box 26.30. coordinated; the spastic bladder will often try to empty
against a closed sphincter. This manifests as both
urgency and an inability to pass urine, which is distress-
Bladder, bowel and sexual disturbance ing and painful. The resultant incomplete bladder
emptying predisposes to urinary infection, and the
Whilst isolated disturbances of bladder, bowel and prolonged high bladder pressure may result in renal
sexual function are rarely the sole presenting features failure; post-micturition bladder ultrasound may
of neurological disease, they are common complica- confirm incomplete bladder emptying. More severe
tions of many chronic disorders such as multiple sclero- lesions of the spinal cord, as in spinal cord compression
sis, stroke and dementia, and are frequently found post or trauma, can result in painless urinary retention, as
head injury. Abnormalities in these functions con- bladder sensation, normally carried in the lateral spino-
siderably reduce quality of life for patients. Incontinence thalamic tracts, will be cut off.
and its management are discussed elsewhere (pp. 472, Damage to the frontal lobes gives rise to loss of aware-
918 and 175). ness of bladder fullness and consequent incontinence.
Coexisting cognitive impairment may result in inappro-
Bladder dysfunction priate micturition. These features are seen typically in
The anatomy and physiology involved in controlling hydrocephalus, frontal tumours, dementia and bifrontal
bladder functions are discussed on page 466 but it subdural haematomas.
is worth emphasising the role of the pontine micturi- When a patient presents with bladder symptoms, it
tion centre, which is itself under higher control via is important to try to localise the lesion on the basis
inputs from the pre-frontal cortex, mid-brain and of history and examination, remembering that most
hypothalamus. bladder problems are not neurological unless there are
In the absence of conscious control (e.g. in coma or overt neurological signs. Clinical features and manage-
1174 dementia), distension of the bladder to near-capacity ment are summarised in Box 26.31.
Functional symptoms
Personality change
Psychiatric disorders
While this is often due to psychiatric illness, neuro-
logical conditions that alter the function of the frontal Psychiatric disorders are described in Chapter 10 but
lobes can cause personality change and mood disorder may cause or result from neurological problems. Care is
(see Box 26.2, p. 1142). Personality change due to a needed in their identification, as effective management
frontal lobe disorder may occur as the result of structural will help the underlying neurological illness.
damage due to stroke, trauma, tumour or hydrocepha-
lus. The nature of any change may help localise the
lesion. FUNCTIONAL SYMPTOMS
Patients with mesial frontal lesions become increas-
ingly withdrawn, unresponsive and mute (abulic), often Many patients presenting with neurological symptoms
in association with urinary incontinence, gait apraxia do not have a defined neurological disease and are best
and an increase in tone known as gegenhalten, in which described as having functional symptoms (p. 236). Some 1175
NEUROLOGICAL DISEASE
suggest hormonal influences. Oestrogen-containing oral treatment for either oral contraception or hormone
contraception sometimes exacerbates migraine, and replacement, although the increased risk of ischaemic
increases the small risk of stroke in patients who suffer stroke is minimal.
from migraine with aura. Doctors and patients often
over-estimate the role of dietary precipitants such as Medication overuse headache
cheese, chocolate or red wine. When psychological With increasing availability of over-the-counter medica-
factors contribute, the migraine attack often occurs after tion, headache syndromes perpetuated by analgesia
a period of stress, being more likely on Friday evening intake are becoming much more common. Medication
at the end of the working week or at the beginning of a overuse headache (MOH) can complicate any other
holiday. headache syndrome, but is especially associated with
migraine and tension headache. The medications that
Clinical features are the most common culprits are compound analgesia
Some patients report a prodrome of malaise, irritability (particularly codeine and other opiate-containing prepa-
or behavioural change for some hours or days. Around rations) and triptans, and MOH is usually associated
20% of patients experience an aura, and are said to have with use on more than 10–15 days per month.
migraine with aura (previously known as classical Management is by withdrawal of the responsible
migraine). The aura is most often visual, consisting of analgesics; patients should be warned that the initial
fortification spectra, which are shimmering, silvery effect will be to exacerbate the headache. Migraine
zigzag lines that march across the visual fields for up to prophylactics may be helpful in reducing the rebound
40 minutes, sometimes leaving a trail of temporary headaches. In severe cases, hospital admission with or
visual field loss (scotoma). In some there is a sensory without a course of corticosteroids may be helpful.
aura of tingling followed by numbness, spreading
over 20–30 minutes, from one part of the body to Cluster headache
another. Dominant hemisphere involvement may also Cluster headaches (also known as migrainous neuralgia)
cause transient speech disturbance. The 80% of patients are much less common than migraine. There is a 5 : 1
with characteristic headache but no ‘aura’ are said male predominance and onset is usually in the third
26
to have migraine without aura (previously called decade.
‘common’ migraine).
Migraine headache is usually severe and throbbing, Pathophysiology
with photophobia, phonophobia and vomiting lasting The cause is unknown, but this type of headache differs
from 4 to 72 hours. Movement makes the pain worse, from migraine in its character, lack of genetic predis-
and patients prefer to lie in a quiet, dark room. position, lack of provoking dietary factors, opposing
Caution should be taken in ascribing the cause of an gender imbalance and different drug effect. Functional
individual’s limb weakness or isolated aura without imaging studies have suggested abnormal hypothalamic
headache to migraine. In such cases, other structural activity. Patients are more often smokers with a higher
disorders of the brain, or even focal epilepsy, need to be than average alcohol consumption.
considered.
In a smaller number of patients, the symptoms of the Clinical features
aura do not resolve, leaving more permanent neuro- Cluster headache is strikingly periodic, featuring runs of
logical disturbance. This persistent migrainous aura may identical headaches beginning at the same hour for
occur with or without evidence of brain infarction. weeks at a time (the eponymous ‘cluster’). Patients may
experience either one or several attacks within a 24-hour
Management period. Cluster headache causes severe, unilateral peri-
Avoidance of identified triggers or exacerbating factors orbital pain with autonomic features, such as unilateral
(such as the combined contraceptive pill) may prevent lacrimation, nasal congestion and conjunctival injection
attacks. Treatment of an acute attack consists of simple (occasionally with the other features of Horner’s syn-
analgesia with aspirin, paracetamol or non-steroidal drome). The pain, though severe, is characteristically
anti-inflammatory agents. Nausea may require an brief (30–90 minutes). In contrast to the behaviour of
antiemetic such as metoclopramide or domperidone. those with migraine, patients are often highly agitated
Severe attacks can be aborted by one of the increasing during the headache phase. The cluster period is typi-
number of ‘triptans’ (e.g. sumatriptan), which are potent cally a few weeks, followed by remission for months
5-hydroxytryptamine (5-HT) agonists. These can be to years, but a small proportion do not experience
administered orally, by subcutaneous injection or by remission.
nasal spray. Care should be taken to avoid accelerating
use. Caution is needed with ergotamine preparations Management
since they may lead to dependence. Overuse of any Acute attacks can usually be halted by subcutaneous
analgesia, including triptans, may contribute to associ- injections of sumatriptan or by inhalation of 100%
ated medication overuse headache. oxygen. The brevity of the attack probably prevents
If attacks are frequent (more than 3–4 per month), other migraine therapies from being effective. Migraine
prophylaxis should be considered. Many drugs can be prophylaxis is often ineffective too but attacks can be
used, but the most frequently used are vasoactive drugs prevented in some patients by sodium valproate, vera-
(calcium channel blockers and β-adrenoceptor ant- pamil, methysergide or short courses of oral cortico-
agonists (β-blockers)), antidepressants (amitriptyline, steroids. Patients with severe debilitating clusters can be
dosulepin) and anti-epileptic drugs (valproate, topiram- helped with lithium therapy, although this requires
ate). Women with aura should avoid oestrogen monitoring (p. 245). 1177
NEUROLOGICAL DISEASE
*Short-lasting, Unilateral, Neuralgiform headache with Conjunctival injection, Tearing, rhinorrhoea and forehead sweating.
Trigeminal neuralgia the trigeminal root is said to have a 90% success rate.
Otherwise, localised injection of alcohol or phenol into
This is characterised by unilateral lancinating facial
a peripheral branch of the nerve may be effective.
pain, most commonly involving the second and/or third
divisions of the trigeminal nerve territory, usually in
patients over the age of 50 years. Headaches associated with
specific activities
Pathophysiology These usually affect men in their thirties and forties.
Trigeminal neuralgia is thought to be caused by an Patients develop a sudden, severe headache with exer-
irritative lesion involving the trigeminal root zone, in tion, including sexual activity. There is usually no vom-
some cases an aberrant loop of artery. Other compres- iting and no neck stiffness, and the headache lasts less
sive lesions, usually benign, are occasionally found. than 10–15 minutes, though a less severe dullness may
Trigeminal neuralgia associated with multiple sclerosis persist for some hours. Subarachnoid haemorrhage
may result from a plaque of demyelination in the needs to be excluded by CT and/or CSF examination
brainstem. (see Fig. 27.12, p. 1246) after a first event. The pathogen-
esis of these headaches is unknown. Although frighten-
Clinical features ing, attacks are usually brief and patients may only need
The pain is repetitive, severe and very brief. It may be reassurance and simple analgesia for the residual head-
triggered by touch, a cold wind or eating. Physical signs ache. The syndrome may recur, and prevention may be
are usually absent, although the spasms may make the necessary with propranolol or indometacin.
patient wince and sit silently (tic douloureux). Similar
symptoms may occur in multiple sclerosis or with other Other headache syndromes
brainstem lesions, in which case there may be associated
A number of rare headache syndromes produce pains
sensory changes in the trigeminal nerve territory or else-
about the eye similar to cluster headaches (Box 26.33).
where. There is a tendency for the condition to remit and
These include chronic paroxysmal hemicrania and
relapse over many years.
SUNCT (short-lasting unilateral neuralgiform head-
Management aches with conjunctival injection and tearing). The rec-
The pain usually responds at least partially to car- ognition of these syndromes is useful since they often
bamazepine. It is wise to start with a low dose and respond to specific treatments such as indometacin.
increase gradually, according to effect. In patients who
cannot tolerate carbamazepine, gabapentin, pregabalin,
amitriptyline or steroids may be effective. The possibil- EPILEPSY
ity of surgical treatment should be entertained, espe-
cially where response is incomplete in younger patients. A seizure can be defined as the occurrence of signs and/
1178 Decompression of the vascular loop encroaching on or symptoms due to abnormal, excessive or synchronous
Epilepsy
26
• Epileptic spasms Fig. 26.24 The pathophysiological classification of seizures.
A A focal seizure originates from a paroxysmal discharge in a focal
area of the cerebral cortex (often the temporal lobe); the seizure may
subsequently spread to the rest of the brain (secondary generalisation) via
neuronal activity in the brain. ‘Epilepsy’ is the tendency diencephalic activating pathways. B In primary generalised seizures the
to have unprovoked seizures. The lifetime risk of seizure abnormal electrical discharges originate from the diencephalic activating
is about 5%, although incidence is highest at the extremes system and spread simultaneously to all areas of the cortex.
of age. Whilst the prevalence of active epilepsy in Euro-
pean countries is about 0.5%, the figure in developing
countries may be higher because of parasitic illnesses potentials. In vivo, epileptic cortex shows repetitive dis-
such as cysticercosis (p. 380). charges involving large groups of neurons.
Historical terms such as ‘grand mal’ (implying tonic– Seizures may be related to a localised disturbance in
clonic seizures) and ‘petit mal’ (intended by its origina- the cortex, becoming manifest in the first instance as
tors to mean ‘absence seizures’ but commonly used to focal seizures. Any disturbance of cortical architecture
describe ‘anything other than grand mal’) have been and function can precipitate this, whether focal infec-
superseded. Subsequent revisions, including terms such tion, tumour, hamartoma or trauma-related scarring. If
as ‘complex partial’ and ‘simple partial’, have been focal seizures remain localised, the symptoms experi-
imprecise and confusing, carrying little information enced depend on which cortical area is affected. If areas
about underlying pathology, treatment or prognosis. in the temporal lobes become involved, then awareness
The modern equivalents for these terms will be given of the environment becomes impaired but without asso-
below, but it is preferable to adhere to the 2010 iteration ciated tonic–clonic movements. When both hemispheres
of the International League Against Epilepsy’s classifica- are involved, either at onset or after spread, the seizure
tion (Box 26.34). becomes generalised (Fig. 26.24).
In seizures that are generalised at onset, the abnormal
Pathophysiology activity probably originates in the central mechanisms
To function normally, the brain must achieve an ongo- controlling cortical activation (see Fig. 26.24) and spreads
ing balance between excitation and inhibition, in order rapidly. Such epilepsies constitute around 30% of all
to remain responsive to the environment without con- epilepsy, and are likely to reflect widespread distur-
tinued unrestrained spontaneous activity. The inhibi- bance of structure or function. Animal models have
tory transmitter gamma-aminobutyric acid (GABA) is revealed mutations in genes for ion channels and recep-
particularly important, acting on ion channels to enhance tors that cause seizures. In humans, many generalised
chloride inflow and reduce the chances of action poten- epilepsies will have a genetic basis, and these almost
tial formation. Excitatory amino acids (glutamate and always become apparent before the age of 35.
aspartate) allow influx of sodium and calcium, produc- Seizure activity is usually apparent on EEG as
ing the opposite effect. It is likely that many seizures spike and wave discharges (see Fig. 26.14, p. 1152).
result from an imbalance between this excitation and Other generalised seizure activity may involve merely
inhibition. Intracellular recordings during seizures dem- brief loss of awareness (absence seizures), single jerks
onstrate a paroxysmal depolarisation shift in neuronal (myoclonus) or loss of tone (atonic seizures), as detailed
membrane potential, predisposing to recurrent action in Box 26.34. 1179
NEUROLOGICAL DISEASE
26 Clinical features
Seizure type and epilepsy type
26.36 Causes of focal seizures
26.37 Causes of generalised tonic–clonic Tonic seizures. These are associated with a generalised
seizures increase in tone and an associated loss of awareness.
They are usually seen as part of an epilepsy syndrome
Generalisation from focal seizures
and are unlikely to be isolated.
• See Box 26.36
Clonic seizures. Clonic seizures are similar to tonic–
Genetic clonic seizures. The clinical manifestations are similar
• Inborn errors of metabolism (p. 64) but without a preceding tonic phase.
• Storage diseases (p. 450)
• Phakomatoses (e.g. tuberous sclerosis, p. 1302)
Seizures of uncertain generalised or focal nature
Cerebral birth injury Epileptic spasms. While these are highlighted in the
Hydrocephalus classification system, they are unusual in adult practice
Cerebral anoxia and occur mainly in infancy. They signify widespread
Drugs cortical disturbance and take the form of marked con-
• Antibiotics: penicillin, isoniazid, metronidazole tractions of the axial musculature, lasting a fraction
• Antimalarials: chloroquine, mefloquine of a second but recurring in clusters of 5–50, often
• Ciclosporin on awakening.
• Cardiac anti-arrhythmics: lidocaine, disopyramide
• Psychotropic agents: phenothiazines, tricyclic Epilepsy syndromes
antidepressants, lithium
• Amphetamines (withdrawal) Many patients with epilepsy fall into specific patterns,
depending on seizure type(s), age of onset and treat-
Alcohol (especially withdrawal) ment responsiveness: the so-called electroclinical syn-
Toxins dromes (Box 26.38). It is anticipated that genetic testing
• Organophosphates (sarin) • Heavy metals (lead, tin) will ultimately demonstrate similarities in molecular
Metabolic disease pathophysiology.
• Hypocalcaemia • Hypoglycaemia Box 26.39 highlights the more common epilepsy syn-
• Hyponatraemia • Renal failure dromes, which are largely of early onset and are sensi-
• Hypomagnesaemia • Liver failure tive to sleep deprivation, hyperventilation, alcohol and 26
Infective
• Post-infectious • Meningitis (p. 1201)
encephalopathy
26.38 Electroclinical epilepsy syndromes
Inflammatory
• Multiple sclerosis (uncommon) (p. 1188) Adolescence to adulthood
• SLE (p. 1109) • Juvenile absence epilepsy (JAE)
Diffuse degenerative diseases • Juvenile myoclonic epilepsy (JME)
• Alzheimer’s disease (uncommonly) (p. 251) • Epilepsy with generalised tonic–clonic seizures alone
• Creutzfeldt–Jakob disease (rarely) (p. 1211) • Progressive myoclonus epilepsies (PME)
• Autosomal dominant epilepsy with auditory features (ADEAF)
• Other familial temporal lobe epilepsies
Less specific age relationship
• Familial focal epilepsy with variable foci (childhood to adult)
Witnesses are usually frightened by the event, often • Reflex epilepsies
believe the person to be dying, and may struggle to give Distinctive constellations
a clear account of the episode. Some may not describe • Mesial temporal lobe epilepsy with hippocampal sclerosis
the tonic or clonic phase, and may not mention cyanosis (MTLE with HS)
or tongue-biting. In less typical episodes, post-ictal con- • Rasmussen’s syndrome
fusion, or sequelae such as headache or myalgia, may be • Gelastic (from the Greek word for laughter) seizures with
the main pointers to the diagnosis. Causes of generalised hypothalamic hamartoma
tonic–clonic seizures are listed in Box 26.37. • Hemiconvulsion–hemiplegia–epilepsy
Absence seizures. Absence seizures (previously ‘petit Epilepsies with structural–metabolic causes
mal’) always start in childhood. The attacks are rarely • Malformations of cortical development (hemimegalencephaly,
mistaken for focal seizures because of their brevity. They heterotopias etc.)
can occur so frequently (20–30 times a day) that they are • Neurocutaneous syndromes (tuberous sclerosis complex,
mistaken for daydreaming or poor concentration in Sturge–Weber etc.)
school. • Tumour
Myoclonic seizures. These are typically brief, jerking • Infection
movements, predominating in the arms. In epilepsy, • Trauma
they are more marked in the morning or on awakening • Angioma
from sleep, and tend to be provoked by fatigue, alcohol • Perinatal insults
or sleep deprivation. • Stroke etc.
Atonic seizures. These are seizures involving brief loss Epilepsies of unknown cause
of muscle tone, usually resulting in heavy falls with or
Conditions with epileptic seizures traditionally not diagnosed
without loss of consciousness. They only occur in the
• Benign neonatal seizures (BNS)
context of epilepsy syndromes that involve other forms • Febrile seizures (FS)
of seizure. 1181
NEUROLOGICAL DISEASE
26.42 How to administer first aid for seizures 26.44 UK driving regulations
• Move person away from danger (fire, water, machinery, Private use
furniture)
Single seizure
• After convulsions cease, turn person into ‘recovery’ position
• Cease driving until at least 6 mths have passed without
(semi-prone)
recurrence. Driver and Vehicle Licensing Authority (DVLA)
• Ensure airway is clear but do NOT insert anything in mouth
may restore a full licence sooner if recurrence risk is low
(tongue-biting occurs at seizure onset and cannot be
prevented by observers) Epilepsy (i.e. more than one seizure over the age of 5 yrs)
• If convulsions continue for more than 5 mins or recur without • Cease driving immediately
person regaining consciousness, summon urgent medical • Licence restored when patient is free from all types of
attention seizure for 1 yr or seizures have occurred exclusively during
• Do not leave person alone until fully recovered (drowsiness sleep for a period of at least 3 yrs
and confusion can persist for up to 1 hr) • Licence will require renewal every 3 yrs thereafter until
patient is seizure-free for 10 yrs
Withdrawal of anticonvulsants
• Cease driving during withdrawal period and for 6 mths
thereafter
26.43 Epilepsy: outcome after 20 years
Vocational drivers (heavy goods and public service vehicles)
• 50% are seizure-free, without drugs, for the previous 5 yrs • No licence permitted if any seizure has occurred after the
• 20% are seizure-free for the previous 5 yrs but continue to age of 5 yrs until patient is off medication and seizure-free
take medication for more than 10 yrs, and has no potentially epileptogenic
• 30% continue to have seizures in spite of anti-epileptic brain lesion
therapy
Many people with epilepsy feel stigmatised and may 26.45 Guidelines for anticonvulsant therapy 26
become unnecessarily isolated from work and social life.
It should be emphasised that epilepsy is a common dis- • Start with one first-line drug (see Box 26.46)
order that affects 0.5–1% of the population, and that full • Start at a low dose; gradually increase dose until effective
control of seizures can be expected in approximately control of seizures is achieved or side-effects develop (drug
70% of patients (Box 26.43). levels may be helpful)
• Optimise compliance (use minimum number of doses
Immediate care per day)
• If first drug fails (seizures continue or side-effects develop),
Little can or needs to be done for a person during a
start second first-line drug, followed if possible by gradual
major seizure except for first aid and common-sense
withdrawal of first
manœuvres to limit damage or secondary complications • If second drug fails (seizures continue or side-effects
(see Box 26.42). Advice should be given that on no develop), start second-line drug in combination with
account should anything be inserted into the patient’s preferred first-line drug at maximum tolerated dose (beware
mouth. The management of status epilepticus is interactions)
described on page 1159. • If this combination fails (seizures continue or side-effects
develop), replace second-line drug with alternative
Lifestyle advice second-line drug
Patients should be advised to avoid activities where • If this combination fails, check compliance and reconsider
they might place themselves or others at risk if they diagnosis (Are events seizures? Occult lesion? Treatment
have a seizure. This applies at work, at home and compliance/alcohol/drugs confounding response?)
at leisure. At home, only shallow baths (or showers) • Consider alternative, non-drug treatments (e.g. epilepsy
should be taken. Prolonged cycle journeys should be surgery, vagal nerve stimulation)
discouraged until reasonable freedom from seizures • Use minimum number of drugs in combination at any one time
has been achieved. Activities requiring prolonged prox-
imity to water (swimming, fishing or boating) should
always be carried out in the company of someone
who is aware of the risks and the potential need for Anticonvulsant therapy
rescue measures. Driving regulations vary between Anticonvulsant drug treatment (anti-epileptic drugs, or
countries, and the patient should be made aware of these AEDs) should be considered after more than one unpro-
(Box 26.44). Certain occupations, such as firefighter or voked seizure. The decision to start treatment should be
airline pilot, are not open to anyone who has a previous shared with the patient, to enhance compliance. A wide
or active diagnosis of epilepsy; further information is range of drugs is available. These agents either increase
available from epilepsy support organisations. inhibitory neurotransmission in the brain or alter neuro-
The recognised mortality of epilepsy should be dis- nal sodium channels to prevent abnormally rapid trans-
cussed at around the time of diagnosis. This should be mission of impulses. In the majority of patients, full
done with care and sensitivity, and with the aim of moti- control is achieved with a single drug. Dose regimens
vating the patient to adapt habits and lifestyle to opti- should be kept as simple as possible. Guidelines are
mise epilepsy control. listed in Box 26.45. For seizures of focal onset, one large 1183
NEUROLOGICAL DISEASE
A B
Fig. 26.25 The Hallpike manœuvre for diagnosis of benign paroxysmal positional vertigo (BPPV). Patients are asked to keep their eyes
open and look at the examiner as their head is swung briskly backwards through 120° to overhang the edge of the couch. A Perform first with the
right ear down. B Perform next with the left ear down. The examiner looks for nystagmus (usually accompanied by vertigo). In BPPV, the nystagmus
typically occurs in A or B only and is torsional, the fast phase beating towards the lower ear. Its onset is usually delayed a few seconds, and it lasts
10–20 seconds. As the patient is returned to the upright position, transient nystagmus may occur in the opposite direction. Both nystagmus and vertigo
1186 typically decrease (fatigue) on repeat testing.
Disorders of sleep
NEURO-INFLAMMATORY DISEASES
Multiple sclerosis
Multiple sclerosis (MS) is an important cause of long-
term disability in adults, especially in the UK, where the
prevalence is about 120 per 100 000. The annual inci-
dence is around 7 per 100 000, while the lifetime risk of
developing MS is about 1 in 400. The incidence of MS is C
higher in Northern Europeans, and the disease is about
twice as common in females.
Pathophysiology
There is evidence that both genetic and environmental
factors play a causative role. The prevalence of MS is low
near the equator and increases in the temperate zones of A
both hemispheres. Most importantly, people retain the A A
risk of developing the disease in the zone in which they
grew up, indicating that environmental exposures B B
during growth and development are important. Preva-
lence also correlates with environmental factors, such as
sunlight exposure, vitamin D and exposure to Epstein–
Barr virus (EBV), although causative mechanisms
remain unclear. Genetic factors are also relevant; the risk
of familial recurrence in MS is 15%, with highest risk in
first-degree relatives (age-adjusted risk: 4–5% for sib-
lings and 2–3% for parents or offspring). Monozygotic
Fig. 26.26 Multiple sclerosis. A Photomicrograph from demyelinating
twins have a concordance rate of 30%. The genes
plaque, showing perivascular cuffing of blood vessel by lymphocytes.
that predispose to MS are incompletely defined but B Brain MRI in multiple sclerosis. Multiple high-signal lesions (arrows)
inheritance appears to be polygenic, with influences seen particularly in the paraventricular region on T2 image. C In T1
from genes for human leucocyte antigen (HLA) typing, image with gadolinium enhancement, recent lesions (A arrows) show
interleukin receptors, CLEC16A (C-type lectin domain enhancement, suggesting active inflammation (enhancement persists for
family 16 member A) and CD226 genes. An immune 4 weeks); older lesions (B arrows) show no enhancement but low signal,
1188 hypothesis is supported by increased levels of activated suggesting gliosis.
Neuro-inflammatory diseases
These recognise myelin-derived antigens on the surface of the disease characterised by progressive and persist-
of the nervous system’s antigen-presenting cells, the ent disability (Fig. 26.27).
microglia, and undergo clonal proliferation. The result-
ing inflammatory cascade releases cytokines and initi- Clinical features
ates destruction of the oligodendrocyte–myelin unit by A diagnosis of MS requires the demonstration of other-
macrophages. Histologically, the resultant lesion is a wise unexplained CNS lesions separated in time and
plaque of inflammatory demyelination, most commonly space (Box 26.53). The peak age of onset of MS is the
in the periventricular regions of the brain, the optic
nerves, and the subpial regions of the spinal cord (Fig.
26.26). This begins as a circumscribed area of disintegra-
tion of the myelin sheath, accompanied by infiltration by
activated lymphocytes and macrophages, often with
conspicuous perivascular inflammation. After the acute Fulminant
attack, gliosis follows, leaving a shrunken grey scar. (< 10%)
Much of the initial acute clinical deficit is caused Primary
by the effect of inflammatory cytokines on transmission progressive
Disability
of the nervous impulse rather than structural disruption (10–20%)
of the myelin, and may explain the rapid recovery of Relapsing-
some deficits and probably the acute benefit from remitting Secondary
corticosteroids. In the long term, accumulating myelin (80%) progressive
loss reduces the efficiency of impulse propagation or
causes complete conduction block, contributing to sus-
tained impairment of CNS functions. Inflammatory
mediators released during the acute attack (particularly
nitric oxide) probably also initiate axonal damage, which
is a feature of the latter stages of the disease. In estab-
lished MS there is progressive axonal loss, probably due
to the successive damage from acute attacks and the
subsequent loss of neurotrophic factors from oligo-
Time 26
Fig. 26.27 The progression of disability in fulminant, relapsing–
dendrocytes. This axonal loss may account for the phase remitting and progressive multiple sclerosis.
26.53 The Macdonald criteria for the diagnosis of multiple sclerosis (2011)1
Clinical presentation2 Additional evidence required for diagnosis of MS
Two or more attacks with either None
Objective clinical evidence of at least
2 lesions
or
Objective clinical evidence of 1 attack with
reasonable evidence (on clinical history) of
at least 1 prior attack
Two or more attacks with objective clinical Dissemination in ‘space’ demonstrated by MRI
evidence of 1 lesion ≥ 1 lesion in at least 2 of the MS-typical regions3 (multiple lesions in different sites) or
Await further clinical attack at different anatomical site
One attack with objective clinical evidence Dissemination in ‘time’ demonstrated by
of ≥ 2 lesions Evolving MRI showing combined enhancing (new) and non-enhancing (old) lesions or
New T2 or enhancing lesion on repeat MRI or
Await further (second) clinical attack at different anatomical site
One attack with clinical evidence of only Dissemination in ‘space’ demonstrated by
1 lesion (clinically isolated syndrome) ≥ 1 T2 lesion in at least 2 MS-typical regions or
Dissemination in ‘time’, demonstrated by simultaneous enhancing and
non-enhancing lesions or
New T2 or enhancing lesions on repeat MRI or
Await further (second) clinical attack
Insidious neurological progression suggestive 1 yr of progression plus 2 of the following:
of MS Evidence for dissemination in space with ≥ 1 T2 lesions in MS-typical regions
Evidence for dissemination in space based on ≥ 2 lesions in the spinal cord
Positive CSF (evidence of oligoclonal band and/or elevated immunoglobulin (Ig) G index)
1
Published by the International Panel on MS Diagnosis (Ann Neurol 2011; 69:292–302). If the clinical presentation in the left-hand column is associated with the
features in the right-hand column, the diagnosis is MS. If there is incomplete association, the diagnosis is ‘possible MS’.
2
Assumes other possible causes for CNS inflammation (e.g. sarcoidosis, SLE) have been excluded.
3
MS-typical regions = periventricular, juxtacortical, infratentorial, spinal cord.
1189
NEUROLOGICAL DISEASE
A
26.56 Corticosteroids in multiple sclerosis
‘There is evidence favouring corticosteroids (methylprednisolone)
for acute exacerbations of multiple sclerosis, but there are
insufficient data to estimate reliably the effect of corticosteroids
on prevention of new exacerbations and reduction of long-term
disability.’
‘There is currently no evidence that long-term corticosteroid
treatment delays progression of long-term disability in multiple
sclerosis.’
• Filippini G, et al. Corticosteroids or ACTH for acute exacerbations in multiple
sclerosis. Cochrane Database of Systematic Reviews, 2000, issue 4. Art. no.:
CD001331.
• Ciccone A, et al. Corticosteroids for long term treatment in multiple sclerosis.
Cochrane Database of Systematic Reviews, 2008, issue 1. Art. no.: CD006264.
(ANNA = anti-neuronal nucleolar antibody; GABAR = GABA receptor; GAD = glutamic acid decarboxylase; GluR = glutamate receptor; PCA = Purkinje cell
antibody; SCLC = small-cell lung cancer; VGCC = voltage-gated calcium channel; VGKC = voltage-gated potassium channel)
A B
(MELAS = mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MERRF = myoclonic epilepsy with ragged red fibres)
1199
NEUROLOGICAL DISEASE
26 26.70 Drug-induced tremor (usually postural)* 26.71 Clinical features of motor neuron disease
• β-agonists (e.g. salbutamol) • Tricyclic antidepressants Onset
• Theophylline • Recreational drugs (e.g. • Usually after the age of 50 yrs
• Sodium valproate amphetamines) • Very uncommon before the age of 30 yrs
• Thyroxine • Alcohol • Affects males more commonly than females
• Lithium • Caffeine
Symptoms
*Drugs causing parkinsonism and associated tremor are listed in • Limb muscle weakness, cramps, occasionally
Box 26.64.
fasciculation
• Disturbance of speech/swallowing (dysarthria/dysphagia)
Signs
• Wasting and fasciculation of muscles
Dystonia • Weakness of muscles of limbs, tongue, face and palate
• Pyramidal tract involvement, causing spasticity, exaggerated
Dystonia is characterised by a focal increase in tone tendon reflexes, extensor plantar responses
affecting muscles in the limbs or trunk. It may be a • External ocular muscles and sphincters usually remain intact
feature of a number of neurological conditions (PD, • No objective sensory deficit
Wilson’s disease), or occur secondary to brain damage Course
(trauma, stroke) or drugs (tardive syndromes). Dystonia
• Symptoms often begin focally in one part and spread
also occurs as a primary disorder. In childhood onset,
gradually but relentlessly to become widespread
the cause is usually genetic and dystonia is generalised
but adult onset is usually focal; examples include a
twisted neck (torticollis), repetitive blinking (blepharo-
spasm) or tremor. Task-specific symptoms (e.g. writer’s 26.72 Patterns of involvement in
cramp, musician’s dystonia) are often dystonic. Treat- motor neuron disease
ment is difficult but botulinum toxin injections or DBS
Progressive muscular atrophy
may be useful.
• Predominantly spinal motor neurons affected
• Weakness and wasting of distal limb muscles at first
Hemifacial spasm • Fasciculation in muscles
• Tendon reflexes may be absent
This usually presents after middle age with intermittent Progressive bulbar palsy
twitching around one eye, spreading ipsilaterally to • Early involvement of tongue, palate and pharyngeal muscles
other facial muscles. The spasms are exacerbated by • Dysarthria/dysphagia
talking, eating and stress. Hemifacial spasm is usually • Wasting and fasciculation of tongue
idiopathic (similarly to trigeminal neuralgia, it has been • Pyramidal signs may also be present
suggested that it is due to an aberrant arterial loop irri-
Amyotrophic lateral sclerosis (ALS)
tating the 7th nerve just outside the pons), but may be
symptomatic and secondary to structural lesions or MS. • Combination of distal and proximal muscle-wasting and
Drug treatment is not effective but injections of botuli- weakness, fasciculation
num toxin into affected muscles help, although these • Spasticity, exaggerated reflexes, extensor plantars
usually have to be repeated every 3 months or so. In • Bulbar and pseudobulbar palsy follow eventually
• Pyramidal tract features may predominate
refractory cases, microvascular decompression may be
considered.
Investigations
26.74 Infections of the nervous system
Clinical features are often typical but alternative diag-
noses should be excluded. Exclusion of treatable causes, Bacterial infections
such as immune-mediated multifocal motor neuropathy
• Meningitis • Neurosyphilis
with conduction block (p. 1224) and cervical myelo-
• Suppurative encephalitis • Leprosy (peripheral
radiculopathy, is essential. Blood tests are usually • Brain abscess nerves)*
normal, other than a mildly raised creatine kinase. • Paravertebral (epidural) • Diphtheria (peripheral
Sensory and motor nerve conduction studies are normal abscess nerves)*
but there may be reduction in amplitude of motor action • Tuberculosis (Ch. 19) • Tetanus (motor cells)
potentials due to axonal loss. Electromyography will
Viral infections
usually confirm the typical features of widespread
denervation and re-innervation. Spinal fluid analysis is • Meningitis • Subacute sclerosing
not usually necessary. DNA testing may become more • Encephalitis panencephalitis (late
important as genetic factors become clearer. • Transverse myelitis sequel)
• Progressive multifocal • Rabies
Management leucoencephalopathy • HIV infection (Ch. 14)
Patients should be managed within a multidisciplinary • Poliomyelitis
service, including physiotherapists, speech and occu- Prion diseases
pational therapists, dietitians, ventilatory and feeding • Creutzfeldt–Jakob disease • Kuru
support, and palliative care teams, with neurological
Protozoal infections
and respiratory input. Riluzole is licensed for ALS but
has only a modest effect (Box 26.73). Non-invasive ven- • Malaria* • Trypanosomiasis*
tilatory support and/or feeding by percutaneous gas- • Toxoplasmosis (in • Amoebic abscess*
trostomy may improve quality of life in selected patients. immune-suppressed)*
Rapid access to palliative care teams is essential for Helminthic infections
patients as they enter the terminal stages of MND. • Schistosomiasis (spinal • Hydatid disease*
cord)*
• Cysticercosis*
• Strongyloidiasis*
26
26.73 Effective treatments for amyotrophic Fungal infections
lateral sclerosis/motor neuron disease
• Candida meningitis or brain • Cryptococcal meningitis
‘Riluzole 100 mg daily is reasonably safe and may prolong abscess
median survival by about 2–3 months in patients with ALS.’
‘Non-invasive ventilation significantly prolongs survival and *These infections are discussed in Chapter 13.
improves or maintains quality of life in people with ALS. Survival
and some measures of quality of life were significantly improved
in the subgroup of people with better bulbar function, but not in
those with severe bulbar impairment.’ The major infections of the nervous system are listed in
Box 26.74. The frequency of these varies geographically.
• Radunovic A, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor Helminthic infections, such as cysticercosis and hydatid
neuron disease. Cochrane Database of Systematic Reviews, 2009, issue 4. Art.
no.: CD004427. disease, and protozoal infections are described in
• Miller RG, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron Chapter 13.
disease (MND). Cochrane Database of Systematic Reviews, 2012, issue 3. Art.
no.: CD001447.
Clinical features
Headache, drowsiness, fever and neck stiffness are the Drowsy, focal signs?
usual presenting features. In severe bacterial meningitis (possible mass lesion, hydrocephalus
the patient may be comatose and later there may be focal or cerebral oedema)
neurological signs. Ninety percent of patients with
meningococcal meningitis will have two of the follow-
No Yes
ing: fever, neck stiffness, altered consciousness and rash.
When accompanied by septicaemia, it may present very
rapidly, with abrupt onset of obtundation due to cere-
bral oedema. Complications of meningococcal septicae- No other CT
mia are listed in Box 26.77. Chronic meningococcaemia contraindication
to lumbar puncture brain
is a rare condition in which the patient can be unwell for
weeks or even months with recurrent fever, sweating,
joint pains and transient rash. It usually occurs in the
middle-aged and elderly, and in those who have previ-
ously had a splenectomy. In pneumococcal and Haemo- No mass lesion,
philus infections there may be an associated otitis media.
Pneumococcal meningitis may be associated with pneu-
hydrocephalus
or other 26
contraindication
monia and occurs especially in older patients and alco- to lumbar
holics, as well as those without functioning spleens. puncture seen
Listeria monocytogenes is an increasing cause of meningi-
tis and rhombencephalitis (brainstem encephalitis) in
the immunosuppressed, people with diabetes, alcoholics
and pregnant women (p. 339). It can also cause menin-
Lumbar
gitis in neonates. puncture
Investigations
Lumbar puncture is mandatory unless there are contra- Fig. 26.31 The investigation of meningitis.
indications (p. 1154). If the patient is drowsy and has
focal neurological signs or seizures, is immunosup- Recommended empirical therapy before the cause of
pressed, has undergone recent neurosurgery or has suf- meningitis is known is given in Box 26.78, and the pre-
fered a head injury, it is wise to obtain a CT to exclude ferred antibiotic when the organism is known after
a mass lesion (such as a cerebral abscess) before lumbar CSF examination is stipulated in Box 26.79. Adjunctive
puncture because of the risk of coning. This should not, corticosteroid therapy is useful in both children and
however, delay treatment of a presumptive meningitis. adults (Box 26.80) in developed countries where the inci-
If lumbar puncture is deferred or omitted, it is essential dence of penicillin resistance is low, but its role in set-
to take blood cultures and to start empirical treatment tings where there are high rates of resistance or in
(Fig. 26.31). Lumbar puncture will help differentiate the under-developed countries where there are high rates of
causative organism: in bacterial meningitis the CSF is untreated HIV is unclear.
cloudy (turbid) due to the presence of many neutrophils In meningococcal disease, mortality is doubled if the
(often > 1000 × 106 cells/L), the protein content is signifi- patient presents with features of septicaemia rather than
cantly elevated and the glucose reduced. Gram film and meningitis. Individuals likely to require intensive care
culture may allow identification of the organism. Blood facilities and expertise include those with cardiac,
cultures may be positive. PCR techniques can be used respiratory or renal involvement, and those with CNS
on both blood and CSF to identify bacterial DNA. These depression prejudicing the airway. Early endotracheal
methods are useful in detecting meningococcal infection intubation and mechanical ventilation protect the airway
and in typing the organism. and may prevent the development of the acute respira-
tory distress syndrome (ARDS, p. 192). Adverse prog-
Management nostic features include hypotensive shock, a rapidly
There is an untreated mortality rate of around 80%, so developing rash, a haemorrhagic diathesis, multisystem
action must be swift. If bacterial meningitis is suspected, failure and age over 60 years.
the patient should be given parenteral benzylpenicillin
immediately (intravenous is preferable) and prompt Prevention of meningococcal infection
hospital admission should be arranged. The only contra- Close contacts of patients with meningococcal infection
indication is a history of penicillin anaphylaxis. (Box 26.81) should be given 2 days of oral rifampicin. In 1203
NEUROLOGICAL DISEASE
26.82 Clinical features and staging of (p. 401). The CSF findings are similar to those of tuber-
tuberculous meningitis culous meningitis, but the diagnosis can be confirmed
by microscopy or specific serological tests.
Symptoms In some areas, meningitis may be caused by spiro-
• Headache • Depression chaetes (leptospirosis, Lyme disease and syphilis –
• Vomiting • Confusion pp. 336, 334 and 419), rickettsiae (typhus fever – p. 350)
• Low-grade fever • Behaviour changes or protozoa (amoebiasis – p. 367).
• Lassitude Meningitis can also be due to non-infective patholo-
Signs gies. This is seen in recurrent aseptic meningitis due to
• Meningism (may be absent) • Depression of conscious SLE, Behçet’s disease or sarcoidosis, as well as a condi-
• Oculomotor palsies level tion of previously unknown origin known as Mollaret’s
• Papilloedema • Focal hemisphere signs syndrome, in which the recurrent meningitis is associ-
ated with epithelioid cells in the spinal fluid (‘Mollaret’
Staging of severity
cells). Recent evidence suggests that this condition may
• Stage I (early): non-specific symptoms and signs without be due to human herpes virus type 2, and is therefore
alteration of consciousness infective after all. Meningitis can also be seen due to
• Stage II (intermediate): altered consciousness without coma direct invasion of the meninges by neoplastic cells
or delirium + minor focal neurological signs (‘malignant meningitis’ – see Box 26.75, p. 1202).
• Stage III (advanced): stupor or coma, severe neurological
deficits, seizures or abnormal movements
Parenchymal viral infections
Clinical features Infection of the substance of the nervous system
The clinical features and staging criteria are listed in Box will produce symptoms of focal dysfunction (deficits
26.82. Onset is much slower than in other bacterial men- and/or seizures) with general signs of infection, depend-
ingitis – over 2–8 weeks. If untreated, it is fatal in a few ing on the acuteness of the infection and the type of
organism.
weeks but complete recovery is usual if treatment is
started at stage I (see Box 26.82). When treatment is initi- 26
ated later, the rate of death or serious neurological Viral encephalitis
deficit may be as high as 30%. A range of viruses can cause encephalitis but only a
minority of patients have a history of recent viral infec-
Investigations tion. In Europe, the most serious cause of viral encepha-
Lumbar puncture should be performed if the diagnosis litis is herpes simplex (p. 325), which probably reaches
is suspected. The CSF is under increased pressure. It the brain via the olfactory nerves. Varicella zoster is
is usually clear but, when allowed to stand, a fine also an important cause. The development of effective
clot (‘spider web’) may form. The fluid contains up to therapy for some forms of encephalitis has increased the
500 × 106 cells/L, predominantly lymphocytes, but can importance of clinical diagnosis and virological exami-
contain neutrophils. There is a rise in protein and a nation of the CSF. In some parts of the world, viruses
marked fall in glucose. The tubercle bacillus may be transmitted by mosquitoes and ticks (arboviruses) are an
detected in a smear of the centrifuged deposit from important cause of encephalitis. The epidemiology of
the CSF but a negative result does not exclude the diag- some of these infections is changing. Japanese encepha-
nosis. The CSF should be cultured but, as this result will litis (p. 328) has spread relentlessly across Asia to
not be known for up to 6 weeks, treatment must be Australia, and there have been outbreaks of West
started without waiting for confirmation. Brain imaging Nile encephalitis in Romania, Israel and New York. HIV
may show hydrocephalus, brisk meningeal enhance- may cause encephalitis with a subacute or chronic pres-
ment on enhanced CT or MRI, and/or an intracranial entation, but occasionally has an acute presentation with
tuberculoma. seroconversion.
Management Pathophysiology
As soon as the diagnosis is made or strongly suspected, The infection provokes an inflammatory response that
chemotherapy should be started using one of the regi- involves the cortex, white matter, basal ganglia and
mens that include pyrazinamide, described on page 693. brainstem. The distribution of lesions varies with the
The use of corticosteroids in addition to anti-tuberculous type of virus. For example, in herpes simplex encepha-
therapy has been controversial. Recent evidence sug- litis, the temporal lobes are usually primarily affected,
gests that it improves mortality, especially if given early, whereas cytomegalovirus can involve the areas adjacent
but not focal neurological damage. Surgical ventricular to the ventricles (ventriculitis). Inclusion bodies may
drainage may be needed if obstructive hydrocephalus be present in the neurons and glial cells and there is
develops. Skilled nursing is essential during the acute an infiltration of polymorphonuclear cells in the
phase of the illness, and adequate hydration and nutri- perivascular space. There is neuronal degeneration and
tion must be maintained. diffuse glial proliferation, often associated with cerebral
oedema.
Other forms of meningitis
Fungal meningitis (especially cryptococcosis – p. 384) Clinical features
usually occurs in patients who are immunosuppressed Viral encephalitis presents with acute onset of head-
and is a recognised complication of HIV infection ache, fever, focal neurological signs (aphasia and/or 1205
NEUROLOGICAL DISEASE
Poliomyelitis Investigations
Pathophysiology The CSF shows a lymphocytic pleocytosis, a rise in
protein and a normal sugar content. Poliomyelitis virus
Disease is caused by one of three polioviruses, which
may be cultured from CSF and stool.
constitutes a subgroup of the enteroviruses. Poliomyeli-
tis has become much less common in developed coun- Management
tries following the widespread use of oral vaccines but
is still a problem in the developing world, especially Established disease
parts of Africa. Infection usually occurs through the In the early stages, bed rest is imperative because exer-
nasopharynx. cise appears to worsen the paralysis or precipitate it. At
The virus causes a lymphocytic meningitis and infects the onset of respiratory difficulties, a tracheostomy and
the grey matter of the spinal cord, brainstem and cortex. ventilation are required. Subsequent treatment is by
There is a particular propensity to damage anterior horn physiotherapy and orthopaedic measures.
cells, especially in the lumbar segments.
Prophylaxis
Clinical features Prevention of poliomyelitis is by immunisation with
The incubation period is 7–14 days. Figure 26.32 illus- live (Sabin) vaccine. In developed countries where
trates the various features of the infection. Many patients polio is now very rare, the live vaccine has been replaced
recover fully after the initial phase of a few days of mild by the killed vaccine in childhood immunisation
fever and headache. In other individuals, after a week schedules.
of well-being, there is a recurrence of pyrexia, headache
and meningism. Weakness may start later in one muscle Herpes zoster (shingles)
group and can progress to widespread paresis. Respira-
tory failure may supervene if intercostal muscles are Herpes zoster is the result of reactivation of the varicella
paralysed or the medullary motor nuclei are involved. zoster virus that has lain dormant in a nerve root gan-
Epidemics vary widely in terms of the incidence of non- glion following chickenpox earlier in life. Reactivation
paralytic cases and in mortality rate. Death occurs from may be spontaneous (as usually occurs in the middle-
respiratory paralysis. Muscle weakness is maximal at
the end of the first week and gradual recovery may then
aged or elderly) or due to immunosuppression (as in
patients with diabetes, malignant disease or AIDS). Full 26
take place over several months. Muscles showing no details are given on page 318.
signs of recovery after a month will probably not regain
useful function. Second attacks are very rare but occa- Subacute sclerosing
sionally patients show late deterioration in muscle bulk panencephalitis
and power many years after the initial infection (this is
termed the ‘post-polio syndrome’). This is a rare, chronic, progressive and eventually
fatal complication of measles, presumably a result of
an inability of the nervous system to eradicate the
virus. It occurs in children and adolescents, usually
many years after the primary virus infection. There
is generalised neurological deterioration and onset is
Infection insidious, with intellectual deterioration, apathy and
clumsiness, followed by myoclonic jerks, rigidity and
dementia.
1 2 3 The CSF may show a mild lymphocytic pleocytosis
and the EEG demonstrates characteristic periodic bursts
Asymptomatic Aseptic meningitis Febrile
seroconversion (encephalitis) illness of triphasic waves. Although there is persistent measles-
specific IgG in serum and CSF, antiviral therapy is inef-
fective and death ensues within a few years.
Anterior horn Recovery
cell infection
Progressive multifocal
leucoencephalopathy
Lower motor This was originally described as a rare complication
neuron paralysis
of lymphoma, leukaemia or carcinomatosis, but has
become more frequent as a feature of AIDS (p. 402). It is
an infection of oligodendrocytes by human polyoma-
Death Recovery virus JC, which causes widespread demyelination of
the white matter of the cerebral hemispheres. Clinical
signs include dementia, hemiparesis and aphasia, which
Complete Residual progress rapidly, usually leading to death within weeks
disability or months. Areas of low density in the white matter are
seen on CT but MRI is more sensitive, showing diffuse
high signal in the cerebral white matter on T2-weighted
Late
deterioration images. The only treatment available is to restore the
immune response (by treating AIDS or any other cause
Fig. 26.32 Poliomyelitis. Possible consequences of infection. of immunosuppression). 1207
NEUROLOGICAL DISEASE
Cerebral abscess
Bacteria may enter the cerebral substance through pen-
etrating injury, by direct spread from paranasal sinuses
or the middle ear, or secondary to septicaemia. The site
of abscess formation and the likely causative organism
are both related to the source of infection (Box 26.83).
Initial infection leads to local suppuration followed by
loculation of pus within a surrounding wall of gliosis,
which in a chronic abscess may form a tough capsule.
Haematogenous spread may lead to multiple abscesses.
Clinical features
A cerebral abscess may present acutely with fever, head-
ache, meningism and drowsiness, but more commonly
presents over days or weeks as a cerebral mass lesion
with little or no evidence of infection. Seizures, raised
intracranial pressure and focal hemisphere signs occur
alone or in combination. Distinction from a cerebral
tumour may be impossible on clinical grounds. B
Investigations
Lumbar puncture is potentially hazardous in the pres-
ence of raised intracranial pressure and CT should
always precede it. CT reveals single or multiple low-
density areas, which show ring enhancement with
contrast and surrounding cerebral oedema (Fig. 26.33).
There may be an elevated white blood cell count and
ESR in patients with active local infection. The possibil-
ity of cerebral toxoplasmosis or tuberculous disease
secondary to HIV infection (p. 402) should always be
considered.
Management and prognosis
Antimicrobial therapy is indicated once the diagnosis is
made. The likely source of infection should guide the
choice of antibiotic (see Box 26.83). In neurosurgical
patients, the addition of vancomycin should be consid-
ered. Surgical drainage by burr-hole aspiration or exci- Fig. 26.33 Right temporal cerebral abscess (arrows), with
sion may be necessary, especially where the presence of surrounding oedema and midline shift to the left. A Unenhanced
a capsule may lead to a persistent focus of infection. CT image. B Contrast-enhanced CT image.
Epilepsy frequently develops and is often resistant to 26.84 Clinical and pathological features of
treatment. neurosyphilis
Despite advances in therapy, the mortality rate
Type Pathology Clinical features
remains at 10–20% and this may partly relate to delay in
diagnosis and initiation of treatment. Meningovascular Endarteritis Stroke
(5 yrs)* obliterans Cranial nerve
Subdural empyema Meningeal exudate palsies
This is a rare complication of frontal sinusitis, osteo- Granuloma Seizures/mass
(gumma) lesion
myelitis of the skull vault or middle ear disease. A col-
lection of pus in the subdural space spreads over the General Degeneration in Dementia
surface of the hemisphere, causing underlying cortical paralysis of cerebral cortex/ Tremor
oedema or thrombophlebitis. Patients present with the insane cerebral atrophy Bilateral upper
severe pain in the face or head and pyrexia, often with (5–15 yrs)* Thickened motor signs
a history of preceding paranasal sinus or ear infection. meninges
The patient then becomes drowsy, with seizures and Tabes dorsalis Degeneration of Lightning pains
focal signs such as a progressive hemiparesis. (5–20 yrs)* sensory neurons Sensory ataxia
The diagnosis rests on a strong clinical suspicion in Wasting of dorsal Visual failure
patients with a local focus of infection. Careful assess- columns Abdominal crises
ment with contrast-enhanced CT or MRI may show a Optic atrophy Incontinence
subdural collection with underlying cerebral oedema. Trophic changes
Management requires aspiration of pus via a burr-hole Any of the above Argyll Robertson
and appropriate parenteral antibiotics. Any local source pupils (p. 1172)
of infection must be treated to prevent re-infection.
*Interval from primary infection.
Spinal epidural abscess
The characteristic clinical features are pain in a root
distribution and progressive transverse spinal cord
syndrome with paraparesis, sensory impairment and and irregular pupils that react to convergence but not
light, as described by Argyll Robertson (see Box 26.28,
26
sphincter dysfunction. Features of the primary focus of
infection may be less obvious and thus can be over- p. 1172), may accompany any neurosyphilitic syndrome,
looked. The resurgence of resistant staphylococcal infec- but most commonly tabes dorsalis.
tion and intravenous drug misuse has contributed to a
recent marked rise in incidence. Investigations
X-ray changes occur late if present, so MRI or mye- Routine screening for syphilis is warranted in many
lography should precede urgent neurosurgical interven- neurological patients. Serological tests (p. 420) are posi-
tion. Decompressive laminectomy with draining of the tive in the serum in most patients, but CSF examination
abscess relieves the pressure on the dura. Organisms is essential if neurological involvement is suspected.
may be grown from the pus or blood. Surgery, together Active disease is suggested by an elevated cell count,
with appropriate antibiotics, may prevent complete and usually lymphocytic, and the protein content may be
irreversible paraplegia. elevated to 0.5–1.0 g/L with an increased gamma globu-
lin fraction. Serological tests in the CSF are usually posi-
Lyme disease tive, but progressive disease can occur with negative
This can cause numerous neurological problems, includ- CSF serology.
ing polyradiculopathy, meningitis, encephalitis and Management
mononeuritis multiplex (p. 334).
The injection of procaine benzylpenicillin (procaine pen-
Neurosyphilis icillin) and probenecid for 17 days is essential in the
treatment of neurosyphilis of all types (p. 421). Further
Neurosyphilis may present as an acute or chronic
courses of penicillin must be given if symptoms are not
process and may involve the meninges, blood vessels
relieved, if the condition continues to advance or if the
and/or parenchyma of the brain and spinal cord. The
CSF continues to show signs of active disease. The cell
decade to 2008 saw a ten-fold increase in the incidence
count returns to normal within 3 months of completion
of syphilis, mostly as a result of misguided relaxation
of treatment, but the elevated protein takes longer to
of safe sex measures with the advent of effective anti-
subside and some serological tests may never revert to
retroviral treatments for AIDS. Parallel increases in
normal. Evidence of clinical progression at any time is
neurosyphilis are inevitable. The clinical manifestations
an indication for renewed treatment.
are diverse and early diagnosis and treatment remain
important.
Clinical features Diseases caused by bacterial toxins
The clinical and pathological features of the three most
common presentations are summarised in Box 26.84. Tetanus
Neurological examination reveals signs indicative of This disease results from infection with Clostridium
the anatomical localisation of lesions. Delusions of gran- tetani, a commensal in the gut of humans and domestic
deur suggest general paresis of the insane, but more animals that is found in soil. Infection enters the body
commonly there is simply progressive dementia. Small through wounds, which may be trivial. It is rare in the 1209
NEUROLOGICAL DISEASE
Transmissible spongiform
encephalopathies
Transmissible spongiform encephalopathies (TSEs)
include a number of veterinary and medical conditions
that are characterised by the histopathological triad of
Fig. 26.34 MRI in variant Creutzfeldt–Jakob disease. Arrows
26
cortical spongiform change, neuronal cell loss and indicate bilateral pulvinar hyperintensity.
gliosis. Associated with these changes, there is deposi-
tion of amyloid made up of an altered form of a nor-
mally occurring protein, the prion protein.
The precise nature of the infective agent is not yet in patients with sporadic CJD (mean time to death is
clear but almost certainly involves the cascade formation over a year). Characteristic EEG changes are not present,
of an abnormal prion protein. TSEs may also occur spon- but MRI brain scans show characteristic high-signal
taneously or as an inherited disorder. Diseases affecting changes in the pulvinar in a high proportion of cases
animals include bovine and feline spongiform encepha- (Fig. 26.34). Brain histology is distinct, with very florid
lopathies (BSE and FSE). These diseases achieved media plaques containing the prion proteins. Abnormal prion
prominence in the 1990s, when a form of Creutzfeldt– protein has been identified in tonsil specimens from suf-
Jakob disease emerged that was associated with prion ferers of vCJD, leading to the suggestion that the disease
protein ingestion. could be transmitted by reticulo-endothelial tissue (like
TSEs in animals but unlike sporadic CJD in humans).
Creutzfeldt–Jakob disease This has caused great concern in the UK, leading to
Creutzfeldt–Jakob disease (CJD) is the best-characterised precautionary measures such as leucodepletion of all
human TSE. Some 10% of cases arise due to a mutation blood used for transfusion, and the mandatory use of
in the gene coding for the prion protein. The sporadic disposable surgical instruments wherever possible for
form is the most common, occurring in middle-aged tonsillectomy, appendicectomy and ophthalmological
to elderly patients. Clinical features usually involve procedures. The incidence of vCJD has now declined
a rapidly progressive dementia, with myoclonus and dramatically but surveillance and research continue.
a characteristic EEG pattern (repetitive slow-wave
complexes), although a number of other features, such
Other TSE syndromes
as visual disturbance or ataxia, may also be seen. These Other extremely rare, inherited human TSEs include
are particularly common in CJD transmitted by inocula- Gerstmann–Sträussler–Scheinker disease, fatal familial
tion (e.g. by infected dura mater grafts). Death occurs insomnia and kuru. Kuru occurred only in members of
after a mean of 4–6 months. There is no effective a cannibalistic New Guinea tribe and was probably
treatment. transmitted by people eating the brains of dead tribal
members. Clinical features include progressive ataxia
Variant Creutzfeldt–Jakob disease and dementia.
A variant of CJD (vCJD) emerged in the late 1990s,
affecting a small number of patients in the UK. The
causative agent appears to be identical to that causing INTRACRANIAL MASS LESIONS AND
BSE in cows, and the disease may have been a result of RAISED INTRACRANIAL PRESSURE
the epidemic of BSE in the UK a decade earlier. Patients
affected by vCJD are typically younger than those with Many different types of mass lesion may arise within the
sporadic CJD and present with neuropsychiatric changes intracranial cavity (Box 26.87). In developing countries,
and sensory symptoms in the limbs, followed by ataxia, tuberculoma and other infections are frequent causes,
dementia and death. Progression is slightly slower than but in the West, intracranial haemorrhage and brain 1211
NEUROLOGICAL DISEASE
Clinical features
In adults, intracranial pressure is less than 10–15 mmHg. Fig. 26.35 Cerebral tumour displacing medial temporal lobe and
The features of RIP are listed in Box 26.88. The speed of causing pressure on the mid-brain and 3rd cranial nerve.
pressure increase influences presentation. If slow, com-
pensatory mechanisms may occur, including alteration Trans-tentorial herniation of the uncus may compress
in the volume of fluid in CSF spaces and venous sinuses, the ipsilateral 3rd nerve and usually involves the pupil-
which minimise symptoms. Rapid pressure increase (as lary fibres first, causing a dilated pupil; however, a false
in aggressive tumours) does not permit these compensa- localising contralateral 3rd nerve palsy may also occur,
tory mechanisms to occur, leading to early symptoms, perhaps due to extrinsic compression by the tentorial
including sudden death. Papilloedema is not always margin. Vomiting, coma, bradycardia and arterial
present, either because the pressure rise has been too hypertension are later features of RIP.
rapid or because of anatomical anomalies of the menin- The rise in intracranial pressure from a mass lesion
geal sheath of the optic nerve. may cause displacement of the brain. Downward dis-
A false localising sign is one in which the pathology placement of the medial temporal lobe (uncus) through
is remote from the site of the expected lesion; in RIP, the the tentorium due to a large hemisphere mass may cause
6th cranial nerve (unilateral or bilateral) is most com- ‘temporal coning’ (Fig. 26.35). This may stretch the 3rd
monly affected, but the 3rd, 5th and 7th nerves may also and/or 6th cranial nerves, or cause pressure on the
be involved. Sixth nerve palsies are thought to be due contralateral cerebral peduncle (causing ipsilateral
either to stretching of the long slender nerve or to upper motor neuron signs), and is usually accompanied
1212 compression against the petrous temporal bone ridge. by progressive coma. Downward movement of the
Intracranial mass lesions and raised intracranial pressure
Brain tumours
primaries in the bronchus, breast and gastrointestinal
Primary brain tumours are a heterogeneous collection of tract (Fig. 26.37). Metastases usually occur in the white
neoplasms arising from the brain tissue or meninges, matter of the cerebral or cerebellar hemispheres, but
and vary from benign to highly malignant. Primary there are diffuse leptomeningeal types.
malignant brain tumours (Box 26.89) are rare, account-
ing for 1% of all adult tumours but a higher proportion Clinical features
in children. The most common benign brain tumour is a
meningioma. Primary brain tumours do not metastasise The presentation is variable and usually influenced by
due to the absence of lymphatic drainage in the brain. the rate of growth. High-grade disease (WHO grade III
There are rare pathological subtypes, however, such as and IV) tends to present with a short 4–6-week history of
medulloblastoma, which do have a propensity to metas- mass effect (headache, nausea secondary to RIP), while
tasise; the reasons for this are not clear. Most cerebral more indolent tumours can present with slowly progres-
tumours are sporadic but may be associated with genetic sive focal neurological deficits, depending on their loca-
syndromes such as neurofibromatosis or tuberous scle- tion (see Box 26.88); generalised or focal seizures are
rosis. Brain tumours are not classified by the usual TNM common. Headache, if present, is usually accompanied
system but by the WHO grading I–IV; this is based by focal deficits or seizures, and isolated stable headache
on histology (e.g. nuclear pleomorphism, presence of is almost never due to intracranial tumour.
mitoses and presence of necrosis), with grade I being the The size of the primary tumour is of far less prognos-
most benign and grade IV the most malignant. Gliomas tic significance than its location within the brain.
account for 60% of brain tumours, with the aggressive Tumours within the brainstem will result in early neu-
glioblastoma multiforme (WHO grade IV) being the rological deficits, while those in the frontal region may
most common glioma, followed by meningiomas (20%) be quite large before symptoms occur.
and pituitary tumours (10%). Although the lower-grade
gliomas (I and II) may be very indolent, with prognosis Investigations
measured in terms of many years, these tumours may Diagnosis is by neuroimaging (Figs 26.38 and 26.39)
transform to higher-grade disease at any time, with a and pathological grading following biopsy or resection
resultant sharp decline in life expectancy. where this is possible. The more malignant tumours are
Most malignant brain tumours are due to metastases, more likely to demonstrate contrast enhancement on
with intracranial metastases complicating about 20% imaging. If the tumour appears to be metastatic, further
of extracranial malignancies. The rate is higher with investigation to find the primary will be required. 1213
NEUROLOGICAL DISEASE
26 A
important for normal function (e.g. motor strip), then There is a small group of highly malignant grade IV
biopsy may be the only safe surgical intervention but, in tumours that can be cured with aggressive therapy.
general, maximal safe resection is the optimal surgical Patients with medulloblastomas have a good chance of
management. Meningiomas and acoustic neuromas long-term survival with maximal surgery followed by
offer the best prospects for complete removal irradiation of the whole brain and spine; younger
and thus cure. Some meningiomas can recur, however, patients may also benefit from concomitant and adju-
particularly those of the sphenoid ridge when partial vant chemotherapy. Older patients do not tolerate this,
excision is often all that is possible. Thereafter, post- however.
operative surveillance may be required, as radiotherapy Once tumours relapse, chemotherapy response rates
is effective at preventing further growth of residual are low and survival is short in high-grade disease. In
tumour. Pituitary adenomas may be removed by a trans- the more uncommon low-grade tumours, repeated
sphenoidal route, avoiding the need for a craniotomy. courses of chemotherapy can result in much more pro-
Unfortunately, gliomas, which account for the majority longed survival.
of brain tumours, cannot be completely excised, since In metastatic disease, radiotherapy offers a modest
infiltration spreads well beyond the apparent radiologi- improvement in survival but with costs in terms of
cal boundaries of the intracranial mass. Recurrence quality of life; treatment therefore needs careful discus-
is therefore the rule, even if the mass of the tumour sion with the patient. Benefits may be superior in breast
is apparently removed completely; partial excision cancer but there is little to separate other pathologies.
(‘debulking’) may be useful in alleviating symptoms Occasional chemosensitive cancers, such as small-cell
caused by RIP, but although there is increasing evidence lung cancer, may benefit from systemic chemotherapy,
that the degree of surgical excision may have a positive but intracerebral metastases represent a late stage of
influence on survival, this has not yet been demon- disease and have a short prognosis.
strated in a randomised study.
Prognosis
Radiotherapy and chemotherapy The WHO histological grading system is a powerful pre-
In the majority of primary CNS tumours, radiation dictor of prognosis in primary CNS tumours, though it
does not yet take account of individual biomarkers. For
and chemotherapy are used to control disease and
extend survival rather than for cure. Meningioma and each tumour type and grade, advancing age and deterio-
rating functional status are the next most important
26
pituitary adenoma offer the best chance of life-long
remission. The gliomas are incurable; high-grade, WHO negative prognostic features. The overall 5-year survival
IV disease still carries a median survival of just over a rate of about 14% in adults masks a wide variation that
year. In this situation, patient and family should always depends on tumour type.
be involved in decisions regarding treatment. The diag-
nosis, and often the symptoms, are devastating, and Acoustic neuroma
support from palliative care and social work is crucial at This is a benign tumour of Schwann cells of the 8th
an early stage. In WHO grade III disease, prognosis is cranial nerve, which may arise in isolation or as part of
a little better (2–4 years) and in rarer, more indolent neurofibromatosis type 2 (see below). When sporadic,
tumours, very prolonged survival is possible. acoustic neuroma occurs after the third decade and is
Advances have been made recently in terms of thera- more frequent in females. The tumour commonly arises
peutic outcome. Standard care for WHO grade IV glio- near the nerve’s entry point into the medulla or in the
blastoma multiforme is now combination radiotherapy internal auditory meatus, usually on the vestibular divi-
with oral temozolomide chemotherapy; although this sion. Acoustic neuromas account for 80–90% of tumours
improves median survival of the population from only at the cerebellopontine angle.
12 to 14.5 months, up to 25% of patients survive for
more than 2 years (compared to approximately 10% with Clinical features
radiotherapy alone). Ten percent will survive more than Acoustic neuroma typically presents with unilateral pro-
5 years with temozolomide (virtually unheard of with gressive hearing loss, sometimes with tinnitus. Vertigo
radiotherapy alone). Benefits are more likely in well- is an unusual symptom, as slow growth allows com-
debulked patients who are younger and fitter. Implanta- pensatory brainstem mechanisms to develop. In some
tion of chemotherapy gives a small survival benefit. cases, progressive enlargement leads to distortion of
Understanding of the molecular biology of brain the brainstem and/or cerebellar peduncle, causing
tumours has allowed the use of biomarkers to guide ataxia and/or cerebellar signs in the limbs. Distortion
therapy and prognostic discussions. In patients with of the fourth ventricle and cerebral aqueduct may
methylation of the promoter region of the MGMT cause hydrocephalus (see below), which may be the
(methyl guanine methyl transferase) gene (about 30% of presenting feature. Facial weakness is unusual at pres-
the population), 2-year survival is almost 50%. MGMT entation but facial palsy may follow surgical removal of
reduces the cytotoxicity of temozolomide, and this the tumour. The tumour may be identified incidentally
mutation also reduces the enzyme’s activity, rendering on cranial imaging.
the tumour more sensitive to chemotherapy. In grade II
and III gliomas, the presence of the loss of heterozygo- Investigations
city (LOH) 1p19q chromosomal abnormality confers MRI is the investigation of choice (see Fig. 26.39).
chemosensitivity and thus improves prognosis. The
presence of a rare mutation in the IDH-1 (isocitrate Management
dehydrogenase) gene confers a very favourable progno- Surgery is the treatment of choice. If the tumour can be
sis in patients with glioblastoma. completely removed, the prognosis is excellent, although 1215
NEUROLOGICAL DISEASE
Choroid plexus
Management
26.92 Physical signs in cervical root compression
Surgical procedures, including laminectomy and ante-
Muscle rior discectomy, may arrest progression of disability but
Root weakness Sensory loss Reflex loss neurological improvement is not the rule. The decision
C5 Biceps, deltoid, Upper lateral Biceps as to whether surgery should be undertaken may be
spinati arm difficult. Manual manipulation of the cervical spine is of
no proven benefit and may precipitate acute neurologi-
C6 Brachioradialis Lower lateral Supinator cal deterioration.
arm, thumb,
index finger Prognosis
C7 Triceps, finger Middle finger Triceps The prognosis of cervical myelopathy is variable. In
and wrist many patients, the condition stabilises or even improves
extensors without intervention. If progression results in sphincter
dysfunction or pyramidal signs, surgical decompression
should be considered.
Clinical features
The patient complains of pain in the neck that may
Lumbar spondylosis
radiate in the distribution of the affected nerve root. The
This term covers degenerative disc disease and osteo-
neck is held rigidly and neck movements may exacer-
arthritic change in the lumbar spine. Pain in the distribu-
bate pain. Paraesthesia and sensory loss may be found
tion of the lumbar or sacral roots (‘sciatica’) is almost
in the affected segment and there may be lower motor
always due to disc protrusion but can be a feature of
neuron signs, including weakness, wasting and reflex
other rare but important disorders, including spinal
impairment (Box 26.92).
tumour, malignant disease in the pelvis and tuberculosis
of the vertebral bodies.
Investigations
Where there is no trauma, imaging should not be Lumbar disc herniation 26
carried out for isolated cervical pain. X-rays offer limited
benefit, except in excluding destructive lesions. MRI is While acute lumbar disc herniation is often precipitated
the investigation of choice in those with radicular symp- by trauma (usually lifting heavy weights while the
toms. Electrophysiological studies rarely add to clinical spine is flexed), genetic factors may also be important.
examination and have become less important with the The nucleus pulposus may bulge or rupture through the
emergence of MRI. annulus fibrosus, giving rise to pressure on nerve
endings in the spinal ligaments, changes in the vertebral
Management joints or pressure on nerve roots.
Conservative treatment with analgesics and physio- Pathophysiology
therapy results in resolution of symptoms in the great
majority of patients, but a few require surgery in the The altered mechanics of the lumbar spine result in loss
form of discectomy or radicular decompression. of lumbar lordosis and there may be spasm of the para-
spinal musculature. Root pressure is suggested by limi-
Cervical myelopathy tation of flexion of the hip on the affected side if the
straight leg is raised (Lasègue’s sign). If the third or
Dorsomedial herniation of a disc and the development fourth lumbar root is involved, Lasègue’s sign may be
of transverse bony bars or posterior osteophytes may negative, but pain in the back may be induced by hyper-
result in pressure on the spinal cord or the anterior extension of the hip (femoral nerve stretch test). The
spinal artery, which supplies the anterior two-thirds of roots most frequently affected are S1, L5 and L4; the
the cord (see Fig. 26.43). signs of root pressure at these levels are summarised in
Clinical features Box 26.93.
The onset is usually insidious and painless, but acute
deterioration may occur after trauma, especially hyper-
extension injury. Upper motor neuron signs develop
in the limbs, with spasticity of the legs usually appearing 26.93 Physical signs in lumbar root compression
before the arms are involved. Sensory loss in the
upper limbs is common, producing tingling, numbness Disc
and proprioception loss in the hands, with progressive level Root Sensory loss Weakness Reflex loss
clumsiness. Sensory manifestations in the legs are much L3/L4 L4 Inner calf Inversion of Knee
less common. Neurological deficit usually progresses foot
gradually and disturbance of micturition is a very late L4/L5 L5 Outer calf Dorsiflexion
feature. and dorsum of hallux/
of foot toes
Investigations
L5/S1 S1 Sole and Plantar Ankle
MRI (see Fig. 26.43) (or rarely myelography) will direct
lateral flexion
surgical intervention. MRI also provides information on foot
the state of the spinal cord at the level of compression. 1219
NEUROLOGICAL DISEASE
26 Clinical features
The onset may be sudden or gradual. Alternatively,
Spinal cord compression
repeated episodes of low back pain may precede sciatica
Spinal cord compression is one of the more common
by months or years. Constant aching pain is felt in the
neurological emergencies encountered in clinical prac-
lumbar region and may radiate to the buttock, thigh, calf
tice and the usual causes are listed in Box 26.94. A
and foot. Pain is exacerbated by coughing or straining
space-occupying lesion within the spinal canal may
but may be relieved by lying flat.
damage nerve tissue either directly by pressure or
indirectly by interfering with blood supply. Oedema
Investigations from venous obstruction impairs neuronal function, and
Plain X-rays of the lumbar spine are of little value in the ischaemia from arterial obstruction may lead to necrosis
diagnosis of lumbar disc disease, although they may of the spinal cord. The early stages of damage are revers-
show other conditions such as malignant infiltration of ible but severely damaged neurons do not recover;
a vertebral body. While CT can provide helpful images hence the importance of early diagnosis and treatment.
of the disc protrusion and/or narrowing of the exit
foramina, MRI is the investigation of choice if available, Clinical features
since soft tissues are well imaged. The onset of symptoms of spinal cord compression
is usually slow (over weeks) but can be acute as a
Management result of trauma or metastases, especially if there is asso-
Some 90% of patients with sciatica recover following ciated arterial occlusion. The symptoms are shown in
conservative treatment with analgesia and early mobi- Box 26.95.
lisation; bed rest does not help recovery. The patient Pain and sensory symptoms occur early, while weak-
should be instructed in back-strengthening exercises ness and sphincter dysfunction are usually late manifes-
and advised to avoid physical manœuvres likely to tations. The signs vary according to the level of the cord
strain the lumbar spine. Injections of local anaesthetic compression and the structures involved. There may be
or corticosteroids may be useful adjunctive treatment
if symptoms are due to ligamentous injury or joint
dysfunction. Surgery may have to be considered if
there is no response to conservative treatment or if 26.94 Causes of spinal cord compression
progressive neurological deficits develop. Central disc
Site Frequency Causes
prolapse with bilateral symptoms and signs and distur-
bance of sphincter function requires urgent surgical Vertebral 80% Trauma (extradural)
decompression. Intervertebral disc prolapse
Metastatic carcinoma (e.g.
breast, prostate, bronchus)
Lumbar canal stenosis Myeloma
This occurs with a congenitally narrowed lumbar spinal Tuberculosis
canal, exacerbated by the degenerative changes that Meninges 15% Tumours (e.g. meningioma,
commonly occur with age. (intradural, neurofibroma, ependymoma,
extramedullary) metastasis, lymphoma,
Pathophysiology leukaemia)
The symptoms of spinal stenosis are thought to be due Epidural abscess
to local vascular compromise secondary to the canal ste- Spinal cord 5% Tumours (e.g. glioma,
nosis, rendering the nerve roots ischaemic and intolerant (intradural, ependymoma, metastasis)
of the increased demand that occurs on exercise. intramedullary)
Clinical features
Patients, who are usually elderly, develop exercise-
induced weakness and paraesthesia in the legs (‘spinal
claudication’). These symptoms progress with contin- 26.95 Symptoms of spinal cord compression
ued exertion, often to the point that the patient can no Pain
longer walk, but are quickly relieved by a short period
• Localised over the spine or in a root distribution, which may
of rest. Physical examination at rest shows preservation
be aggravated by coughing, sneezing or straining
of peripheral pulses with absent ankle reflexes. Weak-
ness or sensory loss may only be apparent if the patient Sensory
is examined immediately after exercise. • Paraesthesia, numbness or cold sensations, especially in the
lower limbs, which spread proximally, often to a level on the
Investigations trunk
The investigation of first choice is MRI, but contraindica- Motor
tions (body habitus, metallic implants) may make CT or • Weakness, heaviness or stiffness of the limbs, most
myelography necessary. commonly the legs
Sphincters
Management
• Urgency or hesitancy of micturition, leading eventually to
Lumbar laminectomy may provide relief of symptoms urinary retention
1220 and recovery of normal exercise tolerance.
Disorders of the spine and spinal cord
(AVM = arteriovenous malformation; HIV = human immunodeficiency virus; HZV = herpes zoster virus; LMN = lower motor neuron; MS = multiple sclerosis;
UMN = upper motor neuron)
1222
Diseases of peripheral nerves
(usually less). Rapid deterioration to respiratory failure deterioration to ventilation and evidence of axonal loss
can develop within hours. Examination shows diffuse on EMG.
weakness with loss of reflexes. Miller Fisher syndrome
presents with internal and external ophthalmoplegia,
ataxia and areflexia. Chronic polyneuropathy
Investigations The most common axonal and demyelinating causes of
The CSF protein is raised, but may be normal in the first polyneuropathy are shown in Box 26.100. A chronic
10 days. There is usually no increase in CSF white cell symmetrical axonal polyneuropathy, evolving over
count (> 10 × 106 cells/L suggests an alternative diagno- months or years, is the most common form of chronic
sis). Electrophysiological changes may emerge after a neuropathy. Diabetes mellitus is the most common
week or so, with conduction block and multifocal motor cause but in about 25–50% no cause can be found.
slowing, sometimes most evident proximally as delayed
F waves (p. 1152). Antibodies to the ganglioside GM1 Hereditary neuropathy
are found in about 25%, usually the motor axonal form. Charcot–Marie–Tooth disease (CMT) is an umbrella
Other causes of an acute neuromuscular paralysis term for the inherited neuropathies. This group of syn-
should be excluded (e.g. poliomyelitis, botulism, diph- dromes has different clinical and genetic features. The
theria, spinal cord syndromes or myasthenia), via the most common CMT is the autosomal dominantly inher-
history and examination rather than investigations. ited CMT type 1, usually caused by duplication of the
PMP-22 gene on chromosome 17. Common signs are
Management distal wasting (‘inverted champagne bottle’ legs), often
Supportive measures to prevent pressure sores and deep with pes cavus, and predominantly motor involvement.
venous thrombosis are essential. Regular monitoring of X-linked and recessively inherited forms of CMT,
respiratory function (vital capacity) is needed in the causing demyelinating or axonal neuropathies, also
acute phase, as respiratory failure may develop with occur.
little warning. Active treatment with plasma exchange
or intravenous immunoglobulin therapy shortens the Chronic demyelinating
duration of ventilation and improves prognosis (Box
26.104). Overall, 80% of patients recover completely
polyneuropathy 26
The acquired chronic demyelinating neuropathies
within 3–6 months, 4% die and the remainder suffer include chronic inflammatory demyelinating peripheral
residual neurological disability, which can be severe. neuropathy (CIDP), multifocal motor neuropathy (see
Adverse prognostic features include older age, rapid above) and paraprotein-associated demyelinating neu-
ropathy. CIDP typically presents with relapsing or
progressive motor and sensory changes, evolving over
26.104 Intravenous immunoglobulin and more than 8 weeks (in distinction to the more acute
plasma exchange in Guillain–Barré syndrome GBS). It is important to recognise, as it usually responds
‘In severe Guillain–Barré syndrome (GBS), intravenous to corticosteroids, plasma exchange or intravenous
immunoglobulin (IVIg) started within 2 weeks of onset hastens immunoglobulin.
recovery as much as plasma exchange (PE). Adverse events are Some 10% of patients with acquired demyelinating
not significantly more frequent with either treatment, but IVIg is polyneuropathy have an abnormal serum paraprotein,
significantly much more likely to be completed than PE.’ sometimes associated with a lymphoproliferative malig-
‘In mild GBS, 2 sessions of PE are significantly superior to none; nancy. They may also demonstrate positive antibodies to
in moderate disease, 4 sessions are significantly superior to 2; myelin-associated glycoprotein (anti-MAG antibodies).
and in severe disease, 6 sessions are not significantly better
than 4. PE is more beneficial when started within 7 days of
disease onset rather than later, but is still beneficial in patients Brachial plexopathy
treated up to 30 days after disease onset.’
Trauma usually damages either the upper or the lower
• Hughes RAC, et al. Intravenous immunoglobulin for Guillain–Barré syndrome. parts of the brachial plexus, according to the mechanics
Cochrane Database of Systematic Reviews, 2012, issue 7. Art. no.: CD002063.
• Raphaël JC, et al. Plasma exchange for Guillain–Barré syndrome. Cochrane of the injury. The clinical features depend on the ana-
Database of Systematic Reviews, 2012, issue 7. Art. no.: CD001798. tomical site of the damage (Box 26.105). Lower parts of
For further information: www.cochrane.org/cochrane-reviews
the brachial plexus are vulnerable to infiltration from
breast or apical lung tumours (Pancoast tumour, p. 701)
Acetylcholinesterase
removes acetylcholine
from neuromuscular Voltage-gated
junction Ca++ calcium channel
Acetylcholine
packets released
by calcium influx
Acetylcholine Acetylcholine
receptor
Myasthenia gravis
Antibodies to
acetylcholine
receptors
In myasthenia
end plate is subject
to cell-mediated
immune assault
(end plate simplified)
Depolarisation Sodium channels
of muscle
membrane
in clefts amplify
potential change 26
Fig. 26.47 Myasthenia gravis and Lambert–Eaton myasthenic syndrome (LEMS). In myasthenia there are antibodies to the acetylcholine
receptors on the post-synaptic membrane, which block conduction across the neuromuscular junction (NMJ). Myasthenic symptoms can be transiently
improved by inhibition of acetylcholinesterase (e.g. with Tensilon® – edrophonium bromide), which normally removes the acetylcholine. A cell-mediated
immune response produces simplification of the post-synaptic membrane, further impairing the ‘safety factor’ of neuromuscular conduction. In LEMS,
antibodies to the pre-synaptic voltage calcium channels impair release of acetylcholine from the motor nerve ending; calcium is required for the
acetylcholine-containing vesicle to fuse with the pre-synaptic membrane for release into the NMJ.
Duchenne muscular dystrophy. Genetic counselling is with exercise intolerance, myalgia and sometimes recur-
important. rent myoglobinuria may have isolated pathogenic muta-
tions in genes encoding for oxidation pathways.
Inherited metabolic myopathies Inherited disorders of the oxidative pathways of the
There are a large number of rare inherited disorders that respiratory chain in mitochondria cause a group of dis-
interfere with the biochemical pathways that maintain orders, either restricted to the muscle or associated with
the energy supply (adenosine triphosphate, ATP) to non-myopathic features (Box 26.109). Many of these
muscles. These are mostly recessively inherited deficien- mitochondrial disorders are inherited via the mitochon-
cies in the enzymes necessary for glycogen or fatty acid drial genome, down the maternal line (p. 53). Diagnosis
(β-oxidation) metabolism (Box 26.108). They typically is based on clinical appearances, supported by muscle
present with muscle weakness and pain. biopsy appearance (usually with ‘ragged red’ and/or
cytochrome oxidase negative fibres), and specific muta-
Mitochondrial disorders tions either on blood or, more reliably, muscle testing.
Mitochondrial diseases are discussed on page 65. Mito- Mutations may be due either to point mutations or to
chondria are present in all tissues and dysfunction deletions of mitochondrial DNA.
causes widespread effects, on vision (optic atrophy, A disorder called Leber hereditary optic neuropathy
retinitis pigmentosa, cataracts), hearing (sensorineural (LHON) is characterised by acute or subacute loss of
deafness), and the endocrine, cardiovascular, gastro- vision, most frequently in males, due to bilateral optic
intestinal and renal systems. Any combination of these atrophy. Three point mutations account for more than
should raise the suspicion of a mitochondrial disorder, 90% of LHON cases.
especially if there is evidence of maternal transmission.
Mitochondrial dysfunction can be caused by altera- Channelopathies
tions in either mitochondrial DNA or genes encoding for Inherited abnormalities of the sodium, calcium and chlo-
oxidative processes. Genetic abnormalities or mutations ride ion channels in striated muscle produce various
in mitochondrial DNA may affect single individuals and syndromes of familial periodic paralysis, myotonia and
single tissues (most commonly muscle). Thus, patients malignant hyperthermia, which may be recognised by
26
26.108 Inherited disorders of muscle metabolism
Disease Clinical features Diagnosis
Carbohydrate Myophosphorylase deficiency Exercise-induced myalgia, Creatine kinase (CK) elevated
(glycogen) metabolism (McArdle’s disease): stiffness, weakness (with ‘second Muscle biopsy
autosomal recessive wind’ phenomenon), myoglobinuria Enzyme assay
Acid maltase deficiency Infantile form: death within 2 yrs CK elevated
(Pompe’s disease): autosomal Childhood: death in 20–30s Blood lymphocyte analysis for
recessive Adult: progressive proximal glycogen granules
myopathy with respiratory failure Muscle biopsy
Enzyme assay
Lipid metabolism Carnitine-palmitoyl Myalgia after exercise, CK normal between attacks
(β-oxidation) transferase (CPT) deficiency myoglobinuria, weakness Urinary organic acids
Enzyme assays
Muscle biopsy
27
Stroke disease
1231
STROKE DISEASE
Pulse 2
Rate and rhythm 7 Sensory system
Touch sensation
Cortical sensory function: sensory
inattention or neglect
Joint position sense
8 Gait
General appearance 1 Able to weight-bear?
Conscious level Ataxic
Posture: leaning to one side? Hemiparetic gait pattern
Facial symmetry
1232
Clinical examination in stroke disease
1233
STROKE DISEASE
Stroke
(acute, focal brain dysfunction due to vascular disease)
Clinical Total anterior Partial anterior Lacunar stroke Posterior Intracerebral Subarachnoid Central venous
classification circulation circulation (LACS) circulation haemorrhage haemorrhage thrombosis
stroke (TACS) stroke (PACS) (20%) stroke (POCS) (10%) (5%) (<1%)
(15%) (30%) (20%)
Anterior
communicating Anterior cerebral
artery (ACoA) artery (ACA)
Small perforating Middle cerebral
vessels artery (MCA) Anterior (carotid)
circulation
Posterior
(vertebrobasilar)
circulation PCA
Vertebral B
A arteries (VA) VA ICA
1234 Fig. 27.2 Arterial circulation of the brain. A Horizontal view. B Lateral view.
Investigations
Vascular imaging
Superior sagittal sinus Various techniques are used to obtain images of extra-
cranial and intracranial blood vessels (Fig. 27.5). The
least invasive is ultrasound (Doppler or duplex scan-
Posterior Anterior ning), which is used to image the carotid and the verte-
bral arteries in the neck. In skilled hands, reliable
information can be provided about the degree of arterial
stenosis and the presence of ulcerated plaques. Blood
27
flow in the intracerebral vessels can be examined using
transcranial Doppler. While the anatomical resolution is
limited, it is improving and many centres no longer
require formal angiography before proceeding to carotid
endarterectomy (see below). Blood flow can also be
detected by specialised sequences in MR angiography
(MRA) but the anatomical resolution is still not compa-
rable to that of intra-arterial angiography, which out-
lines blood vessels by the injection of radio-opaque
Cavernous
sinus contrast intravenously or intra-arterially. The X-ray
images obtained can be enhanced by the use of computer-
Transverse sinus Jugular vein assisted digital subtraction or spiral CT. Because of
the significant risk of complications, intra-arterial con-
Fig. 27.3 Venous circulation of the brain.
trast angiography is reserved for patients in whom
A B
Fig. 27.4 Acute stroke seen on CT scan with corresponding MRI appearance. A CT may show no evidence of early infarction.
B Corresponding image seen on MRI diffusion weighted imaging (DWI) with changes of infarction in middle cerebral artery (MCA) territory (arrows). 1235
STROKE DISEASE
27 A B
C D
Fig. 27.5 Different techniques of imaging blood vessels. A Doppler scan showing 80% stenosis of the internal carotid artery (arrow).
B Three-dimensional reconstruction of CT angiogram showing stenosis at the carotid bifurcation (arrow). C MR angiogram showing giant aneurysm at
the middle cerebral artery bifurcation (arrow). D Intra-arterial angiography showing arteriovenous malformation (arrow).
Lumbar puncture
Lumbar puncture (p. 1153) is largely reserved for the Speech disturbance
investigation of SAH.
Dysphasia and dysarthria are the most common presen-
tations of disturbed speech in stroke (p. 1168). Dyspha-
Cardiovascular investigations sia indicates damage to the dominant frontal or parietal
Electrocardiography (ECG; p. 532) and echocardiogra- lobe (see Box 26.2, p. 1142), while dysarthria is a non-
phy (p. 537) may reveal abnormalities that may cause localising feature reflecting weakness or incoordination
cardiac embolism in stroke. of the face, pharynx, lips, tongue or palate.
1236
Stroke
n 40
Cerebral tatio
odila
blood Vas A
Increased oxygen
volume extraction
30
Blood
flow
20
Cerebral
oxygen Failure of
extraction B electrical function
Symptoms
Cerebral 10
oxygen Failure of ionic pumps
metabolism C
Potassium efflux
Sodium influx
Time (mins/hrs)
Cell death
0
Fig. 27.6 Homeostatic responses to falling perfusion pressure in
the brain following arterial occlusion. Vasodilatation initially maintains Fig. 27.7 Thresholds of cerebral ischaemia. Symptoms of cerebral
cerebral blood flow (A), but after maximal vasodilatation further falls in ischaemia appear when the blood flow has fallen to less than half of
perfusion pressure lead to a decline in blood flow. An increase in tissue normal and energy supply is insufficient to sustain neuronal electrical
oxygen extraction, however, maintains the cerebral metabolic rate for function. Full recovery can occur if this level of flow is returned to normal
oxygen (B). Still further falls in perfusion, and therefore blood flow, cannot but not if it is sustained. Further blood flow reduction below the next
be compensated; cerebral oxygen availability falls and symptoms appear, threshold causes failure of cell ionic pumps and starts the ischaemic
then infarction (C). cascade, leading to cell death.
↓Oxygen
+glucose Thromboxane
Anaerobic Prostaglandins
metabolism
1
Free fatty
H+ ↓ATP Free acids
5 radicals
Ca2+
Fig. 27.8 The process of neuronal
ischaemia and infarction. (1) Reduction of
Glia Fe + H H+ 4 Oedema blood flow reduces supply of oxygen and hence
6
Lipid peroxidases Water ATP. H+ is produced by anaerobic metabolism of
K+ Proteases Na+
NO synthase available glucose. (2) Energy-dependent
Na+/K+ ATPase↓
membrane ionic pumps fail, leading to cytotoxic
2
oedema and membrane depolarisation, allowing
Depolarisation calcium entry and releasing glutamate.
Na+ 3 Ca2+
AMPA NMDA (3) Calcium enters cells via glutamate-gated
↓Glutamate channels and (4) activates destructive
uptake by glia
intracellular enzymes (5), destroying intracellular
organelles and cell membrane, with release of
Glutamate free radicals. Free fatty acid release activates
2
pro-coagulant pathways that exacerbate local
ischaemia. (6) Glial cells take up H+, can no
Ca2+ longer take up extracellular glutamate and also
suffer cell death, leading to liquefactive necrosis
of whole arterial territory.
the blood flow increases again, function returns and the (cytotoxic oedema) and the release of the excitatory
patient will have had a transient ischaemic attack (TIA). neurotransmitter glutamate into the extracellular fluid.
However, if the blood flow falls further, a level is reached Glutamate opens membrane channels, allowing the
at which irreversible cell death starts. Hypoxia leads influx of calcium and more sodium into the neurons.
to an inadequate supply of adenosine triphosphate Calcium entering the neurons activates intracellular
(ATP), which leads to failure of membrane pumps, enzymes that complete the destructive process. The
1238 thereby allowing influx of sodium and water into the cell release of inflammatory mediators by microglia and
Stroke
astrocytes causes death of all cell types in the area of 27.2 Causes of intracerebral haemorrhage and
maximum ischaemia. The infarction process is worsened associated risk factors
by the anaerobic production of lactic acid (Fig. 27.8) and
Disease Risk factors
consequent fall in tissue pH. There have been attempts
to develop neuroprotective drugs to slow down the Complex small-vessel Age
processes leading to irreversible cell death but so far disease with disruption of Hypertension
these have proved disappointing. vessel wall High cholesterol
The final outcome of the occlusion of a cerebral blood Amyloid angiopathy Familial (rare)
vessel therefore depends upon the competence of the Age
circulatory homeostatic mechanisms, the metabolic Impaired blood clotting Anticoagulant therapy
demand, and the severity and duration of the reduction Blood dyscrasia
in blood flow. Higher brain temperature, as occurs in Thrombolytic therapy
fever, and higher blood sugar have both been associated
Vascular anomaly Arteriovenous malformation
with a greater volume of infarction for a given reduction
Cavernous haemangioma
in cerebral blood flow. Subsequent restoration of blood
flow may cause haemorrhage into the infarcted area Substance misuse Alcohol
(‘haemorrhagic transformation’). This is particularly Amphetamines
likely in patients given antithrombotic or thrombolytic Cocaine
drugs, and in patients with larger infarcts.
Radiologically, a cerebral infarct can be seen as a
lesion that comprises a mixture of dead brain tissue white-matter fibre tracts are split apart. The haemor-
that is already undergoing autolysis, and tissue that is rhage itself may expand over the first minutes or hours,
ischaemic and swollen but recoverable (the ‘ischaemic or it may be associated with a rim of cerebral oedema,
penumbra’). The infarct swells with time and is at its which, along with the haematoma, acts like a mass lesion
maximal size a couple of days after stroke onset. At this to cause progression of the neurological deficit. If big
stage, it may be big enough to exert mass effect both enough, this can cause shift of the intracranial contents,
clinically and radiologically; sometimes, decompressive producing transtentorial coning and sometimes rapid
craniectomy is required (see below). After a few weeks,
the oedema subsides and the infarcted area is replaced
death (p. 1212). If the patient survives, the haematoma
is gradually absorbed, leaving a haemosiderin-lined slit 27
by a sharply defined fluid-filled cavity. in the brain parenchyma.
Intracerebral haemorrhage
Intracerebral haemorrhage causes about 10% of acute Clinical features
stroke events but is more common in low-income
countries. It usually results from rupture of a blood Acute stroke and TIA are characterised by a rapid-onset,
vessel within the brain parenchyma but may also occur focal deficit of brain function. The typical presentation
in a patient with an SAH (see below) if the artery rup- occurs over minutes, affects an identifiable area of the
tures into the brain substance as well as into the brain and is ‘negative’ in character (i.e. abrupt loss of
subarachnoid space. Haemorrhage frequently occurs function without positive features such as abnormal
into an area of brain infarction and, if the volume of movement). Provided that there is a clear history of this,
haemorrhage is large, it may be difficult to distinguish the chance of a brain lesion being anything other than
from primary intracerebral haemorrhage both clinically vascular is 5% or less (Box 27.3). If symptoms progress
and radiologically (Fig. 27.9). The risk factors and under- over hours or days, other diagnoses must be excluded.
lying causes of intracerebral haemorrhage are listed in Confusion and memory or balance disturbance are
Box 27.2. The explosive entry of blood into the brain more often due to stroke mimics. Transient symptoms,
parenchyma causes immediate cessation of function in such as syncope, amnesia, confusion and dizziness,
that area as neurons are structurally disrupted and do not reflect focal cerebral dysfunction, but are often
A B
Partial anterior circulation Isolated motor loss (e.g. leg only, Occlusion of a branch
syndrome (PACS) arm only, face) of the middle cerebral
artery or anterior
Leg
Isolated higher cerebral cerebral artery
dysfunction (e.g. aphasia,
Arm Higher neglect) (Embolism from heart
cerebral or major vessels)
functions Mixture of higher cerebral
Face dysfunction and motor loss
(e.g. aphasia with right
Optic
radiations hemiparesis)
Visual cortex
Cerebellum
Cranial nerve
nuclei
Fig. 27.10 Clinical and radiological features of the stroke syndromes. The top three diagrams show coronal sections of the brain, and the
bottom one shows a sagittal section. The anatomical locations of cerebral functions are shown with the nerve tracts in green. A motor (or sensory) deficit
(shown by the red shaded areas) can occur with damage to the relevant cortex (PACS), nerve tracts (LACS) or both (TACS). The corresponding CT scans
show horizontal slices at the level of the lesion, highlighted by the arrows.
Risk factor analysis where results would not influence management, such as
in the advanced stage of a terminal illness. CT remains
Initial investigation includes a range of simple blood
the most practical and widely available method of
tests to detect common vascular risk factors and markers
imaging the brain. It will usually exclude non-stroke
of rarer causes, an ECG and brain imaging. Where there
lesions, including subdural haematomas and brain
is uncertainty about the nature of the stroke, further
tumours, and will demonstrate intracerebral haemor-
investigations are indicated. This especially applies to
rhage within minutes of stroke onset (see Fig. 27.9).
younger patients, who are less likely to have athero-
However, especially within the first few hours after
sclerotic disease (Box 27.6).
symptom onset, CT changes in cerebral infarction may
be completely absent or only very subtle. Changes often
Neuroimaging develop over time (see Fig. 27.11, p. 1245), but small
Brain imaging with either CT or MRI should be per- cerebral infarcts may never show up on CT scans. For
formed in all patients with acute stroke. Exceptions are most purposes, a CT scan performed within 24 hours is 1241
STROKE DISEASE
surgery (Box 27.11). Some patients with large haemato- Coagulation abnormalities
mas or infarction with massive oedema in the cerebral
In those with intracerebral haemorrhage, coagulation
hemispheres may benefit from anti-oedema agents, such
abnormalities should be reversed as quickly as possible
as mannitol or artificial ventilation. Surgical decompres-
to reduce the likelihood of the haematoma enlarging.
sion to reduce intracranial pressure should be consid-
This most commonly arises in those on warfarin therapy.
ered in appropriate patients.
There is no evidence that clotting factors are useful in
the absence of a clotting defect.
Thrombolysis
Intravenous thrombolysis with recombinant tissue plas- Management of risk factors
minogen activator (rt-PA) increases the risk of haem- The approaches used are summarised in Figure 27.11.
orrhagic transformation of the cerebral infarct with The average risk of a further stroke is 5–10% within the
potentially fatal results. However, if it is given within first week of a stroke or TIA, perhaps 15% in the first
4.5 hours of symptom onset to carefully selected patients, year and 5% per year thereafter. The risks are not
the haemorrhagic risk is offset by an improvement in substantially different for intracerebral haemorrhage.
overall outcome (see Box 27.11). The earlier treatment is Patients with ischaemic events should be put on long-
given, the greater the benefit. term antiplatelet drugs and statins to lower cholesterol.
For patients in atrial fibrillation, the risk can be reduced
Aspirin by about 60% by using oral anticoagulation to achieve
In the absence of contraindications, aspirin (300 mg an INR of 2–3. The role of newer oral anticoagulants
daily) should be started immediately after an ischaemic (such as dabigatran) is currently being investigated. The
stroke unless rt-PA has been given, in which case it risk of recurrence after both ischaemic and haemor-
should be withheld for at least 24 hours. Aspirin reduces rhagic strokes can be reduced by blood pressure reduc-
the risk of early recurrence and has a small but clinically tion, even for those with relatively normal blood
worthwhile effect on long-term outcome (see Box 27.11); pressures (Box 27.12).
it may be given by rectal suppository or by nasogastric
tube in dysphagic patients. Carotid endarterectomy
and angioplasty
Heparin A small proportion of patients with a carotid territory
Anticoagulation with heparin has been widely used to ischaemic stroke or TIA will have a greater than 50%
treat acute ischaemic stroke in the past. Whilst it reduces stenosis of the carotid artery on the side of the brain
the risk of early ischaemic recurrence and venous lesion. Such patients have a greater than average risk
thromboembolism, it increases the risk of both intracra- of stroke recurrence. For those without major residual
nial and extracranial haemorrhage. Furthermore, routine disability, removal of the stenosis has been shown
use of heparin does not result in better long-term out- to reduce the overall risk of recurrence, although the
comes, and therefore it should not be used in the routine operation itself carries about a 5% risk of stroke (see
management of acute stroke. It is unclear whether Box 27.12). Surgery is most effective in patients with
heparin might provide benefit in selected patients, such more severe stenoses (70–99%) and in those in whom
as those with recent myocardial infarction, arterial dis- it is performed within the first couple of weeks after
section or progressing strokes. Intracranial haemorrhage the TIA or ischaemic stroke. Carotid angioplasty and
must be excluded on brain imaging before considering stenting are technically feasible but have not been
1244 anticoagulation. shown to be as effective as endarterectomy for the
Stroke
Fig. 27.11 Strategies for secondary prevention of stroke. (1) Lower BP with caution in patients with postural hypotension, renal impairment or
bilateral carotid stenosis. (2) Pravastatin 40 mg can be used as an alternative to simvastatin in patients on warfarin or digoxin. (3) Warfarin and aspirin can
be used in combination in patients with prosthetic heart valves. (4) The combination of aspirin and clopidogrel is only indicated in patients with unstable
angina who demonstrate ECG or enzyme changes.
• 1Antithrombotic Trialists’ Collaboration. BMJ 2002; 324:71–86. • 3PROGRESS Collaborative Group. Lancet 2001; 358:1033–1041.
• 2Heart Protection Study Collaborative Group. Lancet 2002; 360:7–22 and SPARCL • 4Lip GYH, et al. Lancet 2012; 379:648–661.
investigators. N Engl J Med 2006; 355:549–559. • 5Rothwell PM, et al. Lancet 2003; 361:107–116.
Emergency CT
Negative
(15% of subarachnoid
haemorrhage)
feasible, it is now the procedure of first choice. Arterio- 27.14 Clinical features of cerebral venous
venous malformations can be managed either by surgi- thrombosis
cal removal, by ligation of the blood vessels that feed or
Cavernous sinus thrombosis
drain the lesion, or by injection of material to occlude
the fistula or draining veins. Treatment may also be • Proptosis, ptosis, headache, external and internal
required for complications of SAH, which include ophthalmoplegia, papilloedema, reduced sensation in
obstructive hydrocephalus (that may require drainage trigeminal first division
via a shunt), delayed cerebral ischaemia due to vaso- • Often bilateral, patient ill and febrile
spasm (which may be treated with vasodilators), Superior sagittal sinus thrombosis
hyponatraemia (best managed by fluid restriction) and • Headache, papilloedema, seizures
systemic complications associated with immobility, • Clinical features may resemble idiopathic intracranial
such as chest infection and venous thrombosis. hypertension (p. 1217)
• May involve veins of both hemispheres, causing advancing
motor and sensory focal deficits
CEREBRAL VENOUS DISEASE Transverse sinus thrombosis
Thrombosis of the cerebral veins and venous sinuses • Hemiparesis, seizures, papilloedema
• May spread to jugular foramen and involve cranial nerves 9,
(cerebral venous thrombosis) is much less common than
10 and 11
arterial thrombosis. However, it has been recognised
with increasing frequency in recent years, as access to
non-invasive imaging of the venous sinuses using MR
venography has increased. The main causes are listed in
Box 27.13. Investigations and management
MR venography demonstrates a filling defect in the
Clinical features affected vessel.
Anticoagulation, initially with heparin followed by
Cerebral venous sinus thrombosis usually presents with
27
warfarin, is usually beneficial, even in the presence of
symptoms of raised intracranial pressure, seizures and venous haemorrhage. In selected patients, the use of
focal neurological symptoms. The clinical features vary endovascular thrombolysis has been advocated. Man-
according to the sinus involved (Box 27.14 and see agement of underlying causes and complications, such
Fig. 27.3, p. 1235). Cortical vein thrombosis presents as persistently raised intracranial pressure, is also
with focal cortical deficits such as aphasia and hemi- important.
paresis (depending on the area affected), and epilepsy About 10% of cerebral venous sinus thrombosis, par-
(focal or generalised). The deficit can increase if spread- ticularly cavernous sinus thrombosis, is associated with
ing thrombophlebitis occurs. infection (most commonly Staphylococcus aureus), which
necessitates antibiotic treatment. Otherwise, the treat-
ment of choice is anticoagulation.
1247